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Abstract 
Vascular  calcification  (VC)  is  a  health  problem  common  in  ageing 
populations, diabetes and chronic kidney disease. It leads to vascular stiffening and 
heart failure. VC is a regulated process mediated by vascular smooth muscle cells 
(VSMCs),  with  similarities  to  developmental  osteogenesis.  The  exact  molecular 
events responsible for triggering it are unknown. The endoplasmic reticulum (ER) is 
involved  in  folding  of  proteins.  ER  stress  occurs  as  a  result  of  unfolded protein 
accumulation  and  has  been  implicated  in  osteoblast  differentiation  and  bone 
mineralization.  Therefore,  I  hypothesized  that  ER  stress  signalling  regulates 
osteogenic differentiation and calcification of VSMCs.
I showed that calcification of human aortas was associated with changes in 
ER  stress  marker  expression.  Warfarin  and  TNFα,  which  are  both  established 
inducers  of  vascular  calcification,  increased  expression  of  ER  stress  markers  in 
VSMCs.  ER  stress  modelled  in  human  primary  VSMCs  in  vitro increased  their 
calcification and was shown to modulate expression of a number of bone related 
genes, such as BMP-2, Runx2, Osterix, ALP, BSP and OPG in VSMCs  in vitro. I also 
demonstrated  that  ER  stress  activated  features  characteristic  of  a  secretory 
phenotype in VSMCs, such as downregulation of SMC markers and components of 
TGFβ  signalling  related  to  contractile  differentiation,  as  well  as  BMP-2.  Taken 
together these results  suggested that  ER stress can induce changes that  lead to 
osteogenic differentiation.
To  further  explore  the  relationship  between  ER  stress  and  osteogenic 
differentiation of VSMCs Osterix and ALP were studied in more detail. ALP activity 
was upregulated by ER stress, but did not change when VSMCs calcified. Promoter 
analysis showed that ALP might be regulated by ER stress via indirect mechanisms 
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1.1.1. What is vascular calcification?
Vascular calcification is the process of deposition of hydroxyapatite in the
extracellular matrix (ECM) of the blood vessel wall. Hydroxyapatite (HAp) is the main
mineral component of bones and consists of calcium (Ca2+) and phosphate (HPO42-)
ions that crystallise in matrix vesicles on a scaffold of  ECM proteins secreted by
calcifying cells (Demer et al. 2008; Kapustin et al. 2012).
 The  presence  of  vascular  calcification  poses  an  increased  risk  of
cardiovascular  and  all-cause  mortality.  Nearly  all  patients  with  cardiovascular
disease have some degree of calcification, and, in asymptomatic adults, prevalence
of coronary calcification corresponds with age; among 60-year-olds, approximately
60% have vascular calcification (Rennenberg et al. 2009; Sage et al. 2010).
Vascular  calcification can be categorised into two main types:  medial  and
intimal,  depending  on  its  localisation  in  the  vessel  wall  (Karwowski et  al. 2012;
Proudfoot et al. 2001). Each type of calcification is caused by different conditions
and  is  associated  with  different  risk  factors  for  the  cardiovascular  system,
summarised in Table 1.1 (Sage et al. 2010).
Medial calcification, also called Mönckenberg's sclerosis, most often presents
itself as continuous areas of calcified structures along the elastic lamellae of vessels.
The direct result of medial vascular calcification is blood vessel wall stiffening, that
leads  to  many  cardiovascular  complications  such  as  hypertension  and  aortic
stenosis, which in turn give rise to cardiac hypertrophy, myocardial and lower-limb
ischemia, congestive heart failure and can eventually result in death (London et al.
2011). Vascular calcification is a risk factor predictive of cardiac events (Sage et al.
2010;  Karwowski et  al. 2012).  Medial  calcification  is  associated  primarily  with
ageing,  diabetes and chronic kidney disease (CKD). Patients on dialysis are exposed
to a host of risk factors that promote vascular calcification; the most potent of these
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are associated with elevated levels of calcium and phosphate and are caused by the
dysregulated mineral metabolism induced by renal failure (Shanahan 2013). Much
research  on  vascular  calcification  is  focused  on  CKD  as  prevalence  of  vascular
calcification in patients suffering from this disease is very high and nearly half the
deaths in dialysis patients are due to cardiovascular disease (Speer et al. 2004).
Intimal calcifications are dispersed in the vessel wall, discontinuous and co-
localise with atherosclerotic plaques (Sage et al. 2010). Intimal calcification is caused
by  the  same  factors  as  atherosclerosis,  such  as  lipids,  oxidative  stress  and
inflammation.  The  result  of  intimal  calcification  is  an  increased  risk  of  plaque
rupture (Hoshino et al. 2009), which is believed to cause most myocardial infarction
and stroke events.
Vascular smooth muscle cells  (VSMCs) play a crucial role in regulating both
these  types  of  calcification  (Shanahan 2005;  Shanahan et  al. 2011;  Shroff et  al.
2007) and therefore they are the focus of this PhD thesis. However, other cell types
are also known to contribute to the process of vascular calcification. Macrophages
and endothelial cells, which are known to play a role in atherosclerosis (Weber and
Noels, 2011), have also been shown to mediate some of the mechanisms leading to
calcification (New et al. 2013; Yao et al. 2013). It has also been argued that vascular
stem cells present in the vessel wall can contribute to vascular disease (Tang et al.
2012).
Table 1.1. Types of vascular calcification. References are in the text.
Calcification Medial Intimal
Causes CKD, diabetes, ageing atherosclerosis, ageing
Results Vascular stiffening, leads to
hypertension and heart failure.
Plaque rupture, leads to strokes
and myocardial infarcts.
Cells involved VSMCs, vascular stem cells? VSMCs, endothelial cells,
macrophages
1.1.2. Mechanisms of vascular calcification 
Vascular  calcification has long been considered as a passive, degenerative
process related to tissue ageing. However, it is now recognised that both intimal and
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medial calcification are regulated and mediated by VSMCs (Shanahan et al. 1999a;
Sage et al. 2013). In response to cellular stress VSMCs undergo vascular calcification
via several  mechanisms: apoptosis, release of matrix vesicles, loss of calcification
inhibitors, ageing-related DNA damage and osteogenic differentiation  (Figure 1.1).
All these processes are discussed in detail in the following sections.
Figure 1.1.  Mechanisms of vascular calcification. Stresses such as inflammation or serum mineral
imbalance  cause  a  reduction  in  natural  calcification  inhibitors  and  trigger  VSMC  calcification.
Calcifying  VSMCs  exhibit  a  secretory  phenotype  during  which  they  secrete  matrix  vesicles  and
express osteo- and chondrogenic markers (transcription factors and extracellular matrix proteins).
1.1.2.1. Loss of calcification inhibitors
In healthy organisms concentrations of calcium (Ca) and inorganic phosphate















which  they  spontaneously  precipitate).  Their  spontaneous  precipitation  in  soft
tissues is prevented by proteins that act as natural calcification inhibitors, which are
produced by various tissues and circulating in blood. Some of these endogenous
calcification inhibitors (fetuin-A, MGP, OPG, Klotho) have well established roles in
regulating  vascular  calcification,  others  (SMAD6,  fibrillin-1  and  CAII)  are
hypothesized to play a role based on the phenotypes of mouse knock-out models
(Shroff et al. 2007) (Table 1.2). 
Table 1.2. Summary of natural calcification inhibitors and the effects of their disruption in mice and
humans.
Protein Mouse knock-out phenotype
Human mutation/
polymorphism phenotype References
BMP-7 Death 1 month after birth,
skeletal malformations,
retarded ossiﬁcation of bones,
a reduced number of
nephrons, polycystic kidney,
lack of retinal pigmentation,
and retarded lens
development.
Polymorphisms  associated with
inverse relationships between
bone mineralization and vascular
calcification in the coronary,









calcification of small arteries
in a number of organs.
Mutations cause  CAII deficiency
syndrome osteopetrosis, renal
tubular acidosis, and cerebral
calcification.
(Spicer et al. 1989)
(Shah et al. 2004)
ENPP1 Calcification of joints and the
spine and arterial calcification.
Loss of ENPP1 causes 'idiopathic'
infantile arterial calcification:
calcification of the internal elastic
lamina of muscular arteries and
stenosis due to intimal thickening.
(Okawa et al. 1998)
(Rutsch et al. 2003)
Fetuin-A Organ calcification on mineral
and vitamin D–rich diet or
normal diet depending on the
genetic background. Serum
has decreased ability to inhibit
HAp crystal nucleation.
Polymorphisms associated with




(Schafer et al. 2003)
(Stenvinkel et al.
2005)
(Lehtinen  et al.
2007)
Fibrillin-1 Death 2 weeks after birth,
dissecting aneurysm and









(Fietta et al. 2002)





Mutations cause tumoral calcinosis





(Kuro-o et al. 1997)
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Protein Mouse knock-out phenotype
Human mutation/
polymorphism phenotype References
MGP Death within 2 months of
birth due to arterial
calcification that leads to
blood vessel rupture;
calcification of cartilages that
lead to osteopenia and
fractures.
Mutations cause Keutel syndrome:
calcification of cartilage in the
ears, nose, larynx, trachea, and
ribs and extensive medial vascular
calcification at an early age.





(Luo et al. 1997)
(Herrmann et al.
2000)
OPG Osteoporosis and medial
calcification of the aorta and
renal arteries.
Polymorphism in OPG promoter
associated with intimal thickening
of the common carotid artery,
indicative of early atherosclerosis.
(Bucay et al. 1998)
(Brändström et al.
2004)
SMAD6 Heart defects and aortic
calcification.
Not known. (Galvin et al. 2000)
The  first  inhibitor,  fetuin-A  (also  known  as  α2-Heremans-Schmid
glycoprotein), is constitutively produced in the liver and can be found in serum and
extracellular  fluids of  tissues  (Jahnen-Dechent et  al. 1997).  Mice lacking fetuin-A
develop  ectopic  calcifications  of  soft  tissues  (Schäfer et  al. 2003).  Certain
polymorphisms of this gene have been associated with high serum phosphate levels
(Osawa et al. 2005), high prevalence of calcified atherosclerotic plaques (Lehtinen et
al. 2007) and cardiovascular mortality (Stenvinkel et al. 2005) in humans. Low levels
of  circulating  fetuin-A  in  CKD have  been  correlated  to  a  higher  risk  of  vascular
calcification  (Ketteler et  al. 2003).  Fetuin-A  inhibits  calcification  by  forming
complexes with mineral and another calcification inhibitor, matrix γ-carboxyglutamic
acid protein (MGP), and thus preventing mineral precipitation (Ketteler et al. 2002;
Schäfer et al. 2003). Fetuin-A has been shown to colocalise with calcified VSMCs in
vivo, shown by immunohistochemistry of aortic sections. In vitro fetuin-A has been
shown  to  be  taken  up  by  VSMCs  from  serum,  packaged  into  vesicles  and
subsequently secreted to the extracellular  space  (Reynolds et  al. 2005).  Fetuin-A
was also shown to inhibit VSMC apoptosis and increase phagocytosis of apoptotic
bodies (Reynolds et  al. 2005).  This  shows that fetuin-A not only inhibits  mineral
precipitation  but  also  provides  additional  mechanisms  of  inhibiting  VSMC
calcification.
Another  potent  calcification  inhibitor  is  MGP,  which  is  synthesized  by
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chondrocytes and VSMCs and directly inhibits calcium phosphate crystal nucleation
by binding mineral ions to its γ-carboxylated glutamic acid residues (Luo et al. 1997).
MGP knock-out mice die within 2 months of birth due to arterial calcification that
leads to blood vessel  rupture,  and show calcification of  cartilage which leads to
osteopenia and fractures (Luo et al. 1997).  Mutations of MGP in humans, which
cause MGP to be inactive or absent, result in Keutel syndrome. Keutel syndrome
manifests as calcification of cartilage in the ears, nose, larynx, trachea, and ribs and
extensive medial vascular calcification at an early age  (Munroe et al. 1999). MGP
polymorphisms  have  been  linked  to  increased  risk  of  atherosclerotic  plaque
calcification and myocardial infarction (Herrmann et al. 2000). MGP has been shown
to be highly expressed in human atherosclerotic plaques  (Shanahan et  al. 1994).
Calcifying  human  VSMCs  in  vitro also  showed  elevated  expression  of  MGP
(Proudfoot et al. 1998). These findings demonstrate that in stress conditions VSMCs
synthesise high levels of MGP in order to protect themselves from calcification. In
addition,  MGP  has  been  shown  to  negatively  regulate  BMP-2,  a  potent  bone-
inducing cytokine, by binding BMP-2 and preventing it from reaching its receptor on
the cell surface (Zebboudj et al. 2002).
Osteoprotegerin  (OPG)  and Klotho are  two proteins  whose  knock-outs  in
mice have seemingly contradictory effects because they cause both osteoporosis
and soft tissue calcification. OPG deficient mice exhibit a decrease in bone density
and mass and at the same time medial calcification of the aorta and renal arteries
(Bucay et al. 1998). OPG is a secreted factor that decreases osteoclast activity by
inhibiting receptor activator of nuclear factor kappa B ligand (RANKL) activation of
its  receptor  RANK.  This  signalling  is  essential  for  the  maturation  of  osteoclast
progenitors  (Katagiri et  al. 2002),  thus  the  increased  bone  resorption  and
osteoporosis in its absence. OPG is endogenously expressed in the media of the
aorta  (Bucay et  al. 1998),  but  the  mechanisms  by  which  it  inhibits  vascular
calcification are  yet  unknown.  However,  increased  levels  of  serum  OPG were
observed in patients with vascular calcification and cardiovascular disease  (Collin-
Osdoby 2004) and polymorphisms in the OPG promoter have been associated with
intimal thickening of the common carotid artery, indicative of early atherosclerosis
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(Brandstrom et al. 2004).
Klotho deficient mice develop normally until 2 weeks of age and then exhibit
symptoms resembling accelerated ageing, including a short lifespan, infertility, skin
atrophy, osteoporosis and calcification of the aorta and other arteries, accompanied
by intimal thickening. In addition, ectopic calcification of various organs is observed
(Kuro-o et  al. 1997).  In  humans,  a  homozygous Klotho mutation causes tumoral
calcinosis,  which  manifests  itself  with carotid  and dural  artery  calcifications  and
ectopic calcifications of soft tissues  (Ichikawa et al. 2007). Klotho is a cofactor of
FGF23,  a  hormone  that  promotes  renal  phosphate  excretion  by  decreasing
phosphate reabsorption and reducing circulating vitamin D. Therefore its deficiency
results in symptoms produced by a disrupted mineral metabolism (Ichikawa et al.
2007). Decreased Klotho levels have been observed in calcified arteries showing its
important role in inhibiting vascular calcification (Lim et al. 2012).
ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1) is an enzyme
expressed in bone and cartilage on the surface of  cells,  that produces inorganic
pyrophosphate (PPi), a major inhibitor of calcification. ENPP1 deficient mice develop
calcification of  joints  and spine and arterial  calcification  (Okawa et  al. 1998).  In
humans  the  loss  of  ENPP1  causes  'idiopathic'  infantile  arterial  calcification,  a
syndrome characterised by calcification of the internal elastic lamina of arteries and
stenosis  due to intimal  thickening  (Rutsch et  al. 2003).  PPi  directly  inhibits  HAp
deposition and its levels are controlled by alkaline phosphatase (ALP), an enzyme
that catalyses its hydrolysis. It has been shown that in a rat renal failure model of
vascular calcification the activity of ALP is increased in the aorta  (Lomashvili et al.
2008), suggesting that increased PPi hydrolysis is a hallmark of calcification.
Smad6 belongs to the Smad family of proteins, which mediate intracellular
TGFβ superfamily signalling. It has been shown to be expressed predominantly in
the heart and blood vessels. Smad6 deficient mice develop heart defects and aortic
calcification (Galvin et al. 2000). Smad6 inhibits bone morphogenetic protein (BMP)
signalling, which is why the loss of inhibition results in soft tissue calcification in
Smad6 null mice. Because of its effect on mouse development Smad6 is a potential
calcification  inhibitor,  however  its  role  in  vascular  calcification  in  humans  is  not
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known.
Fibrillin-1  is  another  interesting  inhibitor  of  calcification.  It  is  an  ECM
glycoprotein  that  forms  elastic  microfibrills  in  blood  vessel  walls.  Mice  lacking
functional fibrillin-1 die within the ﬁrst 2 weeks after birth because of dissecting
aneurysms  and  rupture  of  the  ascending  aorta.  They  also  develop  vascular
calcifications  (Pereira et  al. 1997;  Ramirez et  al. 1999a).  In  humans  various
mutations  of  the fibrillin-1  gene result  in  Marfan  syndrome with a  spectrum of
skeletal  abnormalities  and  cardiovascular  defects  including  vascular  calcification
(Ramirez et  al. 1999b).  However,  the  role  of  fibrillin-1  in  vascular  calcification
induced by other factors is unknown.
Carbonic anhydrase II (CAII) is the most widespread of 13 isoforms of this
enzyme, which forms protons (H+) and bicarbonate ions (HCO3-) from CO2 and H2O
and thus contributes to the regulation of pH in body fluids. Mice with CAII deficiency
show calcification in small and medium arteries and arterioles (Spicer et al. 1989). In
humans,  mutations of  the CAII  gene are manifested as cerebral  calcification and
osteopetrosis (bones become denser, opposite to osteoporosis;  Shah et al. 2004).
These findings highlight the importance of pH in formation of calcified plaques, but
the exact role of CAII in vascular calcification in other contexts is unknown.
Bone morphogenetic protein 7 (BMP-7), a member or the TGFβ superfamily,
is  an example of  an inhibitor  of  vascular  calcification,  whose knock-out  in mice,
however,  does  not  have  a  vascular  or  soft  tissue  calcification  phenotype.  Mice
lacking BMP-7 show skeletal abnormalities, delayed ossiﬁcation of bones as well as
kidney and eye defects (Jena et al. 1997). Polymorphisms in the BMP-7 gene have
been  linked  to  inverse  relationships  between  bone  mineralization  and  vascular
calcification  in  the  coronary,  carotid,  and  abdominal  aorta  in  diabetes  patients
(Freedman et  al. 2009).  BMP-7  has  also  been  shown  to  play  a  role  in  VSMC
differentiation and maintaining of their differentiated phenotype  in vitro (Dorai et
al. 2000).  Moreover,  treatment with  BMP-7 prevented vascular  calcification in  a
mouse model  of  this  disease  (Davies et  al. 2005).  This  shows that not all  BMPs
favour calcification and that a balance in the signalling of these molecules results in
correct development.
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1.1.2.2. VSMC calcification is vesicle-mediated
VSMCs are the source of two distinct types of vesicles released to the ECM,
apoptotic bodies (ABs) and matrix vesicles (MVs), and both of these play important
roles in initiating vascular calcification (Kapustin and Shanahan 2012).
ABs are membrane-bound fragments of cells, that result from apoptotic cell
death. Through apoptosis the body disposes of damaged cells in a way that does not
elicit  an  inflammatory  response,  as  ABs  are  immediately  phagocytosed  by
macrophages  (Maiuri et al. 2007). Apoptosis has been shown to be important for
both physiological and pathological calcification. ABs have been shown to have HAp
crystal nucleating properties in cartilage (Hashimoto et al. 1998). It was shown later
that  in  VSMCs  cultured  in  vitro apoptosis  occurs  prior  to  the  onset  of  their
calcification and that ABs accumulate calcium and may be sites of crystal nucleation
(Proudfoot et al. 2000). These findings are confirmed by in vivo studies showing that
dialysis triggers VSMC apoptosis and thus accelerates vascular calcification (Shroff et
al. 2008). Apoptosis was also shown to accelerate plaque formation and induce its
calcification in a mouse model of atherosclerosis (Clarke et al. 2008). In addition to
that,  acetylated  low  density  lipoproteins  (acLDL),  which  are  potent  inducers  of
atherosclerosis,  have  been shown  to  induce  VSMC  calcification  by  inhibiting  AB
phagocytosis (Proudfoot et al. 2002).
MVs  are  small  (100nm  in  diameter)  extracellular  membranous  particles,
which  contrary  to  ABs,  are  released  by  living  cells.  They  play  a  crucial  role  in
regulating the mineralisation of ECM during bone growth at the growth plate, where
they are secreted by chondrocytes and initiate the first crystals of HAp  (Anderson
2003). It is now well recognised that MVs are very different from ABs, but they also
play an important regulatory role in vascular calcification. MVs have been shown to
mediate calcification of VSMCs treated with elevated concentrations of Ca and P in
vitro and  to  be  loaded  with  natural  calcification  inhibitors  fetuin-A  and  MGP
(Reynolds et al. 2004). This suggests that VSMCs secrete MVs to protect themselves
by discarding an excess Ca and P bound to calcification inhibitors, however if the
inhibitors  are  depleted,  they  nucleate  calcification.  In  vivo studies  confirm  the
presence of MVs in the ECM of healthy arteries and calcified MVs in the ECM of
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arteries from patients with atherosclerosis, diabetes and CKD (Kapustin et al. 2011).
In addition to VSMCs, macrophages have been proposed to be an alternative source
of MVs in the calcifying vessel wall (New et al. 2013).
Proteomic analysis of MVs secreted by VSMCs carried out by our laboratory
has shown that they contain various endoplasmic reticulum (ER)-resident proteins
(Kapustin et al. 2011) such as chaperones (Hsp70, Grp94, Grp78), various protein
disulphide  isomerases  (PDIA1,  PDIA3,  PDIA6),  calumenin  and  protein
glycosyltransferase  (DAD1)  and  that  their  levels  in  MVs  change  as  VSMCs  are
calcifying. This has provided the first hint that the ER might play a role in VSMC
calcification.
1.1.2.3. Osteogenic transdifferentiation of calcifying VSMCs
VSMC phenotypic plasticity
In contrast to other muscle cells VSMCs do not differentiate terminally and
show phenotypic plasticity. In physiological conditions in the vessel wall they exist as
contractile cells and regulate vascular tone. In response to stress and injury VSMCs
lose expression of contractility-related genes such as SM22α, calponin (CNN1), and
myosin light chain (MLC) (Frid et al. 1992; Huang et al. 1999; Feil et al. 2004). They
also proliferate,  migrate and secrete ECM related proteins,  and thus are able to
repair the injured vessel  (Shanahan et al. 1998; Shanahan et al. 1993). This is the
mechanism that leads to formation of a fibrous cap over an atherosclerotic plaque
(Dzau  et al. 2002). When vascular injury is persistent the phenotypic transition is
dysregulated and VSMCs can undergo an unfavourable transdifferentiation into cells
with characteristics of osteoblasts or chondrocytes (Iyemere et al. 2006; Shanahan
et al. 1999b; Speer et al. 2009). This observation led researchers to the idea that
vascular calcification is caused by pathological induction of a process similar to bone
formation, which normally only occurs during bone development in the embryo.
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VSMC osteogenic transdifferentiation and endochondral bone formation
During embryonic development bone formation occurs via two mechanisms:
endochondral and membranous. During membranous ossification, which gives rise
to flat bones of the skull, osteocytes differentiate directly from mesenchymal stem
cells (MSCs). During endochondral ossification, by which most bones in the body are
made, there is an intermediate step in which MSCs differentiate into chondrocytes
that proliferate and secrete extracellular matrix to form a scaffold for osteoblasts
(Karsenty et al. 2009). Chondrocytes also secrete MVs that later initiate calcification
of  the  ECM  (Anderson  2003).  Then  they  become  hypertrophic  and  direct
perichondral cells to differentiate into osteoblasts (Karsenty et al. 2009; Michigami
2013), and finally undergo apoptosis. All stages of endochondral bone formation can
be found in calcified lesions, including fully formed trabecular bone, and markers
characteristic  for  both  osteoblasts  and  chondrocytes  have  been  found  to  be
expressed by calcifying VSMCs (Qiao et al 2003; Neven et al. 2007; Speer et al. 2009,
Sage et al. 2010).
Chondrocyte  and  osteoblast  proliferation  and  maturation  during
endochondral  bone formation is regulated by a tightly orchestrated transcription
programme activated in MSCs, mediated by secreted factors such TGFβ, Ihh (Indian
hedgehog), PTHrP (parathyroid hormone-related protein),  FGFs (fibroblast growth
factors), BMPs (bone morphogenetic proteins), Wnts and IGFs (insulin-like growth
factors).  Several  key transcription factors act downstream of these pathways and
regulate expression of ECM genes in chondrocytes and osteoblasts. Among these
are Sox9, Runx2 (Cbfa1), Osterix, Dlx5, Msx2, β-catenin Twist-1 and Twist-2, which
regulate transcription of various bone ECM such as collagens, cartilage oligomeric
matrix  protein  (COMP),  bone  sialoprotein  (BSP),  osteocalcin  (OCN)  and  other
regulatory bone proteins such as ALP and osteoprotegerin (OPG), thus leading to
maturation of osteoblasts, mineralisation and bone formation (Karsenty et al. 2009).
Here I  will  discuss  in  more detail  some of  these factors,  that  were found to be
relevant to vascular calcification and are relevant to this project (Figure 1.2).
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Figure 1.2. Factors involved in bone formation during embryonic development, which are relevant for
vascular calcification.
BMP-2,  a  cytokine that  belongs  to the TGFβ superfamily,  regulates  organ
formation during embryonic development.  The knock-out of BMP-2 is embryonic
lethal, with the mice not surviving 10 days of gestation due to heart defects (Zhang
and Bradley  1996).  In  later  stages  of  embryonic  development  BMP-2  is  also  an
important  regulator  of  osteoblast  maturation;  MSCs  treated  with  BMP-2
differentiate into osteoblasts (Nishimura et al. 1998; Chen  et al. 2012). BMP-2, as
well as other members of the TGFβ superfamily, binds to its respective cell surface
receptors, which transduce the signal to the cytoplasm by phosphorylating signalling
molecules called SMADs (Liu et al. 1996). These act by activating target transcription
factors.  BMP-2 is  an established inducer of  VSMC osteogenic  transdifferentiation
and calcification  in vitro  (Li et al. 2008; Nakagawa et al. 2010).  In vivo it has been
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shown  to  be  expressed  in  human  calcified  aortas  and  not  in  healthy  vessels
(Bostrom et al. 1993; Kaden et al. 2004) and to accelerate plaque calcification in a
mouse model of atherosclerosis (Nakagawa et al. 2010). However, BMP-2 has also
been  shown  to  be  expressed  in  the  aorta  during  embryonic  development  and
promote neural crest stem cells to differentiate into smooth muscle cells (Shah et al.
1996), therefore its role in vascular calcification might not be as definite as studies
suggest. 
TGFβ1  is  a  cytokine  with  an  established  role  in  regulating  chondrocyte
growth by inhibiting their hypertrophy and maintaining expression of ECM proteins
(Ballock et al. 1993). This effect appears to be partly mediated by induction of PTHrP
expression (see below). TGFβ1 has also been shown to induce physiological death of
chondrocytes  crucial  for  bone  mineralisation  (Mackie  et  al. 2008).  In  VSMCs
cultured in vitro TGFβ1 promotes contractile differentiation (Shah et al 1996; Hirschi
et al. 1998). However, it has also been shown to induce osteogenic gene expression
(Simionescu et al. 2005, Liu et al. 2014) and to be present at high levels in calcified
human aortas (Jian et al. 2003). This suggests that similar to BMP-2, the role of this
cytokine in vascular calcification and modulation of VSMC phenotype is not clear.
Ihh  and  PTHrP  play  complementary  roles  during  endochondral  bone
formation. Ihh promotes chondrocyte hypertrophy and maturation of osteoblasts,
while  PTHrP  promotes  chondrocyte  proliferation  and  delays  hypertrophy
(Kronenberg  2003;  Nakashima et  al. 2003).  The role  of  Ihh  in  VSMC osteogenic
transdifferentiation is still unknown. PTHrP has been shown to inhibit bovine VSMC
calcification  (Jono  et  al. 1997).  However,  another  study  has  shown  that  it  can
increase expression of osteogenic genes BMP-2 and Runx2 in human VSMCs (Liu et
al. 2012)
Wnts  are  secreted,  lipid-modified  glycoproteins  that  activate  cell  surface
receptor-mediated  signal  transduction  pathways  to  regulate  a  variety  of  cellular
activities,  including  cell  fate  determination,  proliferation,  migration,  polarity,  and
gene expression. The canonical Wnt signaling pathway, where Wnts interact with
Lrp/Fzd  receptor  complexes  to  inhibit  β-catenin  degradation,  promotes  the
proliferation, expansion and survival of osteoblasts. β-catenin is essential for skeletal
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development, null murine embryos died after 7 days of gestation. Specific depletion
of β-catenin in osteoblasts caused a low bone mass phenotype in mice (Westendorf
et  al. 2004).  There  is  some  evidence  that  Wnt3a  and  Wnt7a  signalling  via  the
canonical  pathways  is  involved  in  regulation  of  mouse  VSMC  calcification  by
osteogenic  transcription  factor  Msx2  (Shao  et  al. 2005).  Wnt5a  has  also  been
implicated in promoting VSMC calcification, and is inhibited by PPARγ (Woldt et al.
2005).  In  addition,  another  study  has  shown  that  TGFβ1  upregulates  β-catenin
expression and thus promotes calcification of rat  VSMCs (Liu  et al. 2014).  These
studies show that the Wnt signalling pathway is a regulator of vascular calcification.
An important aspect of bone formation is its regulation by osteoblst- and
chondrocyte-specific transcription factors which are expressed at various stages of
maturation of these cells. Some of these transcription factors have also been shown
to be expressed in calcified aortas and have been hypothesized to regulate VSMC
calcification.
Sox9  is  the  main  transcription  factor  associated  with  regulating
chondrogenesis, essential for its early stages. Sox9 drives transcription of cartilage
matrix proteins such as type 10 and type 2 collagen, aggrecan and COMP (Bi et al.
1999; Liu et al. 2007; Nishimura et al. 2012). Sox9 mutations cause skeletal dysplasia
and XY  sex  reversal,  which  reflects  the  fact  that  apart  from skeletogenesis  it  is
required for the formation of other organs, such as testis (Akiyama 2008). Sox9 has
been  shown  to  regulate  VSMC  chondrogenic  transdifferentiation  by  suppressing
expression of smooth muscle cell markers and activating expression of chondrogenic
markers (Xu et al. 2012; Neven et al. 2007; Neven et al. 2010). Sox9 has been shown
to be expressed in calcified human aortas (Tyson et al. 2003).
Runx2 knock-out mice die just after birth and their skeletons show complete
lack  of  mineralisation  (Komori et  al. 1997).  Runx2,  whose transcriptional  targets
include OCN, BSP, osteopontin (OPN) and Ihh, is essential for osteoblast maturation
as well as chondrocyte hypertrophy (Nishimura et al. 2012). Runx2 has been shown
to be important for VSMC osteogenic transdifferentiation, as it drives expression of
osteogenic  genes  (Speer et  al. 2010) and it  has been shown to be expressed in
calcified blood vessels (Tyson et al. 2003). More recently its crucial role in regulating
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vascular calcification has been demonstrated in a VSMC-specific knock-out mouse
model.  The  mice  exhibited  decreased  calcification  compared  to  wild  type
counterparts,  when  fed  a  high  fat  diet.  Decreased  RANKL  expression  and
macrophage  infiltration  into  the  calcified  lesions  was  observed  in  aortas  of  the
knock-out mice, as well as decreased expression of ALP (Sun et al. 2012).
Dlx5 is a transcription factor that belongs to the distal-less, homeodomain-
containing  family  of  transcription  factors.  Dlx5-knockout  mice  have  craniofacial
abnormalities  with  a  delayed  cranial  ossification  and  abnormal  osteogenesis
(Acampora et  al. 1999).  It  has  been shown to  regulate  expression  of  Osterix  in
osteoblasts (Lee et al. 2003; Ulsamer et al. 2008). The involvement of Dlx5 in VSMC
calcification is not yet known.
Msx2,  a  homeobox  gene,  is  a  mammalian  homologue  of  the  Drosophila
muscle  segment homeobox.  Msx2-deficient  mice  show reduced bone formation,
abnormal calvarial development, and defects in the ectodermal organs including the
teeth, hair, and mammary glands (Ichida et al. 2004). The bone phenotype is caused
by impaired chondrocyte hypertrophy as well as osteoblast maturation. Msx2 has
been shown to promote VSMCs calcification by activating the Wnt pathway (Shao et
al. 2005). It has been shown to mediate TNFα-induced ALP expression in human
VSMCs (Lee et al. 2010) and oxidised LDL-induced Osterix and ALP expression and
calcification of bovine VSMCs (Taylor et al. 2011).
Osterix (Osx, SP7), a zinc-finger containing transcription factor from the SP1
family, is expressed in MSCs and osteoblasts and is essential for extracellular matrix
deposition, osteoblast maturation and bone formation; in Osterix null mice no bone
formation  occurs  (Nakashima et  al. 2002).  Osterix  was  shown  to  act  both
downstream of Runx2 and independently of Runx2 (Lee et al. 2003; Matsubara et
al. 2008). It has also been demonstrated to act downstream of both Dlx5 and Msx2
in osteoblasts  (Matsubara et al. 2008; Ulsamer et al. 2008). Interestingly,  Osterix
inhibits the Wnt/β-catenin pathway in osteoblasts, forming a negative feedback loop
mechanism regulating mineralisation (Zhang et al 2008). Osterix was shown to be
expressed  in  calcified  human  coronary  arteries  alongside  other  bone  markers
(Alexopoulos et al. 2011). Recently three studies have been published shedding light
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on the function of Osterix in VSMCs. The first one shows that upon oxidised LDL
treatment bovine VSMCs undergo an osteogenic transdifferentiation, during which
Osterix is upregulated in an Msx2-dependent manner (Taylor et al. 2011). Another
study shows that Osterix is upregulated in rat VSMCs upon treatment with vitamin
D, a known inducer of calcification (Zebger-Gong et al. 2011). In addition, a miRNA,
miR-125b,  which  targets  Osterix  in  human  VSMCs  undergoing  osteogenic
transdifferentiation has been identified  (Goettsch et  al. 2011).  Inhibition of  miR-
125b was shown to increase calcification of human coronary artery VSMCs, which
was accompanied by increased ALP activity and expression of Runx2. These findings
show  that  Osterix  plays  a  role  in  VSMC  osteogenic  transdifferentiation  and
calcification, but there is poor understanding of what its transcriptional targets and
exact functions in those cells are.
An important  group of  bone formation regulators  are  the Twist  proteins,
Twist-1 and Twist-2. Twist-1 has long been known to be implicated in skeletogenesis
because  haploinsufficiency  at  its  locus  causes  Saethre-Chatzen  syndrome,  which
manifests  with an increase in  bone formation in the skull  (Howard  et  al. 1997).
Twist-1  in  the  skull  and  Twist-2  in  the  appendicular  skeleton  inhibit  osteoblast
differentiation early during skeletogenesis, by interacting with Runx2 and preventing
it  from  binding  to  the  OCN  promoter  (Yousfi  et  al. 2002;  Bialek  et  al. 2004).
Expression of the Twist genes decreases later during embryogenesis and osteoblast
differentiation  can  proceed.  Twist-1  also  inhibits  Runx2  function  in  the
perichondrium and thus controls chondrocyte maturation (Bialek et al. 2004). Twist-
1 has also been shown to negatively regulate Runx2 activity in valvular interstitial
cells  from  calcified  human  aortic  valves  and  decreased  their  osteogenic
differentiation (Zhang et al. 2014).
It  has  recently  emerged  that  for  both  osteoblasts  and  chondrocytes  to
secrete ECM, mature and form bones efficiently ER stress and the unfolded protein
response signalling are essential. This together with the proteomic analysis of MV
data in our laboratory provided evidence for a potential role of ER stress in vascular
calcification.
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1.1.3. Stresses that induce vascular calcification
Further  evidence  supporting  the  idea  that  ER  stress  could  play  a  role  in
vascular  calcification  comes  from the  fact  that  various  factors  that  cause  VSMC
calcification  in vitro and vascular calcification  in vivo have already been shown to
induce or  reduce ER stress  in  other  cell  types  and tissues.  A list  of  calcification
inducers and what is known about their ability to induce ER stress is presented in
Table  1.3 below.  Many  of  these  factors  are  associated  with  diseases  known  to
aggravate  vascular  calcification  such  as  atherosclerosis  (LDLs,  inflammation,
oxidative  stress,  cholesterol),  CKD (high calcium and phosphate,  oxidative  stress,
vitamin D, warfarin) or diabetes (AGEs, oxidative stress, inflammation).
Table 1.3. Inducers of vascular calcification and what is known about their ability to modulate ER























? (Ren et al. 2009)
(Wang et al. 2012a)
(Yin et al. 2012)
(Rasheed et al. 2012)
(Tanaka et al. 2013)
(Yamabe et al. 2013)
(Wu et al. 2014)
BMP-2 + + +
osteoblasts
VSMCs
? (Kaden et al. 2004)
(Li et al. 2008)
(Murakami et al. 2009)
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(Miller et al. 2008)
(Byon et al. 2008)
(Kaneto et al. 2005)
(Cao et al. 2014)
Shear stress
(hypertension)
? + ? +
mouse aortas
(Kalra et al. 2012)
(Kassan et al. 2012)
Stearate + ? +
mouse VSMCs
? (Ting et al. 2011)
(Masuda et al. 2012)
TGFβ + + +
lung fibroblasts
? (Watson et al. 1994)
(Jian et al. 2003)
(Simionescu et al.
2005)
(Baek et al. 2012)
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(Kim et al. 2014)
1.2. Endoplasmic reticulum stress and the unfolded protein response
The ER is the first organelle of the secretory pathway, where most secreted
and transmembrane proteins  are folded and mature.  ER stress occurs when the
influx of unfolded proteins to the ER exceeds its capacity to fold them. It results in
activation of a signalling pathway called the unfolded protein response (UPR) (Ron
and  Walter,  2007;  Walter  and  Ron,  2011).  ER  stress  and  the  UPR  can  also  be
activated by disturbances in calcium homeostasis  as storing Ca2+ is  an important
function of the ER. Ca2+ is required for the maintenance of protein synthesis as the
majority of the ER resident chaperones (for example calreticulin) are Ca2+ -binding
proteins. Therefore, fluctuations of the levels of Ca2+ in the ER can severely impact
folding capacity (Gorlach et al. 2006).
There  are  three  proteins  responsible  for  sensing  an  increased  load  of
unfolded  proteins  in  the  ER,  which  define  three  branches  of  the  UPR:  inositol-
requiring protein-1 (IRE1), activating transcription factor-6 (ATF6) and protein kinase
RNA (PKR)-like ER kinase (PERK).  These transmembrane proteins,  which have ER
luminal and cytosolic domains, are called ER stress transducers as upon sensing ER
stress they transmit the signal  from the ER to downstream effectors  (Figure 1.3)
(Ron and Walter, 2007; Walter and Ron, 2011).
The first ER stress transducer ever to be described is IRE1. Upon unfolded
protein accumulation it  oligomerizes and undergoes autophosphorylation  (Shamu
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et al. 1996). This activates its effector function, which is cleavage of only one known
substrate, XBP1 mRNA. This splicing of XBP1 causes a frameshift and results in a
completely different protein being translated (Yoshida et al. 2001). The spliced XBP1
is more stable and acts as a transcription activator for UPR regulated genes (Calfon
et al. 2002; Yoshida et al. 2001). The protein resulting from unspliced XBP1 mRNA is
unstable and represses UPR target genes (Calfon  et al. 2002). The XBP1 branch of
the  UPR  has  a  role  in  regulating  lipid  biosynthetic  enzymes  and  ER-associated
degradation components, as well as ER biogenesis (Walter and Ron, 2011). It has
also been shown that, apart from splicing XBP1, IRE1 can mediate RIDD (regulated
IRE1-dependent  decay),  whereby  ER-localised  mRNAs  are  degraded  to  limit  the
number  of  newly  synthesized  proteins  and  decrease  the  protein  load  in  the  ER
(Hollien and Weissman, 2006).
The  second  branch  of  the  UPR  is  represented  by  ATF6.  When  unfolded
proteins accumulate in the ER, its Golgi localisation sequences are revealed and it is
translocated to this organelle. In the Golgi ATF6 is processed by site 1 and site 2
proteases, which cleave off the ER luminal and transmembrane domains (Haze  et al.
1999). The resulting cytosolic fragment, which has DNA binding activity, moves to
the  nucleus  and  is  a  transcription  factor  that  activates  transcription  of  UPR-
regulated genes, for example XBP1, Grp78 and Grp94 chaperones (78kDa and 94kDa
glucose regulated proteins) and PDI (protein disulphide isomerase; Haze et al. 1999;
Yoshida et al. 2001).
The third branch of the UPR is mediated by PERK (also known as eukaryotic
initiation  factor  2-alpha  kinase,  3EIF2AK3).  Similar  to  IRE1  it  undergoes
oligomerisation and autophosphorylation upon accumulation of unfolded proteins
in the ER  (Harding et  al. 1999).  However,  unlike IRE1,  PERK also phosphorylates
eukaryotic translation initiation factor 2α (eIF2α). This results in lower translation
initiation levels and decreased flux of new proteins into the ER (Harding et al. 2000).
Some transcripts involved in the UPR are able to avoid this translational block and
are preferentially  translated when eIF2α is limiting,  due to short upstream open
reading frames in their 5' untranslated regions. An example of such a gene is ATF4, a
transcription  factor  that  is  translationally  induced  by  phosphorylation  of  eIF2α
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(Vattem et al. 2004). Another two are CHOP (transcription factor C/EBP homologous



























Figure 1.3. ER stress caused by accumulation of unfolded proteins triggers the UPR, which consists of
three  branches  mediated  by  IRE1,  PERK  and  ATF6,  which  transduce  the  ER  stress  signal  to  the
nucleus. This results in transcription of genes whose products help resolve ER stress.
Activation of all three branches of the UPR results in a decrease in protein
influx to the ER and expression of various genes that help cope with an increased
load  of  unfolded  proteins,  such  as  mentioned  before  chaperones  (for  example
Grp78 and Grp94; Kozutsumi et al. 1988; Luo et al. 2003), PDIs and genes involved in
phospholipid  synthesis  and  ER  biogenesis  (Sriburi et  al. 2004),  which  leads  to
expansion of the ER and its protein folding capacity. Another mechanism activated
in order to cope with an overabundance of unfolded proteins is ERAD (ER-associated
degradation).  In  this  process  misfolded  proteins  are  retrotranslocated  to  the
cytoplasm  and  degraded  by  the  the  proteasome  (Travers et  al. 2000).  Large
aggregates of severely unfolded proteins that are difficult to degrade via ERAD can
also be disposed of via autophagy, which has been shown to be activated during ER
stress (Deegan et al. 2013). However, if ER stress is too overwhelming and cannot be
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resolved it may lead to cell death (Sano and Reed, 2013).
Apoptosis is activated by ER stress via several mechanisms (Szegzedi  et al.
2006; Sano and Reed, 2013). First of all,  IRE1α activates TRAF2 (tumour necrosis
factor  receptor  associated  factor  2)  which  activates  apoptotic-signaling  kinase-1
(ASK1), causing activation downstream of stress kinases Jun-N-terminal kinase (JNK)
and p38 MAPK (mitogen-activated protein kinase), that promote apoptosis (Urano
et al. 2000). Among the apoptosis-inducing substrates of JNK are anti-apoptotic Bcl-
2 and pro-apoptotic Bim, which are inhibited and activated,  respectively,  by JNK
phosphorylation. In addition to IRE1, the ER stress-specific transcription factor CHOP
has been implicated in ER-stress induced apoptosis  (Zinszner  et  al. 1998).  CHOP
expression can be activated by all  three UPR branches. It increases expression of
pro-apoptotic  Bim  and  DR5,  while  decreasing  expression  of  anti-apoptotic  Bcl-2
(Yamaguchi and Wang, 2004; Sano and Reed, 2013). Finally, ER stress can mediate
cell death by disturbance in its calcium metabolism; Bax and Bak have been shown
to  regulate  Ca2+  release  from  the  ER  upon  ER  stress  (Scorrano  et  al. 2013).  All
upstream signals,  such as the activation of transcription factors,  kinase pathways
and the regulation of Bcl-2 family members, ultimately lead to caspase activation,
resulting in the ordered and sequential dismantling of the cell. Caspase 12 has been
proposed as a key mediator of ER stress-induced apoptosis (Nakagawa et al. 2000),
however this caspase is expressed only in rodents; its human homologue has been
silenced by several  mutations during evolution.  Caspase 4 has been proposed to
fulfil the function of caspase 12 in humans (Hitomi  et al. 2004), but this is under
debate, since it has been shown that apoptosis can be induced by ER stress without
its activation (Obeng and Boise, 2005).  
ER stress has been shown to be essential for many physiological processes,
especially those involving professional secretory cells (Moore and Hollien, 2012). For
example differentiation of B cells into plasma cells  (Reimold et al. 2001) or insulin
secretion by pancreatic β-cells (Harding et al. 2001) are associated with increases of
protein folding demand that activate the UPR. However, ER stress has been also
implicated in many pathological processes such as viral infections  (Dimcheff et al.
2003) and atherosclerosis (Minamino et al. 2012).
39
1.3. Unfolded protein response regulates bone formation
When bone formation occurs  during embryonic  development,  osteoblasts
and chondrocytes need to secrete large amounts of ECM and regulatory proteins. It
has been well documented, that in order to cope with the high demand of protein
synthesis  and  secretion  osteoblasts  and  chondrocytes  employ  UPR  signalling
(Tohmonda et al. 2011; Tsang et al. 2010) and the UPR has been shown to activate
transcription of some bone specific genes.
The first hint that ER stress is involved in bone formation comes from a study
which showed that XBP1 was highly expressed in developing skeletons of mouse
embryos using in situ hybridisation. XBP1 was found to be expressed in osteoblasts
forming bones via intramembranous bone formation and chondroblasts, which take
part in the process of endochondral bone formation (Clauss et al. 1993). It was later
shown that XBP1 mRNA expression can be induced by BMP-2 via IRE1 and that IRE1
and XBP1 are required for maturation of preosteoblasts to osteoblasts. XBP1 directly
activated the promoter of Osterix, a key osteogenic transcription factor (Tohmonda
et  al. 2011).  Moreover,  XBP1  has  been  implicated  in  hypertrophic  chondrocyte
differentiation.  It  was  shown  to  be  a  transcription  target  of  ATF6  in  BMP-2
stimulated  chondrocytes  and  to  form  a  complex  with  Runx2.  Cells  in  which
expression of XBP1 was abolished did not express Ihh and expressed low levels of
chondrocytic collagen types 2 and 10, which showed that their differentiation was
impaired (Liu et al. 2012). Another study has shown that transcription of parathyroid
hormone (PTH)/PTH-related peptide receptor (PTH1R) was regulated by the IRE1-
XBP1 pathway in osteoblasts (Tohmonda et al. 2013). In addition, overexpression of
IRE1 was shown to inhibit differentiation of chondrocytes and enhance expression
of PTHrP, which promoted their undifferentiated, proliferating phenotype (Guo  et
al. 2014a).
It has also been demonstrated that BMP-2 can upregulate IRE1, XBP1, CHOP,
PERK,  ATF4  and  ATF6  expression  (Tohmonda et  al. 2011;  Han  et  al. 2013).  The
findings about ATF6 were confirmed in a different study, which showed that BMP-2
activated  Runx2  expression  in  mouse  preosteoblasts,  which  in  turn  activated
transcription of ATF6. It was also shown that ATF6 directly induced transcription of
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OCN (Jang et al. 2011) and XBP1 (Guo et al. 2014b).
The most evidence about the involvement of ER stress in bone formation
comes  from studies  of  the  PERK-ATF4  branch of  the UPR.  PERK knock-out  mice
exhibited  skeletal  dysplasias  at  birth  and  postnatal  growth  retardation.  Skeletal
defects  included  deficient  mineralization,  osteoporosis,  and  abnormal  bone
development  (Zhang et al. 2002). Their osteoblast proliferation and differentiation
was delayed, which was associated with decreased expression of Runx2 and Osterix.
Also,  mineralisation  was  reduced  and  defects  of  the  ER  were  present  due  to
accumulation  of  procollagen.  Interestingly,  ATF4  levels  in  these osteoblasts  were
normal, suggesting the presence of other factors downstream of PERK that regulate
osteoblast  maturation  (Wei et  al. 2008).  However,  Saito  et  al. placed  ATF4
downstream of PERK in osteoblasts showing that knock-outs of these two genes
have the same effects on bone formation. They have also shown that this branch of
UPR  can  be  induced  by  BMP-2  in  osteoblasts  and  confirmed  that  this  drives
osteoblast  differentiation  (Saito et  al. 2011).  Upregulation  of  PERK  has  been
observed in spinal ligament fibroblasts of patients with ossification of the posterior
longitudinal ligament (Chen  et al. 2014). In addition, the PERK-ATF4 pathway was
demonstrated to be crucial  for  transdifferentiation of  myoblasts  into osteoblasts
(Tanaka  et  al. 2014).  This  suggests  that  aberrant  activation  of  these  signalling
pathways could lead to VSMCs assuming an osteo/chondrogenic phenotype.
The role of ATF4 in bone formation was confirmed in another study which
demonstrated that ATF4-deficient mice exhibited a reduction in bone volume and
they  failed  to  ever  achieve  normal  bone  mass.  This  was  because  ATF4  directly
activates  transcription  of  OCN.  What  is  more,  ATF4  is  involved  in  amino  acid
metabolism, so its absence resulted in insufficient amino acid availability for protein
synthesis further disrupting normal bone formation (Yang et al. 2004b). The bones
of  mice  lacking  ATF4  have  also  been  shown  to  be  less  tough  and  more  brittle
compared to those of their wild type conterparts (Makowski et al. 2014). ATF4 has
also  been  shown  to  activate  the  transcription  of  Ihh,  a  cytokine  that  regulates
chondrocyte proliferation in the growth plate  (Wang et al. 2009). Ihh secreted by
chondrocytes due to ATF4 activation has been shown to also have a paracrine effect
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on osteoblasts and contribute to their differentiation (Wang et al. 2012). ATF4 has
also been shown to regulate the expression of β-catenin and form complexes with
this  transcription  factor  in  pre-osteoblasts  (Yu  et  al. 2013).  In  addition,  ATF4
transcriptional  activity has been demonstrated to be regulated in osteoblasts by
Twist-1, an important regulator of Runx2 activity (Dnaciu et al. 2102). Importantly,
ATF4 is not detectable in any other adult tissues except bone, eye and cartilage, but
it can induce the expression of OCN in non-osteoblast cell types (Yang et al. 2004a),
suggesting  that  pathological  activation  of  ATF4  in  tissues  other  than  those
mentioned could cause calcification.
CHOP,  the  main  mediator  or  ER-stress  induced  apoptosis  has  also  been
implicated in bone formation and metabolism in recent studies. CHOP knock-out in
a  pseudoachondroplasia  mouse  model  decreased  chondrocyte  apoptosis  and
aggravated  the  bone  malformation  phenotype,  suggesting  that  CHOP-mediated
apoptosis is important for normal bone formation (Pirog  et al. 2014). In addition,
the UPR, and specifically CHOP, have been shown to play a role in response to injury
and inflammation in osteoarthritic cartilage, where they mediate pro-inflammatory
signals in chondrocytes (Husa et al. 2013).
In  addition  to  the  canonical  ER  stress  transducers,  two  tissue-specific  ER
stress  transducers,  OASIS  and  BBF2H7,  have  been  shown  to  be  involved  in
osteoblast and chondrocyte maturation respectively (Murakami et al. 2009; Saito et
al. 2009). Both of these transcription factors belong to the CREB/ATF family, have a
bZIP (basic leucine zipper) and a transmembrane domain and are ATF6 homologues
(Murakami et al. 2009).
OASIS was first discovered in astrocytes, and not until an in situ hybridisation
experiment  in  mouse  embryos  was  performed  was  its  role  in  bone  formation
revealed.  In  mouse  embryos  OASIS  expression  was  shown  to  overlap  with
expression of osteogenic markers such as osteonectin, type 1 collagen and OPN,
suggesting that it played a role in bone development (Nikaido et al. 2001). A later
study confirmed that the function of OASIS is osteoblast specific, as OASIS deficient
mice exhibited severe osteopenia,  involving a decrease in type 1 collagen in the
bone matrix and a decline in the activity of osteoblasts. That is explained by the fact
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that  OASIS  activates  the  transcription  of  COL1A1  through  an  unfolded  protein
response  element  (UPRE)-like  sequence  in  its  promoter  region.  Moreover,
expression  of  OASIS  and  mild  ER  stress  was  induced  in  osteoblasts  by  BMP-2
(Murakami et al. 2009, Murakami et al. 2010). Mutations in OASIS in humans have
been linked to severe recessive osteogenesis imprefecta, a genetic condition where
bones are brittle and fail to mineralise properly (Symoens et al. 2013).
BBF2H7  is,  like  OASIS,  another  member  of  the  CREB/ATF  family  of
transcription factors  (Kondo et al. 2007). BBF2H7 knock-out mice displayed severe
chondrodysplasia and suffocated shortly after birth. The cartilage of these mice had
disrupted  structure  and  the  chondrocytes  had  abnormally  enlarged  ER  with
accumulated ECM proteins inside,  therefore it  was concluded that this  ER stress
transducer  is  chondrocyte-specific.  It  was  shown  that  upon  ER  stress  induction
BBF2H7  was  activated  by  cleavage  similarly  to  ATF6  and  OASIS  and  activated
transcription of Sec23a, a component of the protein coat of secretory COPII vesicles.
In the absence of  BBF2H7 chondrocytes could not secrete ECM, which impaired
cartilage  formation.  It  was  also  shown  that  Sox9,  the  main  chondrogenic
transcription factor, can induce mild ER stress in chondrocytes and activate BBF2H7
(Saito et al. 2009). A later study by the same group has demonstrated that Sox9
directly regulated transcription of BBF2H7 by binding to its promoter (Hino  et al.
2014). In addition to that BBF2H7 was found to control chondrocyte maturation via
another mechanism, by inhibiting ER-stress induced apoptosis via ATF5 and MCL1
(Izumi et al. 2012).
Finally, the chaperone protein Grp78 (BiP, hspa5, DnaK) has been shown to
be involved in ECM mineralisation. GRP78 is a member of the heat shock protein 70
family. Its primary function is to act as a molecular chaperone in the ER and facilitate
proper protein folding.  However, It has been shown to be expressed and secreted
by osteoblasts; Grp78 also localised on the surface of these cells. It has been shown
to  bind  collagen  type  1  and  nucleate  calcium  and  phosphate  crystals  in  vitro,
suggesting that it plays a role in bone ECM mineralisation (Ravindran et al. 2011). In
a follow-up study the same group has shown that Grp78 expression is increased
during embryonic development in condensing cartilage and MSCs of the alveolar
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bone, endochondral bone and dental pulp, further supporting its important role in
bone formation (Ravindran et al. 2012).
It is evident that ER stress signalling via the canonical ER stress pathways as
well as tissue-specific ER stress transducers plays a major role in bone formation.
The  signalling  pathways  that  link  the  UPR  with  bone  formation  have  been




















Figure 1.4. UPR regulation of bone formation signalling. BMP-2 signalling has been shown to activate
all three branches of the canonical unfolded protein response in osteoblasts as well as OASIS. The
pathway  that  begins  with  Sox9  represents  chondrocyte-specific  signalling.  Blue  –  ER  stress
transducers; grey – other components of the UPR; red – osteogenic transcription factors; yellow –
mineralisation  regulating  proteins;  green  –  components  of  the  Ihh/PTHrP  pathways  regulating
chondrocyte maturation.
1.4. Endoplasmic reticulum stress in VSMCs and vascular calcification
Because ER stress and the unfolded protein response play an important role
during bone formation and calcification of VSMCs resembles osteoblast maturation I
hypothesised  that  ER  stress  plays  a  role  in  vascular  calcification.  This  idea  is
supported by recently published studies. 
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It  has been shown that vascular calcification induced in rats with nicotine
and  vitamin  D  is  accompanied  by  upregulation  of  Grp78  and  Grp94  chaperone
expression in the aorta, which is indicative of ER stress (Duan et al. 2009). Moreover,
markers  of  ER  stress-induced  apoptosis,  CHOP  and  caspase  12  were  also
upregulated in those aortas. A more recent study from the same lab has shown that
ATF4 was a mediator of ER stress-induced calcification, both in the rat model in vivo
and in rat VSMCs in vitro (Duan et al. 2013). They also demonstrated that changes in
calcification  and  ER  stress  markers  correlated  with  osteogenic  gene  expression
(OPN, ALP, Runx2).
The next line of evidence comes from a study which shows that in human
coronary artery vascular smooth muscle cells (HCASMCs) BMP-2-mediated oxidative
stress  increased  ER  stress,  demonstrated  by  increased  expression  of  GRP78,
phospho-IRE1  and  XBP1  (Liberman et  al. 2011).  An  increase  in  NADPH  oxidase
activity and oxidative stress occurred via activation of the BMP-2 receptor 2 and
Smad1 signalling. This study also showed that XBP1 binds to the Runx2 promoter in
BMP-2-treated HCASMCs. Inhibition of oxidative stress or ER stress decreased Runx2
expression,  intracellular  calcium deposition,  and mineralization  of  BMP-2-treated
HCSMCs.
It  has also been shown that in a mouse VSMC line MOVAS-1, stearate (a
saturated  fatty  acid)  induced  calcification  and  ER  stress  (Masuda et  al. 2012).
Stearate  induced  ATF4  mRNA  and  protein  expression  through  activation  of  the
PERK-eIF2α pathway.  It  also  increased CHOP expression  and XBP1 splicing.  ATF4
knock-down blocked osteogenic differentiation (assessed by measurements of OCN
and phosphate transporter Pit-1 mRNA) and mineralization induced by stearate. The
same lab has shown that TNFα induced calcification of MOVAS-1 cells by activating
the PERK-ATF4-CHOP branch of the UPR. They also presented evidence that this
pathway was activated in aortas of  mice with CKD induced by 5/6 nephrectomy
(Masuda et al. 2013).
In  addition  to  these  studies,  several  others  point  to  the  role  of  UPR
components  in  vascular  disease  and  calcification.  CHOP  has  been  found  to  be
upregulated  by  cyclic  stretch  in  rat  VSMCs,  suggesting  that  hypertension  might
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induce ER stress (Cheng et al. 2008). An in vivo study in mice reported that inducing
ER stress resulted in hypertension (Liang et al. 2013) suggesting that there might be
a positive feedback loop mechanism regarding VSMC contractility and phenotype
under mechanical stress. 
Furthermore,  a  study in mouse VSMCs lacking the ENPP1 enzyme, which
synthesizes  pyrophosphate,  a  natural  calcification  inhibitor,  showed  that  the
absence of CHOP in these conditions increased calcification (Serrano  et al. 2014).
These results suggest that in these conditions CHOP protects cells from calcification.
The  studies  described  above  show  that  ER  stress  accompanies  vascular
calcification  induced  by  various  means  in  vivo and  that  it  can  increase  VSMC
mineralisation in  vitro  (Figure 1.5).  However,  these findings  are very limited and
therefore there remains a lack of definitive evidence that would explain what causes
ER stress in vivo and whether it is activated in human calcified aortas. It is unclear
via what mechanisms the factors mentioned in these studies induce ER stress. In
addition, they did not explain how activation of UPR signalling lead to calcification of
VSMCs, apart from increased apoptosis and potential activation of Runx2 expression
by XBP1. A very limited number of osteogenic genes was examined in each of these
reports, hardly allowing any conclusions as to osteogenic transdifferentiation and
phenotype of VSMCs to be made. Each of these studies focused on one branch of
the UPR, not reporting whether others are activated and lead to the same results.
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Figure 1.5. ER stress and the UPR in VSMC calcification (references in the text). Several factors that
activate ER stress in vitro or in rodent models of calcification have been identified. It is still unclear
































Vascular calcification is a regulated, VSMC-mediated process, however the
exact  molecular  events  that  lead  to  vascular  calcification  are  unknown.  The
resemblance of vascular calcification to bone formation lead to the hypothesis that
ER stress  could play an important  role  in  vascular  calcification,  as  it  is  a  crucial
process in osteogenesis. Therefore the main aim of my project was to examine the
role of ER stress in vascular calcification.
I set out to examine potential changes in ER stress associated with vascular
calcification in human aortas in vivo, as well as changes in calcification of VSMCs in
vitro associated with ER stress. Another way of exploring the relationship between
ER  stress  and  vascular  calcification  was  determining whether  ER  stress  can  be
induced in vitro by known calcification-promoting factors. 
Another  part  of  the  project  was  focused  around  vascular  calcification
mechanisms that ER stress could potentially modulate, and therefore I  looked at
apoptosis and osteogenic transdifferentiation of VSMCs.
The final aim was to look at regulation of osteogenic genes in response to ER
stress in VSMCs in detail, and analyse whether osteogenic gene expression can be
directly regulated by ER stress transcription factors.
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Chapter 2: Materials and methods
2.1. Cell culture
2.1.1. Passaging 
Human primary vascular smooth muscle cells (VSMCs) were used for most
experiments. The cells were of aortic origin, collected from organ transplant donors,
characterised and archived in the laboratory. All human materials were handled in
compliance with the Human Tissue Act (2004, UK).
VSMCs were grown in M199 supplemented with 20% foetal bovine serum
(FBS) and 100 U/ml penicillin, 100 U/ml streptomycin and  0.29 mg/ml glutamine
(PSG), in a 4% CO2 at 37°C incubator (Thermo Heraeus HERAcell 150). Cells were
split 1:2 upon reaching 80% of confluency. For splitting VSMCs were washed with
Earl's  balanced  salt  solution  (EBSS)  twice  and  then  incubated  with  0.25%
Trypsin/EDTA for 5 minutes at 37°C. Trypsin was neutralized by addition of complete
culture medium, cells were centrifuged 5 minutes at 700xg at 4°C and cell pellet
resuspended in complete culture medium. Cells were used for experiments between
passages 8-12. 
SAOS-2 and U2OS osteosarcoma cell lines were used as positive controls in
some  experiments.  They  were  grown  in  Dulbecco's  Modified  Eagle's  Medium
(DMEM)  supplemented  with  10%  FBS  and  PSG.  They  were  passaged  1:5  when
confluent, as described above.
2.1.2. Freezing
For  freezing  cells  were  trypsinized  and  cell  pellet  was  resuspended  in
freezing medium (M199 supplemented with 30% FBS and 10% dimethyl sulfoxide  -
DMSO). Freezing vials containing cells were gradually frozen to -80°C in a Mr. Frosty
Freezing Container (Thermo Scientific) for 24 hours and then transferred to liquid
nitrogen.
2.1.3. Cell counting
Cells  were  trypsinised  as  described  above  and  resuspended  in  complete
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culture medium (1 ml of medium per 75cm2 flask surface). 10 μl of the suspension
was  pipetted  into  an  improved  Neubauer  hemocytometer  (Marienfeld).  Cells  in
three squares were counted and their number averaged, the value multiplied by
10000 to give the number of cells per 1ml.
2.1.4. Cell treatment with cytokines, growth factors, inhibitors and mineral ions
 Cells were passaged as described above and incubated in complete cell medium for
24-48 hours. Then they were washed with EBSS twice and incubated in the presence
or absence of additional components (Table 2.1) For the short treatment (24 hours
or less) cells were incubated in M199 supplemented with 0.5% FBS and PSG. For
treatments longer than 24 hours cells were treated in M199 supplemented with 5%
FBS and PSG.
Table 2.1. Reagents for cell treatments.












10mM HCl 0.1mg/ml 100ng/ml
CaCl2 (Ca) Sigma, C7902 H2O 100mM 2.7mM
H2O2 Sigma, H1009 PBS 30% 1-20μM
Hydroxyapatite (HAp) Sigma, 289396 HBSS 15mg/ml 50-150μg/ml












20 ng/μl  2 pg/μl





100 ug/mL 10 pg/μl
Tunicamycin (TM) Sigma, T7765 DMSO 1mg/ml 0.04-0.4μg/ml
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Vitamin D3 Sigma, D1530 20%
ethanol
10-5M 10-9 - 5x10-7M
Warfarin Sigma, P5104 DMSO 100mM 10-200μM
2.1.5. Transient gene knock-down with siRNA and miRNA
SiRNA transfection was performed in order to knock down ATF4, ATF6 and
Osterix in VSMCs. Cells were incubated in the complete medium for 24 hours and
then transfection medium was applied for 48 hours. For one well of a 48 well plate
the  transfection  medium  contained  250μl  M199  with  20%  FBS  and  PSG,  25μl
OptiMEM,  3μl  HiPerfect  and  3pmol  siRNA  oligouncleotide  smartpool  (GE
Dharmacon). MiRNA  transfections  were  performed  using  the  same  protocol,
MISSION miRNA mimcs were purchased from Sigma.
2.1.6. Retroviral transduction
PG13  cells  constitutively  producing  retroviruses  with  an  Osterix  shRNA,
human  Osterix  cDNA  or  empty  vectors  were  kindly  provided  by  professor  Kurt
Hankenson  (University  of  Pennsylvania,  Philadelphia,  United  States) (Zhu  et  al.
2012). PG13 cells were maintained in DMEM supplemented with 10% FBS and PSG
and passaged 1:5 every 2 days.
Virus-containing media was collected from cells and filtered through 0.45μM
filters and added to VSMCs (70% of confluency, 24 hours post-plating) in complete
VSMC growth medium  (M199 with 20% FBS and PSG) supplemented with 8μg/ml
polybrene. For the treatment virus-containing medium was diluted with M199 with
20%  FBS  and  PSG  in  the  following  proportions:  1:2,  1:4  or  1:10.  VSMCs  were
incubated with viral media for 48 hours, and harvested for gene expression analysis. 
Alternatively,  24  hours  after  plating  VSMCs  (70%  of  confluency)  were
centrifuged  90  minutes  at  1200xg in  the  culture  plates  with  undiluted  viral
supernatants and then virus-containing medium was changed to complete growth
medium.  The  procedure  was  repeated  the  following  day.  Gene  expression  was
analysed in 24 hours after the last spin.
51
2.1.7. Lentiviral transduction
VSMCs (80% of confluency) were transduced with four different clones of
TRC1  pLKO.1  Osterix  shRNA  MISSION  Lentiviral  Transduction  Particles  (Sigma),
according to the manufacturer's protocol. Empty vector (TRC1 pLKO.1) was used as a
negative control. Viral particles were added to growth media at MOI (multiplicity of
infection) 2 and 10 in the complete growth medium supplemented with 8μg/ml
hexadimethrine bromide and cell were incubated for 24 hours. The growth media
were changed next  day and cells  were incubated another  24 hours  and protein
expression was evaluated by Western blotting.
To measure the transduction efficiency, SAOS-2 cells were transduced with
pLKO.1-CMV-tGFP MISSION Lentiviral  Transduction Particles  (Sigma)  as  described
above  and  GFP  fluorescence  was  observed  with  Olympus  IX81  microscope  and
pictures  were  taken  with  Hamamatsu  1394  ORCA-ERA  camera  using  Volocity
software (PerkinElmer).
2.2. Cell viability assays
2.2.1. MTT assay
In  an  MTT  assay  cell  viability  is  assessed  by  measuring  the  activity  of
mitochondrial  NAD-dependent dehydrogenases.  In viable cells the soluble yellow
MTT  salt  (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium  bromide)  is
converted by enzymes to purple insoluble formazan crystals. Formazan crystals are
solubilised with acidified isopropanol (isopropanol  mixed with hydrochloric  acid),
and light absorbance of the solution is measured.
VSMCs  were  seeded in  a  96-well  plate  in  triplicate  (5000  cells/well)  and
treated with tunicamycin and thapsigargin. The assay was performed using In Vitro
Toxicology Assay Kit, MTT Based (Sigma) according to the manufacturer’s protocol.
MTT solution (10μl per well) was added and cells were incubated in the cell culture
incubator for 2 hours at 37°C. Next, 100μl of the solubilisation solution was added to
each well to  dissolve the formazan crystals. Absorbance was measured at 560nm
with TECAN Genios Pro Multifunction Microplate Reader. Absorbance at 710nm was
also measured and subtracted from the 560nm measurements as background.
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2.2.2. Apoptosis and necrosis analysis
Analysis of cell death was carried out using the Green FLICA Caspases 3&7
Assay Kit (Immunohistochemistry) according to the manufacturers' protocols. In this
assay Hoechst 33342 is added to cells to stain the nuclei and enable counting the
total  number of  cells.  Carboxyfluorescein FLICA reagent is  based on the caspase
inhibitor  zVAD-FMK,  and  therefore  is  bound  by  apoptotic  cells  with  activated
caspases 3 and 7.  Propidium iodide (PI) is used to stain necrotic cells, as it binds to
DNA in cells with disintegrated plasma membranes.
For each assay cells from a 24 well plate were trypsinized and resuspended in
80μl of fresh medium. 61μl  of the cell  suspension were then taken and 3.3μl of
FLICA reagent and 1.3μl Hoechst 33342 were added for 1 hour at 37°C. Then cells
were pelleted at 400xg for 5 min at 4°C and washed with apoptosis wash buffer
twice  (included  in  the  FLICA  assay  kit).  Cell  pellet  was  resuspended  in  60μl  of
apoptosis wash buffer containing 10 μg/ml of PI and 30μl was transferred into a
measurement chamber of the NC-Slide A2 (Chemometec) and immediately scanned
in  the  NucleoCounter  NC-3000  (Chemometec)  using  a  predefined caspase  assay
protocol. 
The percentage of healthy, apoptotic and necrotic cells in each sample was
determined based on the scatter plots generated by the NucleoCounter software.
Cells  with low green fluorescence signal  (FLICA) and low PI  signal  were deemed
healthy, cells with high FLICA signal were deemed apoptotic and cells with a high PI
signal were considered necrotic.
2.3. Animal tissue preparations
All animal procedures were performed under Home Office license authority
in  accordance  with  the  Guidance  on  the  Operation  of  the  Animals  (Scientific
Procedures) Act, 1986 (UK Home Office).
2.3.1. Mouse aortic rings
Aortas were harvested from wild type C57BL/6 and DBA/2 mice (male and
female), purchased from Harlan Laboratories (UK) and maintained in a pathogen-
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free environment with food and water provided ad libitum. 
Mouse  aortas  (staring  from the  arch  and including  the  abdominal  aorta)
were harvested into serum free M199 and washed extensively in sterile HBSS. The
adventitia was gently stripped away and each vessel was cut into 6-9 pieces (rings),
which were randomly assigned to experimental conditions. The vessel rings were
treated with tunicamycin and thapsigargin for 24 hours, 36 hours, 7 days or 14 days. 
Incubated rings were harvested, each was weighted and homogenised either
for Western blotting or ALP activity assay. For homogenisation aortic ring was placed
in a tube with ceramic beads (MP Bio) with a small volume of lysis buffer, shaken in
a Bertin Technologies Precellys 24 tissue homogeniser twice for 20 seconds,  and
centrifuged in benchtop centrifuge (Eppendorf) at 13 000 rpm for 5 minutes at 4°C
to pellet the tissue debris. Supernatants were transferred to a fresh tubes. 
Alternatively, intact treated vessel rings were fixed for histological analysis as
described in the following sections.
2.3.2. Rat aortic samples
Samples of thoracic aorta from 21-28 day old wild type male Sprague-Dawley
rats were kindly provided by Mr Jayanta Bordoloi,  Cardiovascular  Division, King's
College London, UK. The rats were purchased from Charles River Laboratories (UK)
and fed 3 mg warfarin and 1.5 mg vitamin K1 per 1g of food for 11 days. The control
group consisted of rats fed a standard diet.
For  Western blotting  the  tissue  samples  were  homogenised as  described




Cells were washed twice with PBS and scraped in lysis buffer. Samples were
sonicated for 10 seconds (Branson Sonifier 150) and centrifuged for 15 minutes at
15000  rpm  at  4°C.  Supernatants  were  transferred  to  new  tubes  and  protein
concentration was determined using BioRad DC Protein Assay kit and TECAN Genios
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Pro Multifunction Microplate Reader. Samples were mixed 1:3 with 4x SDS-PAGE
loading buffer and incubated 5 minutes at 95°C.
2.4.2. Nuclear fractionation
Cells  were  washed  with  PBS,  scraped  with  a  small  volume  of  PBS  and
centrifuged for 5 minutes at 5000 rpm at 4°C. Supernatants were discarded and cell
pellets were resuspended in buffer A. Samples were incubated 20 minutes on ice
and then centrifuged for 5 minutes at 5000 rpm at 4°C and the supernatants were
collected  (cytoplasmic  fraction).  The  pellets  were  washed  once  with  buffer  A
(resuspended,  centrifuged  for  5  minutes  at  5000  rpm  at  4°C  and  supernatant
discarded)  and resuspended in  IP  buffer.  Then samples  were  centrifuged   for  5
minutes at 5000 rpm at 4°C the supernatants were collected into new tubes (nuclear
fraction). Protein assay was performed and samples for SDS-PAGE were prepared as
described above.
2.4.3. Sodium dodecyl sulphate – polyacrylamide gel electrophoresis (SDS-PAGE)
Samples  were  analysed  by  using  10%  acrylamide  resolving  gel  and  5%
stacking gel. Equal amounts of protein (determined by protein assay) were loaded
on gels. Gels were immersed in SDS-PAGE running buffer and ran at 80-120V until
bromphenol blue indicator reached the end of the gel.
2.4.4. Western blotting
After SDS-PAGE proteins were transferred to PVDF membranes (Immobilon-P,
Milipore) using a Trans-Blot SD Semi-Dry Transfer Cell (Bio-Rad) in Western blotting
transfer buffer at 25V for 1 hour. Membranes were blocked in PBST with 5% milk for
1 hour at room temperature and then incubated with primary antibody (see Table
2.2)  diluted  in  blocking  buffer,  overnight  at  4°C.  Membranes  were  washed  in
blocking  buffer  (10  minutes)  and  HRP-conjugated  secondary  antibody  (diluted
1:5000 in the blocking buffer) was applied for 1 hour at room temperature. Next,
membranes were washed for  1.5  hours  with 4 changes  of  PBST.  Amersham ECL
Prime  Western  Blotting  Detection  Reagent  (GE  Healthcare)  was  applied  for  5
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minutes.  Protein  bands were visualised on X-ray film (Xograph)  developed in  an
automatic X-ray film processor (Xograph). 
Alternatively, proteins were transferred to Immobilon-FL PVDF membranes,
and  infrared  dye-conjugated  secondary  antibodies  diluted  1:10000  in  blocking
buffer were used. Then protein bands were visualised by using  the Li-Cor Odyssey
CLx infrared scanner.
2.4.5. Membrane stripping
Membranes were incubated with 0.2 M  NaOH for 10 minutes, thoroughly
washed in double-distilled H2O and PBS and then blocked and re-probed.
Table 2.2. Antibodies used for Western blotting.
Antibody Species Dilution Company
Primary ALP rabbit 1:10000 Abcam, ab108337
ATF4 rabbit 1:1000 Santa Cruz, sc-200
BBF2H7 rabbit 1:1000 Abcam, ab102989
CNN1 rabbit 1:5000 Abcam, ab46794
GAPDH rabbit 1:5000 Santa Cruz, sc-25778
Grp78 and Grp94 (KDEL) mouse 1:2500 Assay Designs, SPA-827
OASIS rabbit 1:500 Abcam, ab33051
Osterix rabbit 1:1000 Abcam, ab22552
p-MLC mouse 1:500 Cell Signalling, 36755
Runx2 rabbit 1:500 Abcam, ab48812
SM22a rabbit 1:1000 Abcam, ab14106
SMAD1 rabbit 1:1000 Cell Signalling, 9743S
SMAD2 rabbit 1:1000 Cell Signalling, 3122S
SMAD3 rabbit 1:1000 Abcam, ab40854
SMAD4 rabbit 1:1000 Cell Signalling, 9515S
Sox9 rabbit 1:300 Abcam ab3697
VDR mouse 1:500 Santa Cruz, sc-13133
β-actin mouse 1:10000 Sigma, A2228
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Antibody Species Dilution Company
Secondary anti-mouse sheep 1:5000 GE Healthcare, NA931V
anti-rabbit donkey 1:5000 GE Healthcare, NA934V
Anti-Mouse IRDye 800 CW goat 1:10000 Li-Cor, 926-32210
Anti-Rabbit IRDye 680 RD goat 1:10000 Li-Cor, 926-68071
2.4.6. Quantification of western blots
X-ray films were scanned in an EPSON Perfection 2400 Photo scanner and
densitometry was carried out in Image J. Blots scanned with Odyssey were analysed
using Li-Cor Image Studio Lite 4.0. 
Quantification was carried out in Apache Open Office Calc 4.1.1,  graphics
and statistical analysis were carried out in GraphPad Prism 5. Signal intensity was
normalised to the intensity of expression of house-keeping proteins (GAPDH or β-
actin). Where appropriate one way ANOVA with Tukey or Dunnet post hoc test or t-
tests were carried out to determine statistical significance.
2.5. Immunocytochemistry
VSMCs were grown on glass coverslips in 24 well plates (15000 cells/well).
After treatments cells were washed twice with PBS and fixed with 4% PFA for 10
minutes at 37°C.  Then cells were washed with PBS and were permeabilized with
0.5% NP-40 for 5 minutes at room temperature, washed with PBS twice and blocked
in 2% BSA for 1 hour at room temperature. After blocking cells were incubated with
primary antibody (see Table 2.3) diluted in blocking buffer, overnight at 4°C. The
following day cells were washed three times with PBS and fluorescent dye-labelled
secondary antibodies were applied for 1 hour at room temperature, the coverslips
were protected from light from this stage on. After that DAPI (0.1μg/ml) was applied
for 1 minute at room temperature to visualise nuclei, the coverslips were washed
three times with PBS and mounted in Mowiol mounting medium. The following day
the cells  were observed with Olympus IX81 microscope and pictures were taken
with Hamamatsu 1394 ORCA-ERA camera using Volocity software.
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Table 2.3. Antibodies used for immunocytochemistry.
Antibody Species Dilution Company
Primary CD63 mouse 1:500 BD Pharmingen, 556019
CD107a (LAMP1) mouse 1:250 BD Pharmingen, 555798
EEA1 mouse 1:500 BD Transduction
Laboratories, 610456
Osterix rabbit 1:500 Abcam, ab22552
p-PERK rabbit 1:250 Santa Cruz, sc-32577
IRE1 rabbit 1:250 Santa Cruz, sc-20790
Secondary Alexa fluor 488 anti-
rabbit
goat 1:500 Invitrogen, A-11008
Alexa fluor 568 anti-
mouse
goat 1:500 Invitrogen, A-11004
2.6. Histological analysis of mouse and rat aortas
2.6.1. Hematoxylin and eosin staining of mouse aortic rings
Mouse rings treated as described above were fixed in 4% PFA for 4 hours and
then incubated in 70% ethanol for another 24 hours. After that the tissue samples
were  dehydrated  and  infiltrated  in  paraffin  in  a  Shandon  Hypercenter  XP and
embedded in paraffin wax blocks using a Sakura Tissue-TEK TEC tissue embedding
console. A rotary microtome (Leica RM2125RTF) was used to cut 5 μm sections of
the aortas. 
The sections were dewaxed in xylene for 10 minutes and rehydrated twice in
100% ethanol for 3 minutes and in 70% ethanol for 3 minutes and then in water for
5 minutes.   The sections were stained with hematoxylin to visualise nuclei  for 5
minutes, fixed with acid alcohol (1% HCl in 70% ethanol) and washed in water for 5
minutes. They were incubated in eosin, which stains the cytoplasm, for 3 minutes
and rinsed 5 times with water. Next, samples were dehydrated in 70% ethanol for 1
minute, twice in 100% ethanol for 3 minutes, twice in xylene for  5 minutes and
mounted with DPX mounting medium. 
The following day the sections were observed with Olympus IX81 microscope
and pictures were taken with a Q Imaging Micropublisher 3.3 RTV camera using
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Volocity software (PerkinElmer).
2.6.2. Immunohistochemical staining of rat aortas
Rat aortas were fixed, sectioned and dehydrated as described above. Next,
antigens disrupted by PFA fixing were retrieved by steaming the sections in citrate
buffer (Vector Labs) in a steamer (Russel Hobbs) for 15 minutes. Slides were washed
in PBST and incubated 10 minutes in PBS containing 3% H2O2 and 10% methanol to
quench endogenous horseradish peroxidase (HRP) activity. Then slides were washed
three times with PBST and then were blocked in normal horse or goat serum from
the relevant VECTASTAIN ABC kit (Vector Labs) for 1 hour at room temperature in a
humidifying  chamber.  After  that  primary  antibodies  were  applied  (Table  2.4)
overnight  at  4°C.  The  next  day  sections  were  washed  three  times  in  PBST  and
incubated with HRP-linked secondary antibodies from the VECTASTAIN ABC kit  1
hour at room temperature. They were then washed 3 times in PBST and incubated
30 minutes with the ABC reagent, which amplifies the HRP signal. After another 3
washes sections were incubated with the DAB reagent (Vector Labs) until  brown
colour developed,  the reaction was stopped in water.  The sections  were stained
with hematoxylin, dehydrated  and mounted as described above.
Table 2.4. Antibodies used for immunohistochemistry.
Antibody Species Dilution Company
Primary Grp78 and Grp94
(KDEL)
mouse 1:500 Assay Designs, SPA-827
ATF4 rabbit 1:250 Santa Cruz, sc-200
ALP rabbit 1:250 Abcam, ab108337
Osterix rabbit 1:250 Abcam, ab22552
Secondary VECTASTAIN ABC Kit
mouse
horse - Vector Labs, PK6102
VECTASTAIN ABC Kit
rabbit
goat - Vector Labs, PK6101
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2.7. Quantitative real-time PCR
2.7.1. RNA isolation
RNA was extracted from cells using RNA-STAT 60 according to manufacturer's
protocol. Briefly, cells were scraped with RNA STAT 60, transferred to 1.5ml tubes
and incubated for  5 minutes at  room temperature to let nucleic acids dissociate
from protein  complexes.  Chloroform was  added (in  a  1:5  proportion  to  the cell
lysate) to extract proteins and samples were vortexed. Samples were  centrifuged 15
minutes at 12,000xg at 4°C and isopropanol was added to supernatant to precipitate
RNA for 30 minutes on ice, and then centrifuged for 10 minutes at 12,000xg at 4°C.
The pellet was washed with 75% ethanol, air-dried and then resuspended in DEPC-
treated water. 
Concentration of isolated RNA was determined using a Nanodrop ND-1000
spectrophotometer. A sample was considered pure enough for experiments if the
absorbances at 260/280 and 260/230 ratio were at least 1.8 and 1, respectively. 
2.7.2. Reverse transcription
Reverse transcription (RT) was carried out in 20μl reactions using 0.1μg/μl
RNA,  with 7.5ng/μl  of  Random and Oligo dT primers,  dNTP mix (0.25 mM each
nucleotide), 0.5 U/μl RNAsin RNase inhibitor, 5x MU-MLV buffer and 1 U/μl Mu-MLV
reverse transcriptase.
Primers, RNA and dNTPs were added to 0.2ml PCR tubes and incubated for 5
minutes at 65°C prior to the reaction in order to allow the primers to denature.
Then  buffer,  RNAsin  and  DEPC-treated  water  were  added  and  incubated  for  3
minutes  37°C  incubation  to  activate  the  RNAsin.  The  reverse  transcriptase  was
added and the RT was carried out for 10 minutes at 25°C and then 50 minutes at
37°C with a final incubation at 95°C for 5 minutes, in an Applied Biosystems 2720
Thermal  Cycler.  The  cDNA  was  diluted  with  double-distilled  water  to  the  final
volume 100μl for each 2μg RNA used.
2.7.3. Quantitative real-time PCR
Expression of  all  genes was quantified using the 2-ΔΔCt method (Livak and
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Schmittgen 2001). All primers (see Table 2.5.) were validated for this method (see
appendix).  qPCR  was  carried  out  in  20μl  reactions  with  2x  MESA  GREEN  qPCR
MasterMix  and  a  final  concentration  of  0.125μM  of  each  primer  in  a  Corbette
RotorGene 3000. 40 cycles of 95°C for 15 seconds and 60°C for 60 seconds were
carried out, with a melt curve analysis step at the end.
Table 2.5. Primers used for qPCR.
Gene Primer sequence (5'-3')
Annealing
temperature Amplicon size
ALP F:  ACGAGCTGAACAGGAACAACGT
R:  CACCAGCAAGAAGAAGCCTTTG
55°C 104bp
ATF4 F: CAACAACAGCAAGGAGGATGCCTT 
R: TGTCATCCAACGTGGTCAGAAGGT 
55°C 143bp






BMP-2 From QIAGEN, QT00012544 60°C 148bp 
BSP F:  AGTTTCGCAGACCTGACATCCAGT
R: TTCATAACTGTCCTTCCCACGGCT 
55°C 161bp
CHOP F:  AGTCATTGCCTTTCTCCTTCGGGA
R: AAGCAGGGTCAAGAGTGGTGAAGA
55°C 165bp



































RUNX2 From QIAGEN, QT00020517 60°C 101bp
SEC23A F:TCCTGGAGATGAAATGCTGTCCCA  
R:TTCTAGCGTACCACCAAAGCCCAT
55°C 152bp
SOX9 F: AGCTCTGGAGACTTCTGAACGAGA 
R: ACTTGTAATCCGGGTGGTCCTTCT
55°C 99bp
Initial analysis of qPCR results was carried out in the Rotor Gene software
provided with the thermocycler. Melt curves were inspected for  the presence of
only one sharp peak per primer pair. The cycle thresholds (Ct values) were set in the
middle of amplification curves. Fold change (2-ΔΔCt) calculations were carried out in
Apache  Open  Office  Calc.  Graphs  and  statistical  analyses  were  carried  out  in
GraphPad Prism. Where appropriate, one way ANOVA with Tukey or Dunnet  post
hoc test  or  t-tests  were  carried out  to  determine  statistical  significance.  Graphs
show n=3 unless stated otherwise.
2.7.4.  Human Osteogenesis Primer Library
Human  Osteogenesis  Primer  Library  (HOST-1,  RealTimePrimers.com)  was
used to analyse osteogenic marker expression in VSMCs treated with tunicamycin.
The library consisted of 96 primer pairs, including 8 housekeeping genes. 
RNA was isolated from tunicamycin-treated and control VSMC samples and
RT was carried out as described above. 5μg of RNA was used as a template and
cDNA final volume was 1120μl.
β-2-microglobulin was the housekeeping gene used to normalise the gene
expression,  as  no  changes  in  β-2-microglobulin  expression  were detected  in  the
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tunicamycin-treated sample. The results were analysed using the 2-ΔΔCt method as
described above. 
The  mRNA  expression  data  was  then  overlayed  over  a  protein-protein
interaction  network  retrieved  by  Cytoscape  3.2.0  software.  The  network  was
created  by  feeding  names  of  genes  included  in  the  library  into  Cytoscape  and
retrieving information from all available online interaction databases.
2.7.5. Analysis of gene expression in human aortic samples 
Expression of 4 ER stress markers and 7 osteogenic markers was measured in
RNA  from  human  aortic  samples  previously  characterised  and  archived  in  our
laboratory. Human materials were handled in accordance with the ethical guidelines
of University of Cambridge, where they originated from.
Ten  samples  of  each  of  the  following  groups  were  chosen  for  analysis:
healthy,  fatty  streak  and  calcified.  RT  and  real-time  PCRs  were  carried  out  as
described  above.  Analysis  of  each  primers  pair  had  to  be  split  into  two  qPCRs
because of the large number of samples. Therefore the 2-ΔΔCt analysis could not be
used, as fold changes cannot be compared between separate real-time PCR runs.
Instead, all analyses show –ΔCt values, which reflect the changes in gene expression
in the same way.
2.8. XBP1 splicing assay
2.8.1. Reverse transcription and polymerase chain reaction (RT-PCR)
In  order  to  detect  splicing  of  XBP1  mRNA as  indicator  of  ER stress,  RNA
extraction and reverse transcription were carried out as described above, followed
by  PCR  for  XBP1.  PCR  reactions  were  carried  out  with  2x  Go  Taq  Green  PCR
mastermix in 50μl reactions with 0.25μM of each primer (Table 2.6) with 35 cycles
of 94°C for 10s, 64°C for 30s, 72°C for 30s in an Applied Biosystems 2720 Thermal
Cycler.
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Table 2.6. Primers used for XBP1 assay.






2.8.2. Restriction enzyme digestion
In order to differentiate between the spliced and unspliced XBP1 mRNA, the
PCR product was purified with a QIAquick PCR Purification Kit (Qiagen) according to
the manufacturers protocol and digested with PstI  restriction enzyme (Promega).
Only  unspliced  PCR  product  of  XBPI  gene  is  susceptible  to  PstI  digestion.  The
digestion was carried out in 20μl reactions with buffer H (Promega) for 4 hours at
37°C.
2.8.3. Agarose gel electrophoresis
Following  the digest  products  were  resolved on  a  2% agarose gel  in  TAE
buffer. Samples were resolved at 70V for 30 minutes. Gels images were acquired
using UVP BioSpectrum Imaging System.
2.9. Calcification assays
Cells  were  plated  in  48-well  plates  (10000  cell/well,  for  cresolphthalein
assay) or 24-well plates (20000 cells/well, for Alizarin Red S staining) and incubated
for  24  hours.  Then  the  cells   were  washed  twice  with  EBSS  and  treated  with
calcification media  (M199 supplemented with 5% FBS and PSG, with the addition of
Ca2+ and  PO43-)  in  the presence  or  absence of  TM,  TG and PBA.  The cells  were
incubated for 8 days with the media changed every 3 days.
2.9.1. Cresolphthalein assay
This  assay  was  carried  out  in  order  to  quantify  the  calcium  deposition
mediated by VSMCs. It is based on the ability of o-cresolphthalein to form a purple
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complex with calcium at basic pH. 
Cells were plated with duplicates for each condition, so that they could be
analyased both for calcium deposits and protein content for assay normalisation.
Cells were washed with HBSS and then incubated overnight at 4°C with 100μl 0.1M
HCl in order to lyse the cells and dissolve the mineral deposited in the well, or with
20μl 1%SDS/0.1MNaOH in order to lyse the cells for protein measurements. The
following day, 55μl of each HCl-lysed sample was transferred to a 96-well plate and
25μl  of  ddH2O, 10μl  of  o-cresolphthalein solution and 200μl  of  ammonia buffer
were  added.  Serial  dilutions  of  CaCl2 were made to  form a  standard  calibration
curve.  Absorbance  was  measured  at  540nm  by  using  TECAN  Genios  Pro
Multifunction Microplate Reader.
Calcium concentrations were calculated in  Apache Open Office  Calc  4.1.1
and normalised to protein concentrations which were determined using the Biorad
DC  Protein  Assay.  Fold  changes  of  normalised  calcium  content  were  plotted  in
GraphPad Prism 5 and where appropriate one way ANOVA and Dunnet or Tukey
post hoc statistical significance tests were performed.
2.9.2. Alizarin Red S staining
This assay was used to visualise calcification in wells, as Alizarin Red S stains
calcium deposits red. 
Cells were washed twice in PBS and fixed with 4% PFA for 10 minutes at
37°C, washed twice with water and stained with 2% Alizarin Red S for 5 minutes and
then washed with water twice. The plate was scanned using an EPSON Perfection
2400 Photo scanner.
2.10. Alkaline phosphatase activity assay
2.10.1. Human primary vascular smooth muscle cells
Alkaline  phosphatase  (ALP)  assay  is  a  colorimetric  test  based  on  the
hydrolysis of phosphate group from a colourless substrate  p-nitrophenyl phosphate
(pNPP) by ALK yielding coloured p-nitrophenyl (pNP) product.
Cells were washed with PBS, scraped with 1% Triton X-100 in PBS and lysed
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by freeze-thawing twice. The lysates were centrifuged at 13,000xg for 5 minutes at
4°C and supernatants transferred to fresh tubes.  Equal volumes of each sample
were loaded in triplicate on a 96-well plate. 5mg pNPP was dissolved in 5ml ALP
assay buffer and 100μl of the solution was added to each well with sample and
negative control and mixed. The plate was covered and incubated at 37°C for 30
minutes. After that serial dilutions of 10mM pNP were prepared in the same plate
(to form a standard calibration curve) and absorbance was measured at 405nm by
using a TECAN Genios Pro Multifunction Microplate Reader. Protein concentration in
each  sample  was  measured  using  the  DC  Protein  Assay  according  to  the
manufacturer’s protocol.
Alkaline  phosphatase  activity  was  normalised  to  protein  concentration  in
each sample and was expressed as μM of pNP generated per minute.
2.10.2. Mouse aortic rings
Aortic  ring  homogenates  were  prepared as  described  in  section  3.1.  ALP
assay was carried out using the same protocol as for cells, with the exception of the
freeze-thaw step, which was omitted.
2.11. Alkaline phosphatase promoter analysis
Ten  deletion  constructs  containing  fragments  of  the  human  tissue-
nonspecific alkaline phosphatase (ALP) promoter cloned into the pGL3-BV vector
with  the  firefly  luciferase  gene  were  kindly  provided  by   Dr  Hideo  Orimo  from
Nippon Medical  School  in  Tokyo,  Japan (Orimo  and  Shimada 2005).  The  pRL-TK
renilla luciferase control vector was kindly provided by Dr Alison Brewer from the
Cardiovascular Division, King's College London, UK.
2.11.1. Bioinformatic analysis of ALP promoter DNA sequence
The sequence corresponding to the -122 to -4556 (counting from the first nucleotide
of  the  initiation  codon)  of  the  ALP  promoter  was  analysed  with  Matinspector
(Genomatix) for the presence of transcription factor binding sites.
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2.11.2.  Generation  of  competent  E.  coli DH5α  cells  and  transformation  with
luciferase constructs
E. coli  DH5α cells were cultured in 5ml of antibiotic-free LB broth at 37°C in a
shaking  (220rpm) incubator  for  18 hours.  The  following  day  2ml  of  culture  was
diluted in fresh LB broth and cultured until the OD600 was 0.3. Bacteria cells were
then pelleted by centrifugation at 1200xg for 10 minutes and resuspended in 20ml
of  sterile,  ice  cold  100mM CaCl2.  This  step was repeated and then after  a  final
centrifugation the bacteria were resuspended in 10ml 15% glycerol/100mM CaCl2
and stored in -80°C in 100μl aliquots.
Competency of bacteria was determined by transforming 0.5, 1, 5 and 10ng
pEQPAM plasmid into 50μl competent cells and plating out onto ampicillin-LB agar
(100μg/ml ampicillin) palates. Briefly, plasmid DNA was added to cells in pre-chilled
Falcon 2059 tubes, the reactions were swirled gently and incubated 30 minutes on
ice. They were then heat shocked for 45 seconds at 42°C and cooled on ice for 2
minutes. After that 0.3ml of S.O.C. medium (pre-heated to 37°C) was added and
bacteria were incubated 1 hour at  37°C with shaking at 220rpm. Each reaction was
then spread on two ampicillin-LB agar palates and incubated overnight at  37°C. The
number of colonies formed on each plate was divided by the amount of plasmid (in
μg), anything above 104 CFU/μg was deemed competent.
In  order  to  prepare  sufficient  quantities  of  the  pGL3-BV  and  the  pRL-TK
constructs, the plasmids were transformed into  E. coli  DH5α as described above. A
single  colony  was  picked  from  each  plate  and  grown  in  100ml  of  LB  broth
supplemented with 100μg/ml ampicillin overnight at 37°C with shaking. Plasmids
were isolated using the  NucleoBond Xtra Midi  plasmid purification kit  (Machery-
Nagel)  according  to  the  manufacturer's  protocol. Concentration  and  quality  of
isolated plasmids were determined using a Nanodrop ND-1000 spectrophotometer.
A sample was considered pure enough for experiments if the absorbance 260/280
ratio was at least 1.8.
2.11.3. Luciferase reporter assay
Luciferase  reporter  assays  measure  the  ability  of  a  DNA  sequence
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(hypothetical promoter) to initiate transcription of a luciferase gene that is cloned
downstream of the tested promoter, in this case firefly luciferase behind the ALP
promoter.  The  two  luciferase  enzymes  used  (firefly  and  renilla)  have  different
substrate requirements and emit different wavelengths of light. In each experiment
light emitted by the firefly luciferase is normalised to that of renilla luciferase, which
serves as a 'loading control'.
VSMCs were plated in 48-well plates (10000 cells/well) in triplicates for each
condition. After 24 hours they were transfected with the pGL3-BV ALP promoter
constructs  and  pRL-TK  using  Lipofectamine  LTX  (Table  2.7).  24  hours  after
transfection cells were washed and treated with TM and TG, as described previously
for 24 hours. Luciferase assays were carried out using the Dual-Luciferase Reporter
Assay kit (Promega) according to the manufacturer's protocol. Cells were washed
with PBS and lysed in the supplied passive lysis buffer on a rotary shaker for 15
minutes. 20μl of each lysate was transferred to a white 96-well plate with 100ul of
LARII reagent. Firefly luciferase luminescence was measured in a Berthold Mithras
LB 940 luminometer. After that 100ul of Stop&Glo reagent was added and renilla
luciferase luminescence was measured.
Table 2.7. Transfection of VSMCs with luciferase reporter constructs.







2.11.4.  Analysis  of  transcription  factors  binding  to  the  alkaline  phosphatase
promoter
In  order  to  examine  whether  ATF4  binds  to  the  ER  stress-responsive
fragment of the ALP promoter DNA binding assays were performed. In this assay
streptavidin coated beads were conjugated with a biotinylated fragment of the ALP
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promoter and then incubated with nuclear extracts from VSMCs. Proteins eluted
from  the  biotinylated  DNA  were  then  analysed  by  Western  blotting  or  mass
spectrometry.
2.11.4.1. Generation of biotinylated oligonucleotides
First,  a  biotinylated  oligonucleotide  with  the  promoter  sequence  was
produced  carrying  out  a  PCR  reaction  using  a  biotinylated  forward  and  normal
reverse primers (Table 2.8). The oligonucleotide was then precipitated by adding 1/5
volumes of 3M sodium acetate (pH 5.5), 2.5 volumes of 95% ethanol and incubating
for 30 minutes at -20°C. The DNA was pelleted at 14,000 rpm at 4°C for 15 minutes,
washed with 70% ethanol and centrifuged again.  The pellet  was resuspended in
double-distilled water and the concentration and purity was determined using the
ND-1000 Nanodrop spectrophotometer.








Cells  were plated  in  a  T25  flask  (100 000 cells  per  flask)  and treated  as
described. Then cells were washed with cold PBS/phosphatase inhibitor buffer (PIB,
1:20),  scraped with PBS/PIB and centrifuged at  350xg for  5 minutes at  4°C.  The
pellet was resuspended in 1ml of  hypotonic  buffer and incubated 15 minutes on ice
to  allow cells  to  swell.  Next,  50μl  of  10% NP-40  was  added to  disrupt  the  cell
membranes without damaging nuclear membranes and samples were thoroughly
mixed and centrifuged 1 minute at 14,000xg at 4°C to pellet the nuclei. Then pellets
werein  40μl  nuclear  lysis  buffer  and  incubated  30  minutes  on  ice  with  gentle
rocking. During the incubation the pellets were resuspended every 10 minutes. The
samples  were  then  centrifuged  10  minutes  at  14000xg at  4°C,  after  which
supernatants containing nuclear proteins extracts were saved. Concentrations of the
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extracts were measured with DC Protein Assay and they were stored in -80°C.
2.11.4.3. DNA binding assay
For each tested condition 6μg of the oligonucleotide was conjugated with
20μl  of  magnetic  streptavidin-coated  beads  (Dynabeads  M-270  Streptavidin,
Invitrogen). The optimal amount of DNA for this amount of beads was determined
experimentally (appendix).
 Magnetic  beads  were  washed  3  times  with  10  volumes  of  B&W  buffer.
Biotinylated  DNA  was  added  to  the  beads  resuspended  in  B&W  buffer  and
incubated with rotation 30 minutes at room temperature. After that the beads were
washed 3 times with B&W buffer, twice with transcription factor binding buffer and
aliquoted into fresh tubes. Competitor DNA poly(dI:dC) was added to each aliquot
(5μg for each 20μl of beads) and samples were incubated for 15 minutes at room
temperature with rotating, to decrease unspecific interactions of DNA with proteins.
Next, nuclear extracts (20μg) were added to each sample and incubated 30 minutes
rotating. After that the beads were washed 3 times with transcription factor binding
buffer and bound transcription factors were eluted by resuspending the beads in
SDS-PAGE sample buffer and boiling 5 minutes at 95°C. Samples were analysed by
Western blotting for ATF4 or mass spectrometry.
2.11.4.4. Mass spectrometry
Mass  spectrometry  analysis  was  carried  out  in  order  to  identify  other
proteins that bind with the tested fragment of the ALP promoter. 
A DNA binding assay was carried out as described above, with a sample of
thapsigargin treated VMSCs, and samples were ran on an SDS-PAGE acrylamide gel.
The gel was washed in water, then stained with BioSafe Coomassie for 30 minutes
and then washed 3 times with water,  15 minutes each to wash away unspecific
staining.
The gel was taken to the Proteomics Facility at the Institute of Psychiatry
(King's College London) for proteomics analysis. Briefly, fragments of the gel were
cut out and in-gel reduction, alkylation and digestion with trypsin were performed
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prior to subsequent analysis by liquid chromatography - tandem mass spectrometry
(LC-MS/MS). Raw mass spectrometry data were analysed in Proteome Discoverer
(ThermoScientific;  v1.3.0.339)  utilising  the  Mascot  database.  Samples  were
searched against Uniprot database to identify proteins bound to the biotinylated
ALP  promoter  and  compared  with  proteins  that  nonspecifically  bound  to
unconjugated beads.
2.12. Data analysis
All results represent n=3, unless stated otherwise. Data was analysed using Apache
OpenOffice  4.1.1  and  GraphPad  Prism  software.  Graphs  show  mean  with  SEM.
Where appropriate t-tests or one way ANOVA with Tukey's or Dunnett's  post hoc
tests were performed. Results were considered statistically significant when p<0.05.
Statistical  significance is  indicated with asterisks:  *  denotes p between 0.05 and
0.01, ** denotes p between 0.01 and 0.001, *** denotes p<0.001.
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2.13. Appendix
2.13.1. Real-time PCR primer validations
Before real-time PCR was carried out, primers were tested on a U2OS cDNA
sample to confirm the amplification of one product by each pair of primers. Single
products of the expected sizes (see Table 2.5) were obtained, seen as single bands in


























Figure 2.1. Validation of qPCR primers - agarose gels confirming the amplicon size for each primer
pair. RNA was isolated from U2OS cells, reverse transcription and conventional PCR were carried out,
the products were resolved on 2% agarose gels.
Next, validation reactions were carried out to assess whether amplification
efficiencies are the same for each tested pair of primers and GAPDH primers, which
were used as an internal control.  ΔCT values were plotted against dilution factor of
the cDNA samples on a logarithmic scale and trend lines were fitted (Figure 2.2 and
Figure 2.3).  If the absolute value of the trend line slope is very small (smaller than
0.5) that means that the target and reference gene amplification efficiencies are
similar and the 2-ΔΔCT method may be used for these two sets of primers.
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Gene ATF6 IRE1 PERK ATF4 CHOP OASIS BBF2H7 COL1A1 SEC23A
Slope 0.094 0.438 -0.02136 0.1207 0.00789 0.2022 -0.5216 -0.1590 0.2994
Figure 2.2. Validation of qPCR primers – ER stress markers, osteoblast- and chondrocyte-specific ER
stress transducers and their target genes. Seven 1:2 serial dilutions were made of VSMC cDNA and
qPCR reactions were carried out with these samples. A ΔCT values plotted against dilution factors (log




Gene BMP-2 OSX RUNX2 DLX5 MSX2 OCN OPG BSP ALP SOX9 COMP
Slope -0.213 0.451 0.125 0.126 0.142 0.207 -0.219 0.008 -0.165 -0.026 0.261
Figure 2.3. Validation of qPCR primers – osteo/chondrogenic markers. Seven 1:2 serial dilutions were
made of VSMC cDNA and qPCR reactions were carried out with these samples. A ΔCT values plotted




2.13.2. Optimisation of biotinylated oligonucleotide amount
A test experiment was carried out in order to establish what amount of the
biotinylated ALP promoter fragment will  saturate the amount of beads used and
therefore  allow for  maximal  protein  binding.  Magnetic  beads  (20μl  per  sample)
were washed three times with 10 volumes of B&W  buffer. 10, 8, 6, 4, 2 or 0μg of
the  biotinylated  DNA was  added  to  the  beads  resuspended in  B&W buffer  and
incubated with rotation 30 minutes at room temperature. DNA was eluted with DNA
release buffer for 5 minutes at 70°C and resolved on a 1% agarose gel (Figure 2.4).
The results show that 6μg was the amount that saturated the beads, as increased
amounts of DNA did not result in an increase in eluted DNA.
Figure 2.4. Optimisation of the amount of biotinylated oligonucleotide for DNA binding assay. The
indicated amounts of the oligonucleotide were incubated with 20μl of streptavidin-coated magnetic
beads. Beads were washed, DNA eluted off and resolved on a 1% agarose gel.
2.13.3. List of reagents (in alphabetical order)
Reagent Company
Acetic acid Sigma
Acrylamide/Bis 37.5:1, 30% National Diagnostics/Geneflow
Agarose Starlab
Alizarin Red S Sigma
















DEPC treated H2O Invitrogen
DMEM Sigma
DMSO Sigma






































































2.13.4. Buffers and stock solutions (in alphabetical order)
Alizarin Red S
 2% Alizarin Red S 
 pH to 4.2 (adjusted with 10% NH4OH)










 10% ammonium persulfate
 H2O
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Binding and washing (B&W) Buffer (2X):
 10 mM Tris-HCl (pH 7.5)
 1 mM EDTA















Nuclear fractionation buffer A 
 10mM HEPES pH 7.9
 10mM KCl
 1.5 mM MgCl2
 0.5mM DTT
 0.05% NP-40
 2μl/ml protease inhibitor cocktail
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Nuclear fractionation IP buffer




 2μl/ml protease inhibitor cocktail
Nuclear lysis buffer
 50 mM Tris HCl (pH 8)
 150 mM NaCl
 1% NP-40
 0.5% sodium deoxycholate
 1% glycerol  
 1mM NaVO3







 10x PBS tablets











Resolving gel buffer 
 1.5 M Tris
 pH 8.8
SDS-PAGE running buffer
 25 mM Tris
 250 mM glycine
 0.1% SDS
 pH 8.3
SDS-PAGE sample (loading) buffer, 4x
 40% glycerol
 240 mM Tris/HCl pH 6.8
 8% SDS
 0.04% bromophenol blue
 5% β-mercaptoethanol
Stacking gel buffer




 20mM acetic acid
 and 1mM EDTA
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Transcription Factor Binding Buffer (2X): 
 40 mM HEPES–KOH pH 7.9
 50 mM KCl
 0.2 mM EDTA
 4 mM MgCl2
 1 mM dithiothreitol (DTT)
 0.05% NP-40
 4 mM spermidine
Western blotting lysis buffer 
 0.1M Tris-HCL
 0.15M NaCl
 1% Triton X-100
 2μl/ml protease inhibitor cocktail
 pH 8.1
Western blotting transfer buffer






Chapter 3: Endoplasmic reticulum stress is involved in
vascular calcification
3.1. Introduction
3.1.1. ER stress and vascular calcification
The unfolded protein  response (UPR)  is  a  signalling pathway activated in
response to ER stress, which occurs as a result of unfolded protein accumulation or
perturbations of intracellular Ca2+ homoeostasis. It consists of three branches, each
mediated by a separate ER stress transducer: PERK, ATF6 or IRE1. Each of these
activates expression of genes that help resolve ER stress such as Grp78 and Grp94
chaperones, via distinct downstream targets (Ron and Walter, 2007). In cases when
ER stress cannot be resolved, it can lead to cell death (Rao et al. 2004)
ER stress signalling has been shown to be crucial  for  bone development.
XBP1 was shown to be highly expressed in developing skeletons of mouse embryos
(Clauss et al. 1993). In addition BMP-2, the main bone morphogenetic protein, can
upregulate  IRE1,  XBP1,  CHOP,  PERK,  ATF4  and  ATF6  expression  in  osteoblasts
(Tohmonda  et  al. 2011;  Han  et  al. 2013).  PERK  knock-out  mice  exhibit  skeletal
dysplasias  at  birth  and  postnatal  growth  retardation highlighting its important
role  in  bone  formation  (Zhang  et  al.  2002).  Mice  deficient  in  ATF4,  which  acts
downstream of PERK, exhibit a reduction in bone volume and fail to achieve  normal
bone mass (Yang et al. 2004b). Finally, the chaperone Grp78 was shown to localise
on the surface of osteoblasts, bind collagen  type  1  and  nucleate  calcium  and
phosphate   crystals   in   vitro,  suggesting  that  it  plays  a  role  in  bone  ECM
mineralisation  (Ravindran  et  al. 2011).  Grp78  expression  is  increased  during
embryonic development in condensing cartilage and mesenchymal cells (Ravindran
et al. 2012).
Vascular  calcification  shares  similarities  with  bone  formation.  Calcifying
VSMCs  have  been  shown  to  undergo  an  osteogenic  transdifferentiation,  which
resembles  osteoblast  maturation,  during  which  they  lose  expression  of  VSMC
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markers and start expressing osteo/chondrogenic markers (Shanahan et al. 1999a;
Speer et  al. 2009).  In  addition,  it  was  shown  that  in  VSMCs  cultured  in  vitro
apoptosis  occurs  prior  to  the  onset  of  calcification  and  that  apoptotic  bodies
accumulate  calcium  and  are  sites  of  crystal  nucleation  (Proudfoot et  al. 2000).
These  findings  were  confirmed  by  in  vivo studies  showing  that  dialysis  triggers
VSMC  apoptosis  and  thus  accelerates  vascular  calcification  (Shroff et  al. 2008).
Apoptosis  was  also  shown  to  accelerate  plaque  formation  and  induce  its
calcification  in  a  mouse  model  of  atherosclerosis  (Clarke et  al. 2008).  This  is
important  because  apoptosis  of  chondrocytes  is  an  important  step that  induces
bone  mineralisation  (Karsenty  et  al. 2009).  Because  vascular  calcification  has
similarities with bone formation, I hypothesized that ER stress and UPR signalling
are involved in this pathological process.
VSMC calcification has been linked to ER stress and the UPR in five studies to
date. It has been shown that calcification induced in rat aortas and VSMCs cultured
in vitro is  associated with increased apoptosis as well as expression of ER stress
markers  ATF4,  Grp78,  Grp94  and  CHOP,  and  osteogenic  markers  OPN  and  ALP
(Duan et al. 2009, 2013). Liberman et al. (2011) have shown that BMP-2, the main
inducer of osteoblast differentiation, activates oxidative stress, which results in ER
stress and increased calcification of human coronary artery VSMCs. Finally, Masuda
et al. (2012, 2013) have shown that in mouse VSMCs stearate and TNFα induce
calcification via the PERK-ATF4-CHOP branch of the UPR. However, these studies
offer limited explanation of what mechanisms link ER stress to vascular calcification,
which UPR pathways are involved or whether ER stress can be activated in vivo in
human aortas.
3.1.2. Modelling ER stress
ER  stress  can  be  modelled  in  vitro using  tunicamycin  and  thapsigargin
treatments. Tunicamycin is an inhibitor of N-glycosylation, and causes accumulation
of unglycosylated proteins in the ER (Olden et al. 1979) and therefore it imitates ER
stress induced by an increased load of proteins. This type of ER stress occurs in
osteoblasts,  which  are  professional  secretory  cells  and  therefore  under  greater
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demand to fold and process large quantities of proteins when secreting ECM (Wu
and  Kaufman,  2006).  Thapsigargin  is  an  inhibitor  of  SERCA  (sarco/endoplasmic
reticulum Ca2+ ATPase),  which causes  an increase in cytosolic  Ca2+ as  these ions
cannot be transported back to the ER (Xuan et al. 1992), and represents ER stress
which occurs due to disturbed Ca2+ homeostasis. These chemicals mimic ER stress
induced via different mechanisms and therefore in most experiments both were
used, because it was unclear which would be more relevant to vascular calcification.
In  addition,  both  calcium  and  protein  folding  homeostasis  are  crucial  for  bone
development, therefore it was important to mimic ER stress that disrupts each of
these processes.
ER  stress  can  be  inhibited  by  4-phenylbutyric  acid  (PBA),  a  chemical
chaperone  (Welch  and  Brown,  1996).  Due  to  its  hydrophobic  structure,  PBA
associates with unfolded proteins and facilitates their folding. Although it cannot
completely counter the effects of tunicamycin or thapsigargin, it can attenuate ER
stress to an extent.
3.1.3. Potential factors inducing ER stress in vascular calcification
Vascular calcification is a complex, multifactorial process, and therefore it is
difficult  to single out one inducer that  causes it.  Nevertheless,  there are factors
known  to  contribute  to  this  process.  In  conditions  such  as  diabetes  and  CKD,
oxidative stress is thought to play a role. Mineral homeostasis dysregulation, high
levels  of  vitamin  D  and  warfarin  treatments  are  also  known  to  contribute  to
calcification in dialysis patients (Shanahan 2013). Vascular calcification is associated
with increased levels of various cytokines, such as BMP-2, TGFβ and TNFα (Kaden et
al. 2004; Stenvinkel et al. 2005; Jian et al. 2003). Finally, hydroxyapatite, the result
of calcification, has been shown to promote osteogenic differentiation of VSMCs
(Sage  et al. 2011). The effect of these factors on the UPR and whether they can
induce ER stress in VSMCs is mostly unknown.
TGFβ1  is  a  cytokine  with  an  established  role  in  regulating  chondrocyte
growth  by  inhibiting  hypertrophy  and  maintaining  expression  of  ECM  proteins
(Ballock et  al. 1993).  Clasically,  TGFβ1 has been associated with maintaining the
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contractile phenotype of VSMCs both in vitro and in vivo (Shah et al. 1996; Hirshi et
al. 1998; Grainger et al. 1998). However, at higher concentrations in vitro (10ng/ml
as opposed to 0.5-2ng/ml) it  has been shown to induce VSMC proliferation and
activate osteogenic gene expression (Orlandi et al. 1994; Simionescu et al. 2005). It
has also been shown to be present at high levels in calcified human aortic valves
(Jian et  al. 2003).  However,  another  study has  shown that  VSMCs from SMAD3
knock-out mice (SMAD3 is a mediator of TGFβ1 signalling) calcify more than their
wild-type counterparts when exposed to high calcium and phosphate, suggesting
that TGFβ signalling suppresses calcification (Shimokado et al. 2014). Therefore, the
role  of  TGFβ in  regulating  VSMC  phenotype  and  calcification  in  not  yet  clear.
Importantly, TGFβ has been shown to activate the UPR in lung fibroblasts and thus
induce ECM protein expression (Baek et al. 2011), but its effects on UPR in VSMCs
have not been studied.
PDGF is a growth factor crucial for blood vessel formation during embryonic
development,  where it  regulates  VSMC and pericyte  migration  and proliferation
(Hellstrom et  al. 1999).  In  adult  VSMCs  PDGF  is  an  important  regulator  of
phenotype, which during injury prompts cells to switch to the synthetic phenotype,
lose contractile marker expression, proliferate and synthesise ECM (Wilson et al.
1993, Salabei  et al. 2013). Importantly, PDGF has been shown to promote VSMC
calcification in vitro (Giachelli et al. 2001). ER stress has been shown to protect rat
VSMCs from PDGF-induced proliferation and migration. The same study has shown
that  PDGF did not  induce XBP1 splicing or  Grp78 and Grp94 expression,  but  in-
depth analysis of UPR activation was not carried out (Yi et al. 2012).
BMP-2 is the main osteogenic cytokine and has been widely implicated in
vascular calcification, as it is highly expressed in calcified blood vessels (Kaden et al.
2004). BMP-2 has been shown to activate ER stress in osteoblasts (Murakami et al.
2009). In VSMCs BMP-2 has been shown to activate ER stress via oxidative stress
and NADPH oxidases (Liberman et al. 2011).
TNFα  is  a  ubiquitous  cytokine  with  many  functions,  primarily  linked  to
inflammation. It has been associated with vascular calcification, because elevated
levels are found in atherosclerotic plaques and in vessels of patients with chronic
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kidney  disease,  a  condition  which  is  accompanied  by  medial  calcification  and
systemic  inflammation  (Barath  et  al. 1990,  Stenvinkel  et  al. 2005).  Importantly,
TNFα has been shown to activate ER stress in VSMCs, specifically the PERK-ATF4
branch of the UPR in a mouse VSMC line, and thus lead to increased calcification.
This pathway was also shown to be activated in aortas, when CKD was induced by
5/6 nephrectomy in mice (Masuda  et al. 2013). However, activation of other UPR
branches by TNFα has not been studied.
Chronic  kidney  disease  results  in  a  range  of  health  complications,  all  of
which impact on VSMC physiology. Mineral dysregulation is thought to be one of
the main factors that injure VSMCs in this disease and high levels of calcium and
phosphate have been shown to increase calcification of VSMCs in vitro (Block et al.
1998;  Shroff  et  al. 2010;  Shanahan  et  al. 2011).  Patients  with  CKD  are  often
administered  vitamin  D  (calcitriol,  1,25-dihydroxyvitamin  D3)  supplements  to
counter hypocalcemia and secondary hyperparathyroidism which are the result of
disturbed phosphate metabolism. The role of vitamin D in vascular calcification is
unclear, as both low and high levels (compared to physiological) have been shown
to induce calcification of VSMCs (Jono et al. 1998; Wolisi et al. 2005; Mizobuchi et
al. 2009).  In addition, vitamin D has been shown to inhibit vascular  calcification
induced by TNFα (Aoshima et al. 2012). In terms of ER stress, vitamin D has been
shown to suppress the UPR in macrophages in the context of diabetes (Riek et al.
2012).  The  effect  of  vitamin  D  on  ER  stress  pathways  in  VSMCs  has  not  been
studied. 
Warfarin is an anticoagulant commonly administered to dialysis patients in
order  to  maintain  vascular  access.  It  prevents  blood  clotting  by  inhibiting
carboxylation  of  coagulant  factors  in  the  liver.  Warfarin  promotes  vascular
calcification  as  one  of  its  side  effects  is  inhibition  of  MGP carboxylation  in  the
vasculature. MGP is a natural calcification inhibitor, which needs to be carboxylated
in order to be effective (Danziger 2008; Willems et al. 2014). Warfarin has also been
shown to induce calcification of VSMCs in vitro (Proudfoot et al. 1998; Reynolds et
al. 2004; Lomashvili  et al. 2011). The effect of warfarin on ER stress activation has
not been previously studied in VSMCs or in fact any other cell type.
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Oxidative  stress  is  a  well-established  inducer  of  vascular  disease,  and
accompanies atherosclerosis, diabetes and chronic kidney disease (Xue et al. 2005;
Demer and Tintut,  2014).  It  has  also been implicated in  vascular  calcification in
many studies (Kaneto et al. 2005; Byon et al. 2008). The link between ER stress and
oxidative stress in VSMCs is unclear, as oxidative stress has been shown to induce
ER stress  (Liberman  et  al. 2011;  Chen  et  al. 2014)  and  some studies  make the
reverse conclusion that ER stress induces oxidative stress (Nonaka et al. 2001; Husa
et al. 2013).
Calcium and phosphate crystals (hydroxyapatite) form as a result of ongoing
vascular calcification. Studies have shown that the crystals themselves can further
enhance  osteogenic  transdifferentiation  of  VSMCs  and  increase  calcification  by
inducing apoptosis (Ewence et al. 2008; Sage et al. 2011, Lei et al. 2014). However,
whether this occurs via ER stress signalling has not been examined.
3.2. Aims
In this chapter I set out to examine whether ER stress is involved in vascular
calcification. Specifically I determined:
1. Expression of ER stress markers and osteogenic genes in healthy, fatty streak
and calcified human aortas.
2. Whether  factors  relevant  to  vascular  calcification  promote  ER  stress  in
VSMCs.
3. Which branches of the UPR can be activated in human primary VSMCs  in
vitro by tunicamycin and thapsigargin. 
4. Whether ER stress was associated with increased calcification and apoptosis
of VSMCs. 
 
3.3.  Differential  expression  of  ER  stress  and  osteogenic  markers
between healthy and calcified human aortas
In  order  to  examine  whether  there  are  changes  in  ER  stress  marker
expression  in  vascular  calcification  in  vivo,  expression  of  PERK,  ATF6,  ATF4  and
CHOP  was  measured  in  human  aortas  by  quantitative  real-time  PCR.  Ten  RNA
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samples from healthy, fatty streak and calcified aortas were analysed.
Expression of all four of the examined ER stress markers was lower in fatty
streak and calcified vessels compared to healthy.  In addition, their expression in
calcified vessels was lower than in fatty streak vessels (Figure 3.1.A). For all markers
these changes were just trends, but the decrease in PERK expression in calcified
aortas was statistically significant. These results suggest that ER stress decreases as
vascular disease progresses and leads to calcification.
Next,  expression of a number of osteogenic markers was analysed in the
same samples in order to examine whether osteogenic differentiation correlated
with  levels  of  ER  stress  markers.  Expression  of  three  osteo/chondrogenic
transcription factors – Runx2, Osterix and Sox9 and their downstream targets ALP,
BSP, OPG and COL1A1 was measured  (Figure 3.1.B). 
In the fatty streak group expression of all osteogenic markers was decreased
compared to healthy samples, which means that their expression followed the same
pattern as ER stress markers. However, in the calcified samples levels of expression
of Runx2 and Osx were similar to the healthy samples, Sox9, BSP and COL1A1 were
slightly increased and only ALP and OPG were decreased. None of these differences
were  statistically  significant.  These  trends  suggest  that  as  vascular  disease
progresses  expression  of  osteogenic  markers  at  first  correlates  with  ER  stress
markers, i.e. both are reduced, but later becomes uncoupled and osteogenic gene
expression increases independently of ER stress signalling.
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Figure 3.1. Quantitative real-time PCR analysis of  A ER stress markers and  B osteo/chondrogenic
genes in human aortas. ΔCT values were calculated relative to GAPDH expression in corresponding
samples. Graphs show individual data points and mean, n=2-10, ANOVA with Tukey's post hoc tests
was performed, p values compared to healthy.
The lack of statistical significance of the observed changes might be partially
due to the considerable variability of gene expression within sample groups. This





people, whose aortas were analysed. Table 3.1 shows that patients with calcified
aortas were significantly older than people with healthy aortas, which is consistent
with  the  fact  that  the  prevalence  of  vascular  calcification  increases  with  age
(Rennenberg et al. 2009; Park et al. 2012). In addition, for some of the genes the n
numbers were low, because samples were excluded from analysis if the real time
PCR reactions were not specific (two peaks on the melt curve) or failed completely.
Table 3.1. Demographics of patients, from whom aortic samples were obtained. Differences in mean
age were analysed with one-way ANOVA and Tukey's post hoc test. ** denotes p between 0.01 and
0.001, in comparison with the healthy group.
Group Mean Age Age SD Females Males n
Healthy 38 9 8 2 10
Fatty Streak 43 12 8 2 10
Calcified 51** 7 6 5 11
To further test the relationship between ER stress marker and osteogenic
gene expression in the vessel wall, Pearson correlation tests were carried out for
expression values of pairs of ER stress versus osteogenic markers for samples from
calcified aortas or healthy and fatty streak combined (non-calcified).  Figure 3.2.A
shows analysis  of  ATF4  and ALP  as  an  example,  the  remaining  plots  are  in  the
Appendix (Figures 7.1 - 7.4).  Figure 3.2.B contains a summary of the results and
shows that in healthy and fatty streak vessels expression of tested ER stress markers
(ATF4, CHOP, ATF6, PERK) in most cases significantly correlated with expression of
osteogenic markers Runx2, ALP, BSP and OPG. The exception was PERK, which only
correlated with ALP in this data set. SOX9, COL1A1 and OSX were not analysed due
to low n numbers. In the dataset consisting of samples from calcified aortas none of
the ER stress markers correlated with osteogenic  markers,  apart  form ATF6 and
PERK which both correlated with OPG. This is consistent with OPG and ALP being





Healthy & Fatty Streak Calcified
ATF4 vs Runx2 *** ns
ATF4 vs ALP *** ns
ATF4 vs BSP ** ns
ATF4 vs OPG ** ns
CHOP vs Runx2 *** ns
CHOP vs ALP *** ns
CHOP vs BSP ** ns
CHOP vs OPG *** ns
ATF6 vs Runx2 *** ns
ATF6 vs ALP *** ns
ATF6 vs BSP ** ns
ATF6 vs OPG ** ***
PERK vs Runx2 ns ns
PERK vs ALP * ns
PERK vs BSP ns ns
PERK vs OPG ns **
Figure 3.2. Correlation analysis of ER stress versus osteogenic markers. A.  ΔCT values of ER stress
markers were plotted against ΔCT values of osteogenic genes. Linear regression was plotted, and a
two-tailed Pearson correlation test was carried out. Graphs show individual data points, n=20 for
healthy and fatty streak and n=10 for calcified. B. Summary of correlation analysis of ER stress versus
osteogenic markers; 'ns' denotes p>0.05, * denotes p between 0.05 and 0.01, ** denotes p between
0.01 and 0.001, *** denotes p<0.001.
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The results from this section supported the notion that changes in ER stress
signalling are associated with vascular  disease in human aortas.  However,  more
detailed analysis of ER stress signalling and calcification mechanisms was needed to
establish whether ER stress can regulate vascular calcification.
3.4. ER stress is induced by known calcification-promoting factors
Having ascertained that  ER stress is  involved in vascular  calcification,  the
next important step was to determine what factors that drive calcification are also
associated with changes in ER stress. Therefore, expression of ER stress markers
was examined after  treating cells  with some of  the well-established inducers  of
calcification.
3.4.1. Cytokines involved in regulating VSMC phenotype
The first factors tested were TGFβ and PDGF as they have an established role
in  regulating  VSMC  phenotype.  TGFβ is  classically  associated  with  increased
contractile differentiation, while PDGF promotes the secretory phenotype of VSMCs
as it stimulates ECM secretion and proliferation.
3.4.1.1. TGFβ
VSMCs were treated with 2 ng/ml TGFβ for 5 days, according to a protocol
previously established in the laboratory, and expression of ER stress marker mRNA
was measured by real-time PCR. 
Figure 3.3.A shows that the TGFβ treatment increased the expression of all
measured markers: ER stress transducers IRE1 (1.7 ± 0.5 fold increase), ATF6 (1.4 ±
0.5 fold increase) and PERK (1.3 ± 0.17 fold increase), and downstream targets ATF4
(1.6 ± 0.23 fold increase) and CHOP (4.4 ± 2.18 fold increase). The increase in ATF4
expression was statistically significant.
Next,  Western blotting for  Grp78 and Grp94 was carried out  in  order  to
examine whether TGFβ induced changes in ER stress signalling at the protein level.
A 1.2-fold increase (±0.45) in expression of Grp78 and 1.2-fold increase of Grp94
(±0.55) was observed consistently in n=3 experiments, however the increases did
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not reach statistical significance (Figure 3.3.B and C). Taken together, these results







Figure 3.3. ER stress markers in VSMCs treated with TGFβ. Cells were treated with 2ng/ml TGFβ in
the presence of 2.5% FBS for 5 days. A. ER stress marker expression measured by real-time PCR. B.
Western blotting for Grp78 and Grp94 and C. Quantification of Western blots. All graphs show mean




Next, the effect of PDGF treatment on expression of ER stress markers in
VSMCs was analysed. Cells were treated with 10ng/ml PDGF for 5 days, according to
a protocol previously established in the laboratory.
Expression of ER stress markers measured by real-time PCR did not change
after treatment with PDGF (Figure 3.4.A). Grp78 and Grp94 chaperones expression
measured  by  Western  blotting  was  slightly  increased  (1.4±0.41  fold  increase  in
Grp78, 1.8±1.22 fold increase in Grp94), but the change was not consistent in n=3









Figure 3.4. ER stress markers in cells treated with PDGF. VSMCs were treated with 10 ng/ml PDGF in
the presence of 0.5% FBS for 5 days. A. ER stress marker expression measured by real-time PCR. B.
Western blotting for Grp78 and Grp94 and C. Quantification of Western blots. All graphs show mean
with SEM, n=3, statistical significance of changes was measured using t-tests.
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3.4.2. BMP-2 does not induce ER stress
The  next  cytokine  relevant  to  calcification,  which  was  hypothesised  to
promote ER stress in VSMCs was BMP-2. VSMCs were treated with 100ng/ml BMP-2
for  24 hours,  in  accordance with  published literature  (Liberman  et  al. 2011).  In
parallel,  cells  were  also  treated  with  tunicamycin  or  thapsigargin  as  a  positive
control for ER stress. Activation of ER stress markers was measured by real-time PCR
and XBP1 splicing assay was carried out.
Figure 3.5.A shows that expression of ATF6, CHOP and ATF4 mRNA measured
by real-time PCR did not change after BMP-2 treatment, but increased significantly













CTRL       TM        TG      BMP-2
Figure 3.5. ER stress markers in BMP-2-treated VSMCs. Cells were treated with 0.4μg/ml tunicamycin
(TM),  0.2μg/ml thapsigargin (TG) or  100ng/ml BMP-2 for 24 hours in  medium with 0.5% FBS. A.
mRNA levels of ATF6, CHOP and ATF4 measured by real-time PCR. Graphs show mean with SEM, n=3,
ANOVA  and  Dunnett's  post  hoc test  were  carried  out.  ***  denotes  p<0.001.  B. XBP1  splicing
indicative of UPR activation, n=3, figure shows representative image.
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Western blotting for Grp78 and Grp94 chaperones confirmed that ER stress
was  not  activated,  as  the  levels  of  these  proteins  did  not  change  with  BMP-2
treatment (Figure 3.6.A and quantification B). The results in this section suggest that




CTRL          TG       BMP-2
A
B
Figure 3.6.  BMP-2 does not induce Grp78 and Grp94 expression. Cells were treated with 0.4μg/ml
tunicamycin (TM), 0.2μg/ml thapsigargin (TG) or 100ng/ml BMP-2 for 24 hours in medium with 0.5%
FBS. A. Representative Western blot. B. Quantification. Graphs show mean with SEM, n=3, ANOVA
and Dunnett's post hoc test were carried out.
3.4.3. TNFα increases ER stress in VSMCs
TNFα was previously shown to activate the PERK-ATF4-CHOP branch of the
UPR and induce calcification of mouse VSMCs (Masuda et al. 2013), but activation
of other UPR pathways was not examined in that study. Therefore, expression of all
three  ER  stress  transducers  and  their  target  genes  was  examined  after  TNFα
treatment.  Cells  were treated with 10ng/ml  of  TNFα for  5  days,  according  to  a
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protocol previously established in the laboratory.  Expression of ER stress marker
mRNA was analysed by real-time PCR and Western blotting.
Surprisingly, TNFα significantly increased expression of IRE1 mRNA (1.7 ± 0.3
fold increase; Figure 3.7.A), and only slightly upregulated expression of PERK (1.2 ±
0.24  fold  increase).  Levels  of  ATF6,  ATF4  and  CHOP  remained  unchanged.
Expression  of  Grp78  and  Grp94  chaperones  measured  by  Western  blotting  was
increased  (1.6±0.9  fold  increase  of  Grp78  and  2.2  ±  1.5  of  Grp94),  and  these
changes were consistent across n=3 experiments (Figure 3.7.B and C). These results









Figure 3.7. ER stress markers in cells treated with TNFα. VSMCs were treated with 10ng/ml TNFα in
the presence of 20% FBS for 5 days. A. ER stress marker expression measured by real-time PCR.  B.
Western blotting for Grp78 and Grp94 and C. Quantification of Western blots. All graphs show mean
with SEM, n=3, statistical significance of changes was measured using t-tests, * denotes p between
0.05 and 0.01.
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The results in this section show that BMP-2 and PDGF are not involved in
activating the UPR in VSMCS, but TGFβ and TNFα possibly are.
3.4.4. Factors involved in CKD
Because chronic kidney disease, and specifically dialysis, is a major risk factor
for  developing vascular  calcification,  several  factors  related to this  disease were
examined for their ability to induce ER stress in VSMCs.
3.4.4.1. Warfarin induces ER stress in rat aortas
In order to examine whether warfarin induces ER stress in VSMCs,  aortic
samples from warfarin-fed rats were collected and expression of Grp78 and Grp94
chaperones was examined by Western blotting and compared to that in rats fed a
standard diet.  Figure 3.8 shows that both chaperones were increased in warfarin
fed rats and the change was statistically significant for Grp78 suggesting ER stress
was activated in these aortas.
Figure 3.8. Expression of Grp78 and Grp94 chaperones in aortas of warfarin-fed rats.  A.  Western
blotting for Grp78 and Grp94 chaperones, figure shows representative image.  B. Quantification of
Western blots.  Graphs show mean with SEM, n=3, t-tests have been carried out to examine the
statistical significance of observed changes, *denotes p values between 0.05 and 0.01.
Warfarin feeding is an established method of inducing vascular calcification
in rats  (Price  et  al. 1998;  Atkinson  et  al. 2008).  Therefore  it  was  interesting  to





CTRL     Warfarin
A B
areas of warfarin-fed rat aortas. Immunohistochemistry was carried out for these
chaperones, as well as another ER stress marker ATF4 and osteogenic markers ALP
and Osterix.
Figure 3.9 shows that expression of Grp78, Grp94 and ATF4 was higher in
the warfarin-fed rat aorta compared to control. The expression of these ER stress
markers was not limited to the calcified area, as increased staining was observed in
the whole width of the vessel wall. In contrast, expression of Osterix and ALP in the
vessel  wall  was  similar  in  both  groups  of  rats,  but  increased  expression  was
observed around the calcified area.
These results confirm that ER stress chaperone expression was activated in
VSMCs in the media of warfarin-fed rat aortas, and that this was accompanied by
increased expression of Osterix and ALP in the calcified area, but not the whole of
the vessel wall.
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Figure 3.9. Localisation of osteogenic and ER stress markers in aortas of warfarin-fed rats examined
by immunohistochemistry.  Vessel  sections were stained with  primary antibodies  and HRP-linked
secondary antibodies, staining was developed with DAB (brown); the sections were then stained
with hematoxylin to visualise nuclei (purple). Arrows point to calcified area in warfarin-fed rat aortas.
Negative control – sections stained with secondary antibodies only. N=3, figure shows representative









The next aim was to examine whether warfarin could also induce ER stress in
human primary VSMCs in vitro. Cells were treated with a range of concentrations of
warfarin, and expression of Grp78 and Grp94 was analysed using Western blotting.
Figure  3.10  shows  that  warfarin  increased  the  expression  of  both  chaperones
slightly. Expression of both chaperones was the highest in cells treated with 10μM
warfarin (1.7 ± 0.3 fold increase in Grp78, 1.6 ± 0.8 fold increase in Grp94). 10μM is
within the upper limit of the therapeutic range of 1.6μM to 9.7μM (Osinbowale et
al. 2009).  Even though  the  changes  were consistent,  they were  not  statistically
significant for n=3 experiments.
The results in this subsection suggest that warfarin induces ER stress in rat









Figure  3.10.  Expression of  Grp78 and Grp94 chaperones in  human primary VSMCs  treated with
warfarin or 0.2 μg/ml TM for 24 hours. A. Western blotting for Grp78 and Grp94 chaperones, figure
shows representative image. B. Quantification of Western blots. Graphs show mean with SEM, n=3,
ANOVA and Dunnett's post hoc tests have been carried out to examine the statistical significance of
observed changes, ***denotes p<0.001.
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3.4.4.2. Oxidative stress is a possible inducer of ER stress
In  order  to  model  oxidative  stress  in  vitro,  VSMCs  were  treated  with
hydrogen peroxide (H2O2),  a  source of  the  highly  reactive  hydroxyl  radical  (·OH)
(Droge, 2002). Western blotting for Grp78 and Grp94 chaperones was carried out to
examine whether oxidative stress can activate the expression of these ER stress
markers.
First,  a dose response experiment was conducted, with concentrations of
H2O2 ranging from 2μM to 100μM (considered physiological; Mueller et al. 1997). It
was observed that 10μM and 20μM H2O2 caused an increase in ER stress chaperone
expression,  and  therefore  these  two  concentrations  were  used  for  subsequent
experiments (Figure 3.11.A). Further analysis revealed that 10μM H2O2 induced an
average of 1.3±0.6 fold increase of Grp78 expression and a 1.7±0.6 fold increase in
Grp94, and 20μM H2O2 induced 1.4±0.1 and 1.6±0.6 fold increase in Grp78 and
Grp94, respectively (Figure 3.11.B). These results suggest that oxidative stress is a
possible inducer of ER stress, but it is unknown why it did not induce Grp78 and
Grp94 expression in all experiments.
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Figure 3.11. ER stress activation in cells treated with hydrogen peroxide (H2O2). VSMCs were treated
with H2O2 or 0.4μg/ml tunicamycin (TM) in the presence of 0.5% FBS for 24h. A. Western blotting for
Grp78  and Grp94 chaperones  -  dose  response to  H2O2,  n=1.  B.  Quantification of  Western  blots
repeated  with  just  two  concentrations  of  H2O2.  Graphs  show  mean  with  SEM,  n=3,  statistical
significance of  changes  was  measured  using ANOVA and  Dunnett's  post  hoc test,  **  denotes  p
between 0.01 and 0.001.
3.4.4.3. Hydroxyapatite is possibly an inducer of ER stress in VSMCs
The final potential inducer of ER stress signalling examined were HAp. Cells
were treated with 50μg/ml  or  150μg/ml HAp for  3 days,  the concentration and
time-point were used previously in literature to treat VSMCs (Ewence et al. 2008). 
Western blotting results show that HAp induced an increase in both Grp78
and  Grp94  expression  at  50μg/ml  (3.62±3.07  and  5.3±10.25  fold  increases,
respectively;  Figure 3.12). The results were extremely variable and therefore the
changes were not statistically significant. However, there was strong activation in
some experiments, hence HAp could be an inducer of ER stress in VSMCs, even















Figure  3.12. ER  stress  activation in  cells  treated with  hydroxyapatite.  VSMCs  were treated with
hydroxyapatite, 0.02μg/ml tunicamycin (TM) or 0.02μg/ml thapsigargin (TG) in the presence of 5%
FBS  for  3 days.  A.  Western  blotting for  Grp78 and Grp94 chaperones,  representative  image.  B.
Quantification of  Western blots.  All  graphs show mean with  SEM, n=3,  statistical  significance of
changes was measured using ANOVA and Dunnett's  post hoc test, * denotes p between 0.05 and
0.01.
Results presented in this subsection are summarised in Table 3.2. In addition
to the mentioned factors, Vitamin D and high levels of calcium and phosphate ions
were tested and found not to change the expression of examined ER stress markers
markedly. However, it is evident that most of the calcification-related cytokines and
CKD-related factors can induce ER stress marker expression in VSMCs. Most of these
changes in ER stress marker expression are small but consistent increases.
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Table 3.2. Calcification inducers tested for their ability to induce ER stress in VSMCs. Expression of
Grp78 and Grp94 was analysed by Western blotting in VSMCs treated with each inducer. For some
factors expression of additional ER stress markers (IRE1, PERK, ATF6, CHOP) was examined by real-
time PCR. Table shows fold changes, statistically significant changes in expression are indicated with
'*'.
Factor
Does it induce Grp78 and Grp94? Does it induce other
markers?Grp78 Grp94










BMP-2 0.6±0.6 1.2±1.8 ATF6: 1.1±0.0
ATF4: 1.1±0.2
CHOP:1.1±0.0





CKD - related Warfarin 1.7±0.3 – VSMCs
1.9*±0.5 - rat aorta
1.6±0.8 – VSMCs








HAp 3.6±3.1 5.3±10.3 Not examined





Ca+P 1.2±0.2 1.1±0.5 Not examined
3.5.  Tunicamycin  and  thapsigargin  increase  expression  of  ER  stress
markers in VSMCs
Having  established  that  ER  stress  is  potentially  associated  with  vascular
calcification and that some calcification-inducing factors can activate ER stress in
VSMCs  in vitro it was important to model ER stress in VSMCs in vitro in order to
examine  its  effect  on  known  UPR  components,  calcification  and  mechanisms
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regulating  calcification.  First,  VSMCs  were  treated  with  tunicamycin  and
thapsigargin for 24 hours and expression of ER stress markers was analysed with
quantitative  real-time PCR.  Results  show that  expression  of  all  tested  ER  stress
markers (IRE1, ATF6, PERK, together with ATF4 and CHOP, which are downstream
targets  of  PERK)  was  elevated  in  VSMCs  in  response  to  thapsigargin  treatment
(Figure 3.13). Tunicamycin upregulated ATF6, ATF4 and CHOP mRNA expression, but
did not change IRE1 and PERK expression, suggesting that there are differences in
the mechanisms of UPR induction between tunicamycin and thapsigargin.
Figure 3.13.  Quantitative real-time PCR analysis of ER stress activation in VSMCs. Cells were treated
with  0.4μg/ml  tunicamycin  (TM)  or  0.2μg/ml  thapsigargin  (TG)  for  24  hours.  N=3,  ANOVA with
Dunnett's  post  hoc tests  were  performed.  Statistical  significance  is  indicated  with  asterisks:  *
denotes p between 0.05 and 0.01, ** denotes p between 0.01 and 0.001, *** denotes p<0.001.
In order to further examine activation of the IRE1-mediated branch of the
unfolded protein response, splicing of its downstream target XBP1 was examined.
XBP1 splicing is indicative of ER stress and UPR activation. Figure 3.14 shows that
XBP1 is spliced even under control conditions, since a faint band corresponding to
the  spliced  PCR  product  is  visible,  which  reflects  the  fact  that  under  normal
conditions some basal, 'maintenance' levels of ER stress are activated in VSMCs (Wu
et  al. 2006;  Tsang  et  al. 2010).  However,  it  is  apparent  that  XBP1  splicing  was
induced  by  thapsigargin  and  to  a  lesser  extent  by  tunicamycin,  as  the  bands












CTRL     TM        TG
Figure 3.14. Analysis of XBP1 splicing in VSMCs treated with 0.4μg/ml tunicamycin (TM) or 0.2μg/ml
thapsigargin (TG) for 24 hours. Tunicamycin and thapsigargin induce XBP1 splicing, a marker of ER
stress. N=3, figure shows representative image.
To determine whether mRNA increases corresponded to increased ER stress
measured by protein changes, Western blots were performed for the chaperones
Grp78 and Grp94, which are downstream targets of all three UPR branches. Figure
3.15  shows  that  expression  of  both  chaperones  was  increased  by  a  24  hour
tunicamycin or thapsigargin  treatment.
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Figure 3.15. Western blotting analysis of Grp78 and Grp94 in response to ER stress in VSMCs treated
with  0.4μg/ml  tunicamycin  (TM)  or  0.2μg/ml  thapsigargin  (TG)  for  24  hours. A.  Representative
Western blot showing increased levels of ER stress markers Grp78 and Grp94 as a result of TM and
TG treatment. B. Quantification of the Western blots. Graph shows mean with SEM, n=8. Statistical
significance was tested with ANOVA with Dunnett's  post hoc tests; * denotes p between 0.05 and
0.01, ** denotes p values between 0.01 and 0.001.
In addition, as shown by immunocytochemistry in  Figure 3.16, levels of ER
Grp78 and Grp94 chaperones, ER stress transducers IRE1 and phosphorylated PERK
(p-PERK)  increased as  a result  of  tunicamycin and thapsigargin  treatments.  Both
IRE1  and  PERK  are  localised  in  the  ER  membrane.  In  basal  conditions  p-PERK
localised around the nucleus, and with tunicamycin and thapsigargin the staining
was stronger both around the nucleus and in the cytoplasm. IRE1 showed similar
nuclear staining at baseline, however upon ER stress treatment the staining became
most intensive in a reticular area close to the nucleus, with little staining in the
cytoplasm. The staining of both these ER stress transducers is consistent with their
ER localisation. The ER is connected with the nuclear membrane and in VSMCs often
spreads through the majority of the cell volume, this is illustrated by staining for
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Grp78  and  Grp94.  Western  blotting  for  ATF6,  IRE1  and  PERK,  both  total  and
phosphorylation-specific, was carried out, however it was unsuccessful, most likely
due to low abundance of these proteins in VSMCs (data not shown).
Taken together, these changes are indicative of a comprehensive activation














Figure 3.16. Increased levels of phosphorylated PERK (p-PERK), IRE1, Grp78 and Grp94 in response to
ER  stress  treatment  visualised  by  immunocytochemistry.  VSMCs  were  treated  with  0.4μg/ml
tunicamycin (TM) or 0.2μg/ml thapsigargin (TG) for 24h. N=3, figure shows representative images.
Scale bars are 20μm.
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Next,  I  analysed  changes  in  viability,  caspase  activation  and  necrosis  in
VSMCs in response to tunicamycin and thapsigargin treatments. The induction of
cell  death  by  the  ER  stress  treatments  could  interfere  with  interpretation  of
subsequent experiments, as it would be impossible to determine whether effects of
tunicamycin and thapsigargin are due to UPR signalling or the effect of apoptosis.
Figure 3.17.A  shows the results  of an MTT assay,  where tunicamycin and
thapsigargin decreased cell viability in a dose-dependent manner, with the highest
concentrations tested (1μg/ml)  causing a 60% drop in cell  viability  compared to
untreated cells (for which viability was set as 100%) after a 24 hour incubation.
Therefore in subsequent experiments concentrations that did not decrease viability
were used -  0.2μg/ml thapsigargin and 0.4μg/ml tunicamycin.
The caspase activation and necrosis assay was performed in order to look at
specific cell death pathways  (Figure 3.17.B). The 24 hour incubation of VSMCs at
baseline  condition  resulted  in  approximately  70%  of  cells  being  viable  (CTRL
sample).  The  addition  of  0.2μg/ml  thapsigargin  and  0.4μg/ml  tunicamycin
significantly increased the percentage of healthy cells to >80%, via a decrease in
apoptosis. The percentage of apoptotic cells was lowered by half. Tunicamycin and
thapsigargin did not change the percentage of necrotic cells. Staurosporine (SSP), a
known inducer of cell death (Bertrand  et al. 1994) was used as a positive control
and caused a marked increase in both apoptosis and necrosis. These results suggest




Figure 3.17. VSMC viability in response to ER stress. A. Tunicamycin and thapsigargin decrease VSMC
viability  dose-dependently.  Cells  were  treated with  tunicamycin  or  0.2μg/ml  thapsigargin  for  16
hours in M199 with 2% FBS. B. TM and TG treatments decrease apoptosis. Cells were treated with
0.4μg/ml tunicamycin (TM) or 0.2μg/ml thapsigargin (TG) for 24 hours in 0.5% FBS with TM and TG
for 3h with 0.5μg/ml staurosporine (SSP), caspase activation and necrosis was quantified with the
NucleoCounter  NC-3000.  Graphs show mean with  SEM, n=3 (except  SSP,  where n=1).  Statistical
significance was tested with ANOVA with Dunnett's  post hoc tests; * denotes p between 0.05 and
0.01, ** denotes p between 0.01 and 0.001.
3.6. ER stress increases calcification of VSMCs in vitro
The next  step was to examine whether induction of  ER stress influenced
calcification of VSMCs  in vitro. A different treatment protocol was established for
this experiment to reflect that vascular calcification is a process that happens over
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time. Therefore VSMCs were treated for 8 days and lower concentrations of the ER
stress inducers were used. Cells  were treated with increased levels  of  Ca and P
(2.7mM Ca2+, 2.5mM PO43-) to induce calcification and compared with control cells
in  medium  with  physiological  Ca  and  P  concentrations  (1.8mM  and  1mM,
respectively)  in  the presence or  absence of  low concentrations  of  the ER stress
inducers  tunicamycin  (0.02μg/ml),  thapsigargin  (0.01μg/ml)  and  the  ER  stress
inhibitor PBA. 
The optimal concentration of PBA was established based on a dose response
experiment (Figure  3.18).  Concentrations  ranging  from 0.05mM to  0.5mM were
tested. 0.5mM PBA was chosen for further experiments as it was most effective in
decreasing  Grp94  expression,  Grp78  did  not  change  in  this  experiment.  Higher
concentrations were not tested because they were likely to be toxic. There is no
literature on the use of PBA in human primary VSMCs, the studies that mention the
use of this compound treated rat VSMCs with 5mM PBA, but for a 1 hour treatment
(Liu  et al. 2011b).  Therefore for  a  longer time-point to treat  the more sensitive
human VSMCs I tested lower concentrations.
Figure 3.18. Attenuation of ER stress by 4-phenylbutyric acid (PBA). Western blot showing levels of
ER stress markers Grp78 and Grp94 in VSMCs treated with 0.02μg/ml tunicamycin (TM) or 0.01μg/ml
thapsigargin (TG) and 0-0.5mM PBA in M199 with 5% FBS for 5 days, n=1.
Alizarin  Red  S  staining  of  cells  treated  with  calcifying  conditions  (Figure
3.19.A) showed that  VSMCs  did  not  calcify  when  treated  with  tunicamycin  and
thapsigargin  alone.  However  in  the presence of  high  Ca  and P  calcification  was
increased by the addition of tunicamycin and thapsigargin. This effect was blocked
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These results were confirmed by quantification of calcium levels using the o-
cresolphthalein assay (Figure 3.19.B). Tunicamycin and thapsigargin alone did not
cause  a  significant  increase  in  calcification.  PBA  alone  and  in  combination  with
tunicamycin, thapsigargin and Ca and P did not cause any changes in calcification
compared  to  the  control  samples  (data  not  shown).  Treatment  with  Ca  and  P
induced  calcification  (Figure  3.19.B).  In  the  presence  of  Ca  and  P  tunicamycin
induced a 60-fold increase in calcification; this was reduced by PBA by half. In the
presence of Ca and P thapsigargin induced a 120-fold increase in calcification. PBA
was able to reduce this increase in calcification to approximately 50-fold. 
In  summary,  both  tunicamycin  and thapsigargin  increased calcification  of
VSMCs in the presence of high Ca and P, and PBA was able to reduce these effects




Figure 3.19. ER stress increases calcification of VSMCs. Cells were treated with 2.7mM Ca2+, 2.5mM
PO43-  (CaP), 0.04μg/ml tunicamycin (TM) or 0.01μg/ml thapsigargin (TG), 0.5mM PBA for 8 days in
M199 with  5% FBS.  A.  Alizarin  Red S  staining  of  VSMCs.  B. Calcification  quantified  with  the o-
cresolphthalein assay.  Graph shows mean with SEM, n=5. Statistical  significance was tested with
ANOVA with Tukey's post hoc tests; * denotes p between 0.05 and 0.01. Only relevant comparisons
are indicated.
The next step was to examine the effect of the calcification treatments on
cell death, since apoptosis is a well-established mechanism contributing to vascular
calcification. Figure 3.20 shows that at baseline, after 8 days in treatment conditions
cell viability was low, i.e. about 70% of cells had undergone necrosis and apoptosis.
This was in stark contrast to the 24 hour time-point, where only around 30% cells
were apoptotic or necrotic (Figure 3.17). 
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Tunicamycin and thapsigargin  alone caused only  a  small  and insignificant
increase in caspase activation, and did not change the percentage of necrotic cells.
High  Ca  and  P  treatment  did  not  change  the  percentage  of  healthy  cells,  but
changed  the  ratio  of  apoptotic  and  necrotic  cells,  with  a  significant  increase  in
necrosis. PBA alone and in combination with tunicamycin, thapsigargin and Ca and P
did not cause any changes in cell death rates compared to the control samples (data
not shown).
In the presence of Ca and P tunicamycin did not cause a significant change in
cell  death,  and  the  addition  of  PBA  had  no  effect  on  cell  viability.  However,
thapsigargin decreased apoptosis in the presence of Ca and P and increased the
percentage of healthy cells. This would suggest that thapsigargin can protect the
cells from apoptosis. PBA did not counter this effect.
Importantly, cell death rates were the same in pairs of samples treated with
TM versus  TM with PBA in the presence of  Ca and P,  and in corresponding TG
treated  samples,  where  differences  in  calcification  levels  were  observed (Figure
3.19).  This  means  that  decreasing  ER  stress  with  PBA  protected  VSMCs  from
calcification,  but  not  cell  death.  Therefore  the  differences  in  calcification  levels
between these pairs of samples cannot be attributed to changes in cell death rates.
This  suggests  that  cell  death  is  not  a  mechanism by  which  ER  stress  increased
calcification.
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Figure 3.20. The effect of ER stress on caspase activation and necrosis in calcifying VSMCs; measured
with  the NucleoCounter  NC-3000.  Cells  were treated with  2.7mM Ca2+,  2.5mM PO43-,  0.04μg/ml
tunicamycin (TM) or 0.01μg/ml thapsigargin (TG), 0.5mM PBA for 8 days in M199 with 5% FBS. Graph
shows mean with SEM, n=3. Statistical significance was tested with ANOVA with Tukey's  post hoc
tests; * denotes p between 0.05 and 0.01, ** denotes p between 0.01 and 0.001.
120
3.7. Discussion
3.7.1.  Vascular  calcification  is  associated  with  changes  in  ER  stress  marker
expression
In the first part of this chapter I showed that expression of ER stress markers
was  decreased in  fatty  streak  and  calcified  human aortic  samples  compared to
healthy. Expression of ER stress markers has never been measured in human aortas
before.  Studies  that  examined  ER  stress  activation  in  the  context  of  VSMC
calcification  either  showed the  expression  of  ER  stress  markers  in  cells  in  vitro
(Masuda et al. 2012, 2013 show increased PERK, ATF4, CHOP expression and XBP1
splicing; Liberman et al. 2011 – increased levels of Grp78, p-IRE1 and spliced XBP1)
or in rat  aortas  (Duan  et al. 2009, 2013 – Grp78, Grp94, PERK,  ATF4 and CHOP
expression). These studies, contrary to my results, demonstrated that calcification
was  associated  with  increased  ER  stress.  However,  it  is  difficult  to  draw  any
conclusions  from  comparing  animal  studies  with  my  results.  In  animal  models
vascular  calcification  was  induced  by  high  dose  vitamin  D  and  nicotine.  It  is
impossible to tell how relevant this model is to naturally occurring calcification.
Expression of osteogenic markers in the same human aortic samples was in
most  cases  decreased  in  fatty  streak  samples  compared  to  control  vessels  and
increased again to the level of healthy vessels in calcified aortas. The fatty streak
represents an earlier stage of atherosclerosis that can progress into calcified lesions
(Berliner et al. 2005). There is no literature on osteogenic gene expression in fatty
streak  vessels.  Increased  expression  of  osteogenic  markers  in  calcified  human
aortas is well documented (Shanahan et al. 1999a; Tyson et al. 2003) and thought to
be an indicator of their osteogenic differentiation. 
Further analysis of my results showed that expression of osteogenic markers
significantly correlated with ER stress markers in healthy and fatty streak but not in
calcified aortas, which is a completely novel finding. These results strongly suggests
that  in the initial  stages of  vascular  disease ER stress regulates osteogenic gene
expression in VSMCs. A major limitation of  these experiments was the fact  that
gene  expression  was  analysed  only  at  the  mRNA  level,  and  thus  might  not  be
121
consistent with changes in protein expression. What is more, even though the aortic
wall  is  mainly  built  of  VSMCs,  the samples  likely  have some contributions  from
endothelial cells and macrophages which might skew the results, as these cell types
have been shown to activate ER stress in various circumstances (Sanson et al. 2009;
Orso et al. 2011).
All  in  all,  these  results  suggest  that  ER  stress  regulates  expression  of
osteogenic  genes  in  the  initial  stages  of  vascular  disease,  but  that  vascular
calcification was associated with a decrease in ER stress marker expression in the
vessel wall.
3.7.2. Calcification-promoting factors induce ER stress in VSMCs in vitro
In order to better understand the relationship between vascular calcification
and ER stress it was important to examine whether known calcification-promoting
factors can change ER stress marker expression in human primary VSMCs in vitro.
First, I tested a range of cytokines which are reported to regulate VSMC phenotype
or promote vascular calcification in the literature.
I  began with TGFβ and PDGF as  these two cytokines are known to have
opposing  effects  on  the  phenotype  of  VSMCs.  TGFβ  increased  ATF4  and  CHOP
mRNA  expression.  In  VSMCs in  vitro the  effects  of  TGFβ  are  concentration
dependent.  At  low  concentrations,  consistent  with  my  experiments,  it  blocks
proliferation  and  promotes  the  contractile  phenotype  (Hirschi  et  al. 1998),  and
unpublished results from our laboratory show that it inhibits calcification of VSMCs.
At higher concentrations TGFβ mainly acts by stimulating growth and extracellular
matrix production, and has been shown to promote vascular calcification (Orlandi
et al. 1994; Simionescu  et al. 2005). As far as ER stress signalling is concerned, in
osteoblasts TGFβ has been shown to suppress ATF4 activity by increasing vimentin
expression (Lian et al. 2012), but in lung fibroblasts it increased ER stress via ROS
production, which in turn stimulated their myofibroblast differentiation (Baek et al.
2014). These studies suggest that the effects of TGFβ are context-dependent and
the same pathways might have different effects in different cell  types. They also
suggest that ER stress is activated only in differentiated VSMCs. This is consistent
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with  my  results  from  human  aortas  showing  that  ER  stress  marker  expression
decreases  as  the  vessels  progress  towards  calcification  and  perhaps  become
dedifferentiated.
Large variation was observed in results from experiments testing different
inducers  of  ER  stress.  In  each  repeat  of  the  experiment  the  inducers  caused a
change in the same direction, but to a different extent. This suggests that some of
the changes did not reach statistical significance because of low n numbers.
PDGF, which induces proliferation and migration of VSMCs, did not induce
ER  stress  in  my  experiments.  This  was  consistent  with  the  study  by  Yi  and
colleagues, who treated cells with PDGF and showed that it did not induce XBP1
splicing  or  Grp78  and  Grp94  chaperones.  They  also  showed  that  tunicamycin
inhibited PDGF signalling in rat primary VSMCs (Yi et al. 2012). This suggests that in
VSMCs PDGF does not act via the UPR.
Next, I went on to examine whether BMP-2 induced ER stress in VSMCs and I
found that it did not. This is in contrast to the findings of Liberman and colleagues,
who showed that BMP-2 induced ER stress via oxidative stress, as mentioned above
(Liberman  et  al. 2011).  In  addition,  in  my  experiments  BMP-2  was  not  able  to
increase the expression of osteogenic genes (data not shown). Research has shown
that BMP-2 can increase expression of osteogenic genes, among others Runx2, in
VSMCs  and  thus  promote  calcification  (Chen  et  al. 2006;  Li  et  al. 2008).  The
inconsistency  with  my  results  might  be  explained  by  the  fact  that  Chen  and
colleagues used bovine VSMCs and Li et al. used twice as much BMP-2 and in both
studies  VSMCs  were  treated  for  longer  time-points.  A  potential  issue  with  my
results is that I did not examine a positive control for BMP-2 effects, which would
indicate that BMP-2 was active in these treatments. I should have analysed SMAD1
and SMAD5 phosphorylation in order to be sure.
The  inflammatory  cytokine  TNFα  significantly  upregulated  IRE1  mRNA
expression.  As  TNFα  promotes  calcification,  these  findings  could  be  a  potential
mechanism that implicates ER stress in calcification. My results are partially in line
with research published by Masuda and colleagues (Masuda et al. 2013), who found
that TNFα triggered ER stress in mouse VSMCS. However, they report activation of
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the PERK, rather than IRE1, branch of the UPR. Again, the difference could be due to
the effect of TNFα on ER stress signalling being species-specific.  In addition,  my
experiments were limited to mRNA expression and Western blotting for Grp78 and
Grp94 chaperones,  which are  activated  by  all  three branches,  therefore  further
experiments are needed to explain this difference.
Next,  I  tested  a  range  of  conditions  relevant  to  CKD,  as  it  is  one  of
pathological contexts in which vascular calcification is highly prevalent.
Warfarin, which is administered to dialysis patients, induces expression of
ATF4, Grp78 and Grp94 in rat aortas. Experiments with human VSMCs treated with
warfarin  showed  a  trend  towards  an  increase  of  Grp78  and  Grp94  expression,
indicative of ER stress activation. It seems there would be an obvious link between
warfarin treatments and ER stress,  as warfarin inhibits carboxylation of proteins,
which happens in the ER (Rost et al. 2004), and that might be expected to induce ER
stress by a mechanism similar to tunicamycin, causing uncarboxylated proteins to
accumulate. However, these two processes have not been connected. In addition, it
is interesting to note that by immunohistochemistry warfarin increased expression
of the ER stress chaperones and ATF4 in the whole vessel wall, but ALP or Osterix
only in the calcified area. This is consistent with results from calcified human aortas
presented  in  this  chapter  because  it  suggests  an  uncoupling  of  ER  stress  and
osteogenic gene expression in calcification in an in vivo setting
Hydrogen  peroxide  treatments  did  not  consistently  induce  ER  stress  in
VSMCs. Liberman and colleagues (Liberman et al. 2011) have found that in human
primary coronary artery SMCs oxidative stress induced ER stress, observed as IRE1
phosphorylation, XBP1 splicing and Grp78 expression. However, the authors used
BMP-2 to  increase  ROS production,  not  hydrogen  peroxide and coronary  artery
VSMCs as opposed to aortic cells in my experiments. Therefore the differences in
the results could be due to a different mode of activating oxidative stress  and the
fact that cells from different vascular bed are known to have different properties
(Zhang  et  al. 2014;  Leroux-Berger  et  al. 2011).  A  potential  explanation  for  the
variability in my results was the lack of a positive control for oxidative stress, which
means I could not confirm whether oxidative stress was indeed activated in each of
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the experiments.  I  carried out Western blotting for  hyperoxidised peroxiredoxin,
but the antibody did not work (data not shown). Therefore, it is difficult to draw
conclusions about oxidative stress and ER stress in VSMCs.
HAp crystals, the endpoint of the process of calcification, were examined for
their ability to induce Grp78 and Grp94 expression. I have shown that  treatment
with  synthetic  HAp  did  not  consistently  increase  the  expression  of  these
chaperones.  The  reason  why  in  some  experiments  an  increase  was  observed,
whereas  in  some they did  not  change  might  be due to  technical  issues,  as  the
crystals  are  a  suspension  rather  than  solution  and  therefore  it  is  difficult  to
consistently  apply  the  same  amount.  In  addition,  calcium  phosphate  crystal
preparations have been shown to be quite heterogenous with respect to the size of
crystals,  which  might  also  explain  their  different  effect  on  cells  (Motskin  et  al.
2009). Calcium phosphate particles have been shown to induce osteogenic gene
expression and cell  death in VSMCs (Ewence  et  al. 2008; Sage  et al.  2011),  but
whether they do so via ER stress remains inconclusive. It is also worth noting that
the calcium phosphate particles used in the studies mentioned above might have
had different properties than the synthetic hydroxyapatite from Sigma, with respect
to particle size and calcium to phosphate ratio within the crystals.
Mineral  dysregulation,  common  in  dialysis  patients  with  CKD,  in  my
experiments modelled by treating VSMCs with high concentrations of Ca and P, did
not induce Grp78 and Grp94 expression. This is in contradiction to the findings of
Duan et al.  (2013),  who have shown that  treatment of  rat  primary VSMCs with
similar levels of Ca and β-glycerophosphate as a phosphate donor induced Grp78,
Grp94, PERK, ATF4 and CHOP expression. In my experiments I only looked at Grp78
and Grp94 chaperone expression, and not other UPR components. However, these
chaperones are activated downstream of all three UPR branches (Wang et al. 1998;
Wang et al. 2000; Luo  et al.  2003) and therefore serve as a good indicator of ER
stress  in  cells.  Based  on  that  I  can  conclude  in  human  VSMCs  high  Ca  and  P
treatment does not induce ER stress.
The  final  CKD-related  factor  tested  was  vitamin  D.  In  my  experiments  I
demonstrated that it does not induce Grp78 and Grp94 chaperone expression, or
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mRNA of other ER stress markers. In fact there was a trend of vitamin D decreasing
ER stress. My results were consistent with the only existing study linking ER stress
and vitamin D, which shows that in macrophages similar concentrations of vitamin
D attenuate ER stress and thus promote their anti-atherogenic phenotype (Riek et
al. 2012).
3.7.3. ER stress enhances calcification of VSMCs in vitro
To further examine the connection between ER stress and calcification in
VSMCs I modelled ER stress in vitro. The results show that ER stress can be induced
in human primary VSMCs in vitro by tunicamycin and thapsigargin and that all three
branches of the UPR were activated. 
The expression of ER stress markers was activated to a different extent by
the  two  ER  stress  inducers.  Differences  in  activation  of  the  UPR  branches  by
tunicamycin and thapsigargin have not been  studied, but research shows that in
VSMCs these two compounds can have different effects on expression of  other
genes, for example iNOS, and the fact was attributed to the different mechanisms
of action of the two inducers (Ohta et al. 2011).
In  calcification  assays  the addition of  ER stress  inducers  enhanced VSMC
calcification.  This is  consistent with existing literature showing that increased ER
stress leads to calcification (Masuda et al. 2012, 2013; Liberman et al. 2011; Duan
et  al. 2009,  2013)  and  suggests  that  in  my  experiments  ER  stress  activated
mechanisms  that  lead  to  calcification.  In  these  experiments  tunicamycin  and
thapsigargin  differed  in  their  ability  to  promote  calcification,  with  thapsigargin
increasing calcification more.  This  suggests that  the two inducers might  activate
different pathways leading to calcification.
One potential mechanism leading to vascular calcification is apoptosis. Duan
and colleagues (Duan et al. 2013) have shown that calcification of rat VSMCs was
associated with ER stress-dependent apoptosis. However, my results show that cell
death  was  not  involved  in  ER  stress-enhanced  calcification.  On  the  contrary,  I
demonstrated that thapsigargin decreased the rate of apoptosis. In addition, high
levels of Ca and P induced more necrosis alone than in the presence of tunicamycin
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and thapsigargin. These results suggest that ER stress protected the cells from cell
death. This inconsistency with the study mentioned above might be due to the fact
that a different species of cells and a different inducer was used (rat cells and high
Ca and P versus human cells and tunicamycin and thapsigargin).
3.7.4. Conclusions
To  summarise,  in  this  chapter  I  showed  that  vascular  calcification  is
associated with changes in ER stress marker expression.  I  demonstrated that ER
stress can be activated in VSMCs  in vitro and that it increased calcification in the
presence  of  Ca  and  P.  I  also  showed  this  was  not  associated  with  increased
apoptosis, and that ER stress decreased Ca and P induced cell death. Following from
that I examined potential inducers of calcification for their ability to induce ER stress
and found that ER stress is activated by factors that both inhibit (TGFβ) or promote
(TNFα, warfarin) calcification, suggesting that the connection between ER stress and
vascular calcification is complex.
My results  also  demonstrate  that  many  of  the  tested  ER stress  inducers
caused a small but consistent increase in ER stress marker expression. This could
reflect the fact that a single factor that induces ER stress strongly might not exist,
just as no condition in the body is characterised by a change in just one parameter.
Vascular calcification is a complex process and is caused by an interplay of a host of
factors, each contributing a little. It is therefore likely a host of factors can modulate
ER stress, each only to a degree.
In this chapter I explored apoptosis as a mechanism which could mediate ER-
stress induced calcification and found that it was not involved. Since expression of
osteogenic genes correlated with expression of ER stress markers in human aortas I
wanted to explore whether ER stress can influence expression of osteogenic genes
in VSMCs in vitro and modulate their phenotype.
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Chapter  4:  ER  stress  regulates  osteo/chondrogenic
gene expression in VSMCs
4.1. Introduction
In the previous chapter I established that ER stress increases calcification of
VSMCs in vitro in association with a key calcification inducer, such as high Ca and P
levels,  and  that  some factors  that  promote  vascular  calcification  can  induce  ER
stress. This suggests that ER stress might be a component regulating calcification,
but  is  not  capable  of  inducing  it  alone.  I  have  also  shown  that  changes  in
calcification  in  response  to  ER  stress  did  not  involve  apoptosis.  Expression  of
osteogenic markers correlated with ER stress markers in healthy and fatty streak
vessels but not in calcified aortas. These results suggested that osteo/chondrogenic
differentiation  of  VSMCs  could  be  linked  to  ER  stress  signalling  and  therefore
involved in ER stress-regulated VSMC calcification.
4.1.1. Osteo/chondrogenic differentiation of VSMCs
Osteo/chondrogenic  differentiation  is  a  result  of  phenotypic  transition  of
VSMCs.  In  the  vessel  wall  VSMCs  do  not  differentiate  terminally  and  show
phenotypic  plasticity.  They  regulate  vascular  tone  and  exist  as  contractile  cells
expressing  proteins  such  as  SM22α,  calponin  and  myosin,  which  are  proteins
associated  with  the contractile  function  (Shanahan et  al. 1993;  Shanahan et  al.
1998). In response to stress and injury VSMCs can proliferate, migrate and secrete
ECM proteins, decrease expression of contractility-related genes, and thus they are
able to repair the vessel (Shanahan et al. 1998; Shanahan et al. 1993). In conditions
when injury is persistent the phenotypic transition is dysregulated and VSMCs can
undergo  an  unfavourable  transdifferentiation  into  cells  with  characteristics  of
osteoblasts or chondrocytes  (Iyemere et al. 2006). During this process they start
expressing osteo/chondrogenic markers (Shanahan et al. 1999b; Speer et al. 2009).
The  observation  that  VSMCs  in  calcifying  blood  vessels  undergo  a  phenotypic
change  to  osteoblast/chondrocyte-like  cells  has  led  to  the  idea  that  vascular
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calcification  is  caused  by  pathological  induction  of  a  process  similar  to  bone
formation, which normally only occurs during bone development in the embryo. 
4.1.2. ER stress regulates osteo/chondrogenic gene expression in osteoblasts and
chondrocytes
Components  of  all  three  branches  of  the  UPR  (mediated  by  ER  stress
transducers  IRE1,  ATF6  and  PERK)  have  been  implicated  in  transcription  of  a
number of bone specific genes, which have been shown to be involved in vascular
calcification. 
For example, BMP-2 can activate IRE1 signalling, which results in increased
XBP1 expression, and IRE1α and XBP1 are required for maturation of preosteoblasts
to osteoblasts. XBP1 also directly activates the promoter of Osterix (Tohmonda  et
al. 2011) and it was shown to be a transcription target of ATF6 in BMP-2 stimulated
chondrocytes and to form a complex with Runx2 (Liu et al. 2012). 
BMP-2 was shown to upregulate CHOP, PERK, ATF4 and ATF6 expression in
osteoblasts (Tohmonda et al. 2011). A different study, also in osteoblasts, showed
that  Runx2 activated  expression  of  ATF6,  and  that  ATF6  directly  induced
transcription of OCN) (Jang et al. 2011), suggesting that there is a positive feedback
loop between ER stress and osteogenic gene expression.
Knock-outs of PERK and ATF4 in mice cause skeletal dysplasias at birth and
postnatal growth retardation (Yang  et al. 2004b; Saito et al. 2011). Furthermore,
ATF4  was  shown to directly  activate  transcription of  OCN and Ihh  (Wang  et  al.
2009).
In  addition to  the three  canonical  ER  stress  transducers  (IRE1,  ATF6  and
PERK) and their signalling pathways, two tissue-specific ER stress transducers OASIS
and  BBF2H7  have  been  shown  to  be  involved  in  osteoblast  and  chondrocyte
maturation,  respectively (Murakami et al. 2009; Saito et al. 2009).  Expression of
OASIS is induced by BMP-2 signalling in osteoblasts and it activates the transcription
of the collagen type 1 gene. Expression of BBF2H7 is induced in chondrocytes by
Sox9,  the  main  chondrogenic  transcription  factor  (Hino  et  al. 2014).  BBF2H7
activates  transcription of  Sec23a,  a  component  of  the protein  coat  of  secretory
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COPII vesicles, which are crucial for secretion of ECM (Saito et al. 2009). These two
ER stress transducers have not been shown to be expressed in VSMCs.
4.1.3. ER stress in osteogenic differentiation of VSMCs
It is evident that ER stress signalling via the canonical UPR pathways as well
as  tissue-specific  ER  stress  transducers  play  a  major  role  in  bone  formation.
Therefore,  drawing  on  the  similarities  between  bone  formation  and
osteo/chondrogenic  differentiation  of  VSMCs,  I  hypothesized  that  the  UPR  is
involved in regulating expression of osteo/chondrogenic genes in VSMCs.
Existing  studies  of  ER stress  in  vascular  calcification seem to point  to  an
important role for ATF4 in this process. It has been shown that ATF4 knock-down in
mouse VSMCs decreased stearate-induced calcification and expression of OCN, ALP
and Pit-1 (Masuda et al. 2012). Another study has shown that knock-downs of PERK,
ATF4 and CHOP decreased calcification of mouse VSMCs induced by TNFα, and that
it was accompanied by a decrease in osteogenic markers Pit-1, OCN, OPG, Osterix,
Runx2, and ALP (Masuda et al. 2013). In addition, in rat VSMCs, ATF4 knock-down
decreased expression of OPN, OCN and Runx2 and ALP activity (Duan et al. 2013).
Finally, in the only study in human cells, XBP1 was shown to bind and activate the
Runx2 promoter in BMP-2-treated coronary artery VSMCs (Liberman  et al. 2011).
However, none of these studies present an in-depth analysis of the UPR component
activation or osteogenic gene expression in VSMCs.
In  this  chapter  I  set  out  to  characterise  the  expression  of
osteo/chondrogenic genes in tunicamycin- and thapsigargin-treated human primary
VSMCs  in  vitro and  to  investigate  the  effect  of  specific  UPR  component  knock-
downs on the expression of these genes. 
4.2. ER stress regulates VSMC phenotype in vitro
4.2.1. Regulation of osteogenic gene expression
VSMCs were treated with tunicamycin and thapsigargin for  24 hours and
osteogenic  gene  expression  was  measured with  quantitative  real-time PCR.  The
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analysed osteogenic genes represent three levels of signalling (Figure 4.1), (1) bone
formation  inducers:  BMP-2,  (2)  transcription  factors  that  act  downstream  from
BMP-2:  Runx2,  Osterix,  Msx2,  Dlx5  and  Sox9  and  (3)  ECM  proteins  and
mineralisation  regulators  whose  expression  is  regulated  by  the  upstream
osteo/chondrogenic transcription factors: ALP, BSP, OCN, OPG and COMP. Sox9 and
COMP are chondrocyte-specific genes, the rest are characteristic of osteoblasts.
Bone formation inducers
Transcription factors
ECM proteins, mineralisation regulators
BMP-2
Runx2 Osterix Msx2 Dlx5 Sox9
ALP BSP OCN OPG COMP
Figure 4.1.  Regulation of  osteo/chondrogenic gene expression during bone formation.  Schematic
illustrating  components  of  osteo/chondrogenic  pathways,  whose  expression  was  examined  in
subsequent experiments in this chapter.
Expression  of  BMP-2,  the  main  osteogenic  cytokine,  decreased  in  cells
treated with both ER stress inducers (Figure 4.2.A).
The  expression  of  chondrogenic  transcription  factor  Sox9  mRNA  was
decreased by both ER stress inducers, however the expression of its transcriptional
target COMP did not change (Figure 4.2.B).
Levels of transcription factors, which are regulated by BMP-2 in osteoblasts,
were also changed by ER stress treatments, however they did not follow the same
pattern as BMP-2 (Figure 4.2.C). Osterix expression was increased by both inducers.
Expression  of  Runx2  was  increased  by  tunicamycin,  but  did  not  change  after
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thapsigargin  treatment.  Expression  of  Msx2  increased  after  tunicamycin  and
thapsigargin treatments (1.4 and 1.5-fold increase, respectively) and expression of
Dlx5 decreased (0.6 and 0.7-fold change), but these changes were not statistically
significant.
 A  selection  of  ECM  proteins  and  mineralisation  regulators,  which  are
downstream  targets  of  BMP-2  signalling,  was  examined  next  (Figure  4.2.D).
Expression of BSP, ALP and OPG was significantly increased with at least one of the





Figure 4.2. Quantitative real-time PCR analysis  of  osteogenic  gene expression in response to ER
stress.  A BMP-2 –  inducer of  bone formation,  B chondrogenic  genes,  C osteogenic  transcription
factors  and  D ECM  proteins  and  mineralisation  regulators.  VSMCs  were  treated  with  0.4μg/ml
tunicamycin (TM) or 0.2μg/ml thapsigargin (TG) for 24 hours. Graphs show n=4-14, mean and SEM,
ANOVA  with  Dunnett's  post  hoc tests  was  performed.  Statistical  significance  is  indicated  with
asterisks: * denotes p between 0.05 and 0.01,  ** denotes p between 0.01 and 0.001, *** denotes
p<0.001.
Western  blotting  analysis  was  performed  in  order  to  examine  whether
changes in mRNA expression correspond to changes at the protein level. 
VSMCs  were  treated  with  tunicamycin  and  thapsigargin  in  the  same
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conditions  as  the  real-time  PCR  experiments,  and  expression  of  osteogenic
transcription factors was analysed by Western blotting (Figure 4.3.B and C). Runx2
expression  did  not  change  in  response  to  ER  stress  (1.1  fold  change  with  both
inducers). Osterix increased 5.8 fold with tunicamycin treatment and decreased 0.3
fold  with  thapsigargin.  Expression  levels  of  Sox9,  the  main  chondrogenic
transcription factor, increased by 1.3 fold with tunicamycin, but decreased by 0.8
fold with thapsigargin. None of these changes were statistically significant in n=3
experiments.  From the  three  transcription  factors  analysed,  only  in  the  case  of
Osterix increased protein levels in tunicamycin-treated cells corresponded with the
same trend in mRNA levels measured by real-time PCR.
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Figure 4.3. Western blotting analysis of osteogenic gene expression in VSMCs. A. Validation of anti-
bodies. VSMCs and U2OS cell lysates probed for Runx2 (100kDa specific band, nonspecific 25kDa
band). HEK293T cells transfected with an Osterix-myc construct probed for Osterix (bands of 40-
50kDa - different states of phosphorylation; 60kDa band  - myc-tagged Osterix, nonspecific bands at
25 and 80 kDa). SAOS-2 cell lysates probed for Sox9 (specific 55kDa band, strong nonspecific bands at
100-150kDa). B. VSMCs were treated with 0.4μg/ml tunicamycin (TM) or 0.2μg/ml thapsigargin (TG)
for 24 hours, representative images. C. Quantifications (mean with SEM, n=3, ANOVA with Dunnett's
post hoc tests was performed).
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4.2.2.  Osteoblast-  and  chondrocyte-specific  ER  stress  transducers  OASIS  and
BBF2H7 are expressed in VSMCs
Next, in order to examine whether tissue specific UPR components played a
role  in  osteo/chondrogenic  differentiation  on  VSMCs,  expression  of  ER  stress
transducers OASIS and BBF2H7 and their target genes was examined. In osteoblasts,
OASIS  expression  is  activated  by  BMP-2,  and  it  leads  to  increase  expression  of
COL1A1.  In  chondrocytes,  Sox9  activates  expression  of  BBF2H7,  which  leads  to
increased expression  of  Sec23a  (Figure  4.4).  Expression  of  both  these  ER  stress
transducers has not been shown in VSMCs before.
 
Bone formation inducers/ER stress inducers
ER stress transducers/Transcription factors




Figure 4.4. Tissue-specific ER stress transducers and regulation of osteo- and chondrogenic signalling
pathways.
Real-time  PCR  analysis  showed  that  expression  of  OASIS  decreased
significantly  with  thapsigargin  treatment  and  did  not  change  with  tunicamycin
treatment  (Figure  4.5.A).  Expression  of  its  transcriptional  target  gene  COL1A1
mRNA  followed  the  exact  same  pattern.  Expression  of  chondrocyte-specific  ER
stress transducer BBF2H7 mRNA was significantly  decreased by tunicamycin and
unchanged by thapsigargin treatment. Sec23a, the transcriptional target of BBF2H7
followed the same pattern (Figure 4.5.A).
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Expression of  OASIS  and BBF2H7 was  also analysed  by  Western  blotting.
Figure 4.5.C and D shows that expression of cleaved OASIS increased 1.6 fold (±0.6)
with tunicamycin and did not change with thapsigargin (1.06±0.4 fold change). The
levels of full-length BBF2H7 were unchanged by either tunicamycin or thapsigargin
(1±0.2 and 1.1±0.2 fold change, respectively).
These results suggest that while ER stress suppressed expression of OASIS
and BBF2H7 mRNA, this did not translate into changes at the protein level. COL1A1
and Sec23a mRNA followed the same expression pattern as the transcription factors
regulating their expression, they were downregulated by one inducer but not the
other. Together this suggests that both these pathways (BMP-2-OASIS-COL1A1 and
Sox9-BBF2H7-SEC23A) as a whole were suppressed, each by a different ER stress
inducer.
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Figure 4.5. Expression of tissue specific ER stress transducers OASIS and BBF2H7 and their target
genes in VSMCs. A. Real-time PCR analysis. VSMCs were treated with 0.4μg/ml tunicamycin (TM) or
0.2μg/ml thapsigargin (TG) for 24 hours, mean and SEM, n=3, ANOVA with Dunnett's post hoc tests
was performed, * denotes p between 0.05 and 0.01, ** denotes p between 0.01 and 0.001, *** de -
notes p<0.001. B. Validation of antibodies for Western blotting - U2OS cell lysate probed for OASIS
and BBF2H7 (OASIS - a specific 50kDa band corresponding to the cleaved OASIS, several nonspecific
30kDa, 75 kDa and 100kDa bands; BBF2H7 - full-length protein at 80kDa, unspecific bands 25-30kDa).
C. Western blotting analysis of VSMC lysates probed for OASIS and BBF2H7, representative image. D.















































































4.2.3. ER stress downregulates SMC contractile marker expression
Osteogenic differentiation of VSMCs is accompanied by the loss of smooth
muscle cell-specific contractile markers (Shanahan  et al. 1998; Steitz  et al.  2001;
Iyemere  et al. 2006).  Therefore, expression of three components of  the smooth
muscle cell contractile machinery was examined alongside osteogenic markers, to
characterise the effect of ER stress on this aspect of VSMC phenotype.
The mRNA levels of SM22α (TAGLN), a contraction regulating protein, was
significantly decreased by both tunicamycin and thapsigargin (0.5±0.2 and 0.6±0.1
fold decrease, respectively; Figure 4.6.A), and this corresponded to a slight decrease
in protein  expression  (0.8±0.1  and  0.9±0.3  fold  decrease,  respectively;  Figure
4.6.B). 
Another two markers were only analysed by Western blotting. Protein levels
of  calponin  1  (CNN1,  an  actin  binding  protein)  were  decreased by 0.9±0.2  and
0.8±0.1 fold by tunicamycin and thapsigargin,  respectively (Figure 4.6. B and C).
Phosphorylated myosin light chain protein (p-MLC, or MYL2), which is also involved
in regulating SMC contraction, was significantly downregulated by both tunicamycin
and thapsigargin (0.7±0.1 and 0.5±0.2 fold decrease, respectively; Figure 4.6. B and
C).  These results suggest that in VSMCs ER stress induces loss of the contractile
phenotype.
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Figure 4.6. Expression of SMC contractile markers in response to ER stress. VSMCs were treated with
0.4μg/ml  tunicamycin  (TM)  or  0.2μg/ml  thapsigargin  (TG)  for  24  hours.  A. Analysis  of  SM22α
expression  by  real-time  PCR.  B.  Representative  Western  blots  of  CNN1,  SM22α  and  p-MLC.  C.
Quantification of western blots. All graphs show n=3, mean with SEM. ANOVA with Dunnett's post
hoc tests was performed. Statistical significance is indicated with asterisks: * denotes p between 0.05
and 0.01, ** denotes p between 0.01 and 0.001.
The results  so far,  summarised in Table  4.1,  show that  tunicamycin-  and
thapsigargin-induced ER stress has an effect on osteogenic gene and SMC marker
expression in VSMCs. From the summary it is apparent that expression of very few
of the tested genes did not change with tunicamycin or thapsigargin treatments.
Changes in osteogenic and SMC marker expression are consistent with a role of ER
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Looking  at  real-time  PCR  results,  BMP-2  expression  was  downregulated,
while many of its downstream targets – transcription factors or ECM components
were upregulated. This suggests that the expression of the downstream targets is
uncoupled from BMP-2 expression in VSMCs in response to ER stress. This is also
consistent  with  results  from  the  previous  chapter  showing  that  BMP-2  did  not
induce ER stress or osteogenic gene expression in VSMCs. 
Another observation is that Osterix was the only osteogenic marker which
responded to ER stress at the protein level.
Table 4.1. Regulation of osteo/chondrocytic gene and SMC marker expression by ER stress in VSMCs
analysed by real-time PCR and Western blotting, fold changes in expression, compared to untreated
cells. '*' denote statistically significant changes. Data regarding Dlx5 and Msx2 come from  real-time
PCR results in the next section of this chapter.  †ALP – data in the WB columns are activity levels,
experiments shown in the next chapter.
Gene Description
qPCR WB
TM TG TM TG
1 BMP-2 Main bone morphogenetic cytokine. 0.3* 0.4*
2 Runx2 Osteogenic transcription factors downstream of BMP-2,
they regulate expression of many extracellular matrix 
(ECM) components and mineralisation-regulating 
proteins.
1.9* 0.93 1.1 1.1
3 Osterix 2.6* 2.1 5.8 0.3
4 Dlx5 0.6 0.7
5 Msx2 1.4 1.5
6 BSP Bone ECM component, binds hydroxyapatite. 4.7* 3.7*
7 ALP† Promotes mineralisation by providing phosphate. 2.8* 4* 1.7* 0.8
8 OPG Mineralisation inhibitor. 0.4 2.2*
9 OCN Late osteoblast marker, regulates mineralisation. 1.1 1.1
10 Sox9 Chondrogenic transcription factor. 0.2* 0.5* 1.3 0.8
11 COMP Cartilage ECM component, target of Sox9. 1.2 1.1
12 OASIS Osteoblast-specific ER stress transducer. 0.7 0.6* 1.6 1.1
13 COL1A1 Bone ECM protein, target of OASIS. 0.9 0.5*
14 BBF2H7 Chondrocyte-specific ER stress transducer. 0.6* 1 1 1.1
15 SEC23A Target of BBF2H7, involved in vesicle transport of ECM 
proteins.
0.5* 1.1
16 SM22α VSMC-specific markers, involved in regulating cell 
contractions.
0.5* 0.6* 0.8 0.9
17 CNN1 0.9 0.8
18 p-MLC 0.7 0.5*
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4.3.  Specific  UPR  pathways  regulate  osteogenic  gene  expression  in
VSMCs
In  order  to  distinguish  which  ER  stress  pathways  mediate  the  observed
changes  in  osteo/chondrogenic  gene  expression,  siRNA  knock-downs  of  the
canonical ER stress transducers IRE1, PERK, ATF6 as well as ATF4, which is activated
downstream of PERK, were carried out. Cells were then treated with tunicamycin
and thapsigargin and osteogenic gene expression was measured by real-time PCR.
All of the initially tested osteogenic genes were examined (Figure 4.1, Table 4.1).
Even though not all changed with ER stress, it was hypothesized that their baseline
expression could be controlled by UPR components.
First, expression of all  three ER stress transducers (IRE1, ATF6, PERK) and
ATF4 was measured to examine whether the siRNA knock-downs were efficient.
Figure 4.7 shows that each siRNA smartpool substantially lowered the levels of its
target mRNA. 
Figure 4.7. Quantitative real-time PCR analysis of ER stress markers in VSMCs treated with with IRE1,
ATF6,  PERK  or  ATF4  siRNA  or  non-targetting  siRNA  (Neg  Ctrl)  for  48  hours  and  then  0.4μg/ml
tunicamycin (TM) or 0.2μg/ml thapsigargin (TG) for 24 hours. Graphs show mean and SEM, n=3,
ANOVA with Tukey's post hoc tests was performed. Statistical significance is indicated with asterisks:
* denotes p between 0.05 and 0.01, *** denotes p<0.001.
Next, osteo/chondrogenic gene expression was analysed after knock-down
of the UPR components. The first gene analysed was BMP-2, an inducer of bone
formation.  Knock-downs  of  ATF6  and  ATF4  caused  BMP-2  mRNA  expression  to
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increase at baseline, but not in tunicamycin- and thapsigargin-treated cells (Figure
4.8). IRE1 and PERK knock-downs had no effect on BMP-2 expression. These results
suggest that in normal conditions ATF4 and ATF6 suppress BMP-2 expression, and
that  additional  factors  must  exist,  apart  from the tested  UPR components,  that
regulate BMP-2 expression in ER stress conditions.
Figure 4.8. Quantitative real-time PCR analysis of BMP-2 expression in VSMCs treated with with IRE1,
ATF6,  PERK  or  ATF4  siRNA  or  non-targetting  siRNA  (Neg  Ctrl)  for  48  hours  and  then  0.4μg/ml
tunicamycin (TM) or 0.2μg/ml thapsigargin (TG) for 24 hours. Graphs show n=3, mean with SEM,
ANOVA with Tukey's post hoc tests was performed. Statistical significance is indicated with asterisks:
* denotes p between 0.05 and 0.01.
Next, expression of osteogenic transcription factors, which act downstream
of  BMP-2,  was  analysed  in  the  absence  of  the  UPR  components  (Figure  4.9).
Expression  of  Runx2  mRNA did  not  change  significantly  with  any  of  the  knock-
downs,  but  increased  by  approximately  0.5-fold  in  the  absence  of  ATF4,  which
suggests that ATF4 could potentially suppress its expression. Expression of Osterix
was very variable, therefore only trends were observed – it was decreased by IRE1,
PERK and ATF4 knock-downs. Similarly, expression of Msx2 was very variable, but it
was decreased approximately 1.5-fold by ATF6 knock-down and increased 2-fold by
ATF4 knock-down. Expression of Sox9 was not changed by any of the knock-downs.
Dlx5,  whose  expression  was  only  measured  after  IRE1  and  PERK  knock-downs,
increased by approximately 0.5-fold after both, but the change was not statistically
significant in n=3 experiments.
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Figure 4.9. Quantitative real-time PCR analysis of osteo/chondrogenic transcription factors in VSMCs
treated with with IRE1, ATF6, PERK or ATF4 siRNA or non-targetting siRNA (Neg Ctrl) for 48 hours and
then 0.4μg/ml tunicamycin (TM) or 0.2μg/ml thapsigargin (TG) for 24 hours. Graphs show n=3, mean
with SEM, ANOVA with Tukey's post hoc tests was performed.
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Finally,  expression of selected ECM and mineralisation-regulating proteins
was analysed in the absence of IRE1, ATF6, PERK and ATF4 (Figure 4.10). Results
show that ALP expression did not change after IRE1 knock-down, but decreased
with ATF6, PERK and ATF4 knock-downs. Only in the absence of ATF4 was the ER-
stress induced increase in ALP expression completely attenuated. Expression of BSP
increased by approximately 2-fold with IRE1 knock-down, and did not change after
knock-downs of the other UPR components. OPG expression was decreased by IRE1
and PERK knock-downs in thapsigargin treated cells. It increased by 0.5-fold with
ATF4 knock-down at baseline and in thapsigargin treated cells. None of the changes
in OPG expression were statistically significant. OCN expression was analysed only
after  ATF4  knock-down.  Even  though  OCN  expression  did  not  change  after
tunicamycin  and  thapsigargin  treatments  (Figure  4.2),  it  was  increased  by  the
knock-down  of  ATF4  in  all  three  conditions,  and  the  change  was  statistically
significant in thapsigargin treated cells.  This  suggests  that  ATF4 suppressed OCN
expression both at baseline and in ER stress conditions. 
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Figure 4.10. Quantitative real time PCR analysis of osteo/chondrogenic genes in VSMCs treated with
with  IRE1,  ATF6,  PERK  or  ATF4 siRNA or  non-targetting siRNA (Neg Ctrl)  for  48 hours  and then
0.4μg/ml tunicamycin (TM) or 0.2μg/ml thapsigargin (TG) for 24 hours. Graphs show n=3, mean with
SEM, ANOVA with Tukey's  post hoc tests was performed.  Statistical significance is indicated with
asterisks: * denotes p between 0.05 and 0.01.
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The knock-down results are summarised in Table 4.2; it is evident that UPR
pathways regulate osteogenic gene expression components. The results described
in this section are put in the context of UPR signalling in Figure 4.11, which also
shows  changes  that  were  trends.  These  results  suggest  that  regulation  of
osteo/chondrogenic genes by ER stress is very complex, with some genes regulated
by more than one branch of the UPR.
Table 4.2. Regulation of osteo/chondrocytic gene and SMC marker expression by UPR components in
VSMCs analysed by real-time PCR and Western blotting. Key: '+' denotes increase, '-' decrease and 'o'
no change, blank means analysis was not carried out. Statistically significant changes are indicated
with '*'. †ALP – data in the WB columns are activity levels, experiments shown in the next chapter.
Gene
Compared to CTRL Compared to baseline response to ER stress
qPCR WB IRE1 ATF6 PERK ATF4
TM TG TM TG CTRL TM TG CTRL TM TG CTRL TM TG CTRL TM TG
1 BMP-2 -* -* o o o +* o o o o o +* o o
2 Runx2 + o o o o o o o o o o o o + + +
3 Osterix +* + +* - o - o o - o o - o o - -
4 Dlx5 o o o + + o + +
5 Msx2 o o o o o + - - o o o o + o
6 Sox9 -* -* o o o o o o o o o o o o o o
7 BSP +* +* o + o o o o o o o o o o
8 ALP† +* +* +* o o o o o - - o - - o - -*
9 OPG o +* o o - o o - o o +
10 OCN o o + + +*
ATF4 knock-down affected expression of the most genes, which is consistent
with  its  well-established roles  in  bone  formation  and  potentially  calcification  of
VSMCs. However, the knock-down results suggest that ATF4 inhibits expression of
OPG, OCN, Msx2, Runx2 and BMP-2, and activates ALP and Osterix (Figure 4.11),
which is not consistent with its role as a calcification-promoting transcription factor.
In  addition,  the results  show that  knock-down of  PERK did  not  cause the same
changes in gene expression as knock-down of ATF4, its downstream target, in fact
knock-down of PERK did not cause a decrease in ATF4 expression (data not shown).


















Figure 4.11. Regulation of osteogenic genes by the unfolded protein response transducers IRE1,
PERK and ATF6, and PERK downstream target ATF4. Arrows denote activation and blunt ends mean
inhibition. Statistically significant changes are marked with red lines. Levels of Sox9 did not change
markedly with any of the knock-downs, therefore it was placed outside the UPR signalling pathway.
4.4. Global downregulation of TGFβ signalling in tunicamycin-treated
VSMCs
Given the variability in responses shown in the previous experiments, a real-
time  PCR  array  was  used  as  a  second  approach  to  examine  the  regulation  of
osteogenic gene expression in response to ER stress. The expression of a total of 88
genes, including some already examined, was tested by real-time PCR in response
to tunicamycin treatment. Tunicamycin was chosen, as in the initial real-time PCR
results  it  changed the  expression  of  more  osteogenic  genes  than thapsigargin.  
Figure  4.12  shows  that  among  the  genes  which  could  be  successfully
measured,  most decreased in response to ER stress.  PHEX and PDGFRB were of
special  interest,  as  they  were  among  the  few  genes  whose  expression  was
consistently upregulated.
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Figure 4.12. Osteogenic real-time PCR array results. VSMCs were treated with 0.4μg/ml tunicamycin
for  24  hours.  Graph  shows  mean  and  SEM,  n=3,  t-tests  were  performed  for  control  versus
tunicamycin-treated  samples  for  each  gene.  Statistical  significance  is  indicated  with  asterisks:  *
denotes p between 0.05 and 0.01.
To  validate  some of  the  differences  in  gene  expression,  and to  examine
whether thapsigargin had the same effect on the genes that showed the biggest
changes in the array, conventional real-time PCRs and Western blots were carried
out.  Figure  4.13.A shows that  by real-time PCR BMP-7,  COL14A1,  PDRGFRB and
PHEX  were  indeed  upregulated  by  tunicamycin,  but  not  thapsigargin.  However,
MMP8  was  upregulated  by  thapsigargin,  not  tunicamycin,  and  MMP9  was
downregulated by both treatments. In addition, similar to what was observed in the
array, tunicamycin treatment downregulated expression of VDR (both mRNA and
protein), but thapsigargin had no effect (Figure 4.13.B). BMP-7, COL14A1, PDRGFRB,
PHEX,  MMP8  and  MMP9  are  not  known  to  interact  with  each  other  or  to  be
involved in the same signalling pathways.
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Figure 4.13. Validation of real-time PCR array results  A by real-time PCR and  B Western blotting.
VSMCs were treated with 0.4μg/ml tunicamycin (TM) or 0.2μg/ml thapsigargin (TG) for 24 hours.
Graphs show mean and SEM, n=3, ANOVA with Dunnett's post hoc tests was performed. Statistical
significance is indicated with asterisks: * denotes p between 0.05 and 0.01,  ** denotes p between
0.01 and 0.001, *** denotes p<0.001.
In  order  to draw conclusions  regarding  signalling  pathways,  in  which  the
products of the genes analysed in the array are involved, the array results were
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databases by Cytoscape (Figure 4.14). It  became apparent that a large cluster of
interacting proteins that were regulated simultaneously belong to the TGFβ family
signalling pathways – TGFβs, BMPs and their receptors and SMADs, and that they
were downregulated by ER stress.
Figure 4.14. Osteogenic array results overlaid over a protein-protein interactions network retrieved
by  Cytoscape.  Expression  levels  are  colour  coded  –  red  means  upregulation  and  blue  means
downregulation, the intensity of the colour reflects the magnitude of the change.
Some of these findings were then validated further by real-time PCR. The
results show that tunicamycin treatment decreased TGFBR1 and TGFBR2 mRNA by
0.5-fold, and increased SMAD1, but had no effect on SMAD5 or TGFB2 expression
(Figure  4.15).  Thapsigargin  treatment  increased  SMAD1  and  decreased  TGFBR1
mRNA but had no effect on the other tested genes. None of the observed changes
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were statistically significant in n=3 experiments (Figure 4.15), which means that the
array results were not repeatable and therefore could not be validated.
Figure 4.15. Validation of real-time PCR array – TGFβ family signalling. VSMCs were treated with
0.4μg/ml tunicamycin (TM) or 0.2μg/ml thapsigargin (TG) for 24 hours. Graphs show mean and SEM,
n=3, ANOVA with Dunnett's post hoc tests was performed.
SMAD expression was also analysed by Western blotting. As shown in Figure
4.16,  SMAD1  protein  expression  levels  reflect  its  mRNA,  since  no  change  was
observed with either of the ER stress treatments. SMAD2 was increased with both
ER stress treatments, but the changes were not statistically significant. Thapsigargin
(but not tunicamycin) caused a significant decrease in the levels of SMAD3. SMAD4
expression did not change.
In the TGFβ family signalling TGFβ/BMP binding leads to the assembly of a
receptor complex in which the type II  receptor phosphorylates and activates the
type  I  receptor.  Pathway  restricted  SMADs  (SMAD2  and  SMAD3  for  TGFβ  and
SMAD1  and  SMAD5  for  BMPs)  are  then  phosphorylated,  which  leads  to
heterodimerization with SMAD4, a common-mediator SMAD. The complex is then
translocated to the nucleus, where it binds directly to DNA and affects transcription
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of specific genes (Heldin et al. 1997). In this light, the fact that SMAD1 expression
was increased by tunicamycin and thapsigargin might mean that BMP signalling is
increased.  Expression  of  both  TGFβ  receptors  was  decreased  by  ER  stress,  but
SMAD2 and SMAD3 were differentially regulated in these experiments. Therefore it
is difficult to draw definite conclusions about this signalling pathway. In addition,
because SMADs are activated by phosphorylation, it is important to remember that
changes or lack of changes of protein levels might not correspond to actual changes
in signalling. These findings were not pursued further as the real-time PCR results
were not reproducible and only small changes were observed at the protein level.
Therefore  it  was  deemed  impractical  to  test  further,  phosphorylation-specific
antibodies against SMADs.
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Figure 4.16. Validation of the real-time PCR array – SMAD expression. VSMCs were treated with
0.4μg/ml tunicamycin (TM) or 0.2μg/ml thapsigargin (TG) for 24 hours. Graphs show mean and SEM,
n=3, ANOVA with Dunnett's  post hoc tests was performed.  Statistical significance is indicated with
asterisks: ** denotes p between 0.01 and 0.001.
4.5. Discussion
In  this  chapter  I  have  shown  that  ER  stress  regulates  expression  of
osteogenic genes in human primary VSMCs via specific unfolded protein response
pathways.
4.5.1. ER stress modulates VSMC phenotype
Tunicamycin and thapsigargin treatments changed expression of almost all
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examined  osteo/chondrogenic  genes  in  VSMCs.  Some  of  the  changes  were
decreases (BMP-2, Sox9 by both inducers, OPG by tunicamycin) and some increases
(Runx2 by tunicamycin, Osterix, BSP, OPG by thapsigargin). The fact that all these
genes  are  not  regulated  in  the  same  direction  might  reflect  the  fact  that  in
osteogenic differentiation of VSMCs the expression of these genes has no temporal
pattern as it is regulated by aberrant signals, in contrast to osteoblasts where during
bone formation these proteins are expressed in a concerted manner, following a
strict order. During embryonic development BMP-2 activates Runx2 signalling, Osx,
Dlx5 and Msx2 play secondary roles (Nakashima  et al. 2003, Komori  et al. 2006,
Karsenty et al. 2009).
There is  a  lack  of  literature  on the regulation  of  osteogenic  pathways  in
VSMCs  in  the  context  of  vascular  calcification,  which  is  surprising  because
expression  of  osteogenic  genes is  widely  mentioned as  one of  the hallmarks  of
vascular calcification (Shao et al. 2006; Speer et al. 2009). Osteogenic markers are
either reported to be present in calcified arteries or not mentioned at all,  which
suggests that little thought is given to their regulation and role in VSMCs. My results
are  therefore  the  first  comprehensive  analysis  of  the  effects  of  ER  stress  on
osteogenic gene expression in VSMCs.
Another important finding is the fact that at the protein level expression of
Osterix  was  upregulated  by  tunicamycin,  but  Runx2  was  not.  Thapsigargin
decreased the expression of Osterix at the protein level, but did not change the
expression of Runx2. Osterix acts downstream of Runx2 in osteoblasts (Nakashima
et  al. 2002;  Matsubara  et  al. 2008),  however  in  VSMCs  its  regulation  by  other
osteogenic genes is unknown. Runx2 is important for VSMC calcification both  in
vivo and  in  vitro,  but  mechanisms  of  its  regulation  in  these  cells  are  unknown
(Bostrom et al. 2011; Sun et al. 2012). My results suggest that in VSMCs an increase
in Runx2 expression is not required for an increase in Osterix expression. 
I  have  also  included  two  tissue-specific  ER  stress  transducers  OASIS  and
BBF2H7 in the osteogenic gene analysis and demonstrated that they are expressed
in VSMCs,  which has not  been shown before.  I  found that  their  expression was
decreased by tunicamycin and thapsigargin. OASIS and BBF2H7 expression was not
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examined in subsequent knock-down experiments, because their expression was
not  induced  by  ER  stress  and  also  because  they  are  ER  stress  transducers
themselves  and  therefore  unlikely  to  respond  to  changes  in  levels  of  other
transducers.
In  this  chapter  I  also  presented  evidence  that  VSMC  contractile  marker
expression was downregulated by tunicamycin and thapsigargin treatments (SM22α
mRNA and p-MLC protein). The expression of these markers in the context of ER
stress has not been studied before, therefore these findings are novel. VSMCs have
been shown to lose expression of contractile markers when they calcify (Iyemere et
al. 2006;  Speer  et  al. 2009),  so these results  support  the notion  that  ER  stress
promotes  transdifferentiation  to  a  secretory  or  osteo/chondrogenic  phenotype.
Moreover,  results  from  the  real-time  PCR  array  show  that  ER  stress  increased
expression  of  PDGFRB  associated  with  the  synthetic  phenotype,  and  decreased
expression  of  SMAD3 which  mediates  TGFβ signalling  classically  associated  with
contractile differentiation. On the other hand, these results could be interpreted
that ER stress induces transition to the synthetic phenotype, which cells assume in
response to injury and which provides a way for them to cope with environmental
stress. This conclusion is also supported by the fact that ER stress decreased the
expression  of  BMP-2,  and  that  the  knock-down of  ATF6  and ATF4  increased its
expression,  which means that  although a transition to a  secretory phenotype is
activated,  osteogenic  differentiation is  not promoted. In addition,  in Chapter 3 I
showed that pro-contractile TGFβ can induce ER stress. In the light of the current
results this is consistent with ER stress protecting from osteogenic phenotype, as a
result of TGFβ signalling, and could mean that there is a negative feedback loop of
TGFβ activating ER stress and then ER stress inhibiting TGFβ signalling.
4.5.2.  Tunicamycin  and thapsigargin  have different  effects  on osteogenic  gene
expression
In  the  previous  chapter  I  discussed  the  fact  that  tunicamycin  and
thapsigargin enhanced calcification to different extents. This was also reflected in
the results presented in this chapter, as tunicamycin and thapsigargin had different
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effects on the expression of some osteogenic genes (Runx2, OPG, OASIS, BBF2H7). It
is possible that apart from the UPR  each inducer activated a separate, ER stress-
unrelated signalling pathway, caused for example by secondary effects of the lack of
certain  glycosylated proteins or  excess calcium in the cytoplasm. However,  ALP,
BMP-2, Osterix and BSP were robustly regulated by both inducers therefore are the
most likely associated with ER stress.  In  addition,  in  this  chapter  I  showed that
osteogenic  gene  expression  is  affected  by  UPR  component  knock-downs  in
tunicamycin-  and thapsigargin-treated  VSMCs,  which  means  that  these  inducers
regulate osteogenic gene expression specifically via ER stress.
4.5.3. ATF4 – a possible inhibitor of VSMC osteogenic differentiation?
An important trend that has emerged from the knock-down experiments is
that ATF4 inhibits more osteogenic genes than it activates, as its knock-down more
often caused an increase in osteogenic gene expression than a decrease.  This is
contradictory to studies both in osteoblasts (Yang and Karsenty, 2004a; Saito et al.
2011) and in VSMCs (Masuda et al. 2012, 2013; Duan et al. 2013), where ATF4 has
been shown to promote osteogenic gene expression. The idea that ER stress inhibits
osteogenic differentiation is not a completely novel notion. It has been shown that
tunicamycin  inhibited  a  BMP-2-induced  increase  in  ALP  and  OCN  expression  in
mouse osteoblasts, however activation of the three canonical UPR branches was
not examined in that study (Jang et al. 2013). Another study has shown that ATF4
was  required  for  TGFβ-mediated  suppression  of  OCN expression  and  osteoblast
differentiation (Lian et al. 2012). The authors of these papers did not comment on
the fact, that the majority of evidence suggests the exact opposite role for ER stress
and  ATF4  in  osteoblast  differentiation.  These  studies  suggest  that  even  in
osteoblasts  the  role  of  ER  stress  signalling  is  not  as  clear-cut  as  suggested  in
previous reports and might be context dependent. This further supports the notion
that ER stress could be a protective mechanism in VSMCs, to provide phenotypic
regulation. It should be noted, however, that the experiments described here are
short-term treatments with ER stress inducers. In the long-term calcification assays
from the previous chapter ER stress enhanced calcification, however, as shown in
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the  next  chapter,  this  was  not  accompanied  by  an  increase  in  ATF4  or  ALP
expression.  That  could  mean  that  when  ER  stress  is  prolonged  it  ceases  to  be
protective and promotes calcification. 
An alternative explanation for ATF4 inhibiting osteogenic gene expression is
that  it  acts  independently  of  ER  stress.  In  my experiments,  the  effects  of  ATF4
knock-down were different from PERK knock-down. In the literature this has not
been the case, studies both in osteoblasts and in VSMCs (Saito et al. 2011, Masuda
et al. 2013) show that the effects of these knock-downs are consistent with these
two proteins representing the same signalling pathway. However, it is possible that
ATF4 is additionally activated by other pathways. It has been shown to be activated
by  metabolic  stress  (glucose  or  amino  acid  deprivation),  hypoxia  and  oxidative
stress as well as ER stress in various tissues (Ameri and Harris, 2008). Low serum
conditions used in my experiments could have potentially caused metabolic stress. I
have  not  tested  this,  but  in  fibroblasts  serum  deprivation  has  been  shown  to
activate ATF4 expression (Dennis et al. 2013).
4.5.4. Real-time PCR array provides further evidence for phenotypic regulation of
VSMCs by ER stress
I carried out an osteogenic real-time PCR array as a more global approach to
identifying the effect of ER stress on osteogenic gene expression. The array results
confirmed that activating ER stress with tunicamycin is associated with changes in
expression of osteogenic genes in VSMCs. A few were upregulated (BMP-7, PHEX,
COL14A1, PDGFRB) but expression of the majority was reduced. 
As  mentioned  previously,  the  upregulation  of  PDGFRB,  receptor  for  the
cytokine  PDGF,  could  be  indicative  of  cells  assuming  a  secretory,  proliferative
phenotype (Wilson et al. 1993; Salabei et al. 2013) in response to ER stress.
BMP-7, a member of the TGFβ family is important for bone formation during
embryonic  development  (Jena et  al.  1997),  but  it  is  also  a  known  inhibitor  of
vascular calcification (Davies et al. 2005). BMP-7 has been shown to play a role in
VSMC differentiation and maintaining of their contractile phenotype in vitro (Dorai
et al. 2000). Interestingly, BMP-7 counteracted the action of PDGF and TGFβ1 in an
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experiment where both these cytokines were shown to increase cell proliferation
(Dorai et al. 2001), so its activation by ER stress could be part of a negative feedback
loop,  where  TGFβ  activated  ER  stress  but  ER  stress  activated  BMP-7,  which
counteracts pro-secretory aspects of TGFβ signalling.
Another gene found to be upregulated was Collagen 14 α1, whose function
is to regulate Collagen type 1 fibril formation (Plenz  et al. 2003). Interestingly, its
expression has been shown to decrease in coronary artery VSMCs after stimulating
them  with  TGFβ1  (Schmidt  et  al. 2006),  which  is  consistent  with  a  contractile
phenotype-promoting function of this cytokine. The upregulation of this collagen by
tunicamycin in VSMCs supports the notion that a synthetic phenotype is activated
by ER stress.
PHEX, another gene found to be increased by tunicamycin in VSMCs, is a zinc
metalloendopeptidase,  which  catalyses  cleavage  of  a  group  of  proteins  that
regulate  mineralisation.  Mutations  in  this  gene  cause  autosomal  recessive
hypophosphatemic rickets, as PHEX modulates FGF23 expression, which regulates
phosphate and vitamin D metabolism (Rowe, 2012). This is the first time it has been
shown this gene is expressed in VSMCs, as its role in this cell type is unknown.
Among genes that were found to be downregulated by tunicamycin, of note
was a large group of genes related to TGFβ family signalling. I have validated that
expression of SMAD3, which carries TGFβ1 signals, is decreased by thapsigargin at
the protein level. In the previous chapter I showed that TGFβ1 induces ER stress in
VSMCs.  Therefore  these results  suggest  that  there  is  a  feedback  loop of  TGFβ1
increasing ER stress and ER stress decreasing TGFβ signalling. This is consistent with
studies showing that high levels of TGFβ promote osteogenic differentiation and
vascular calcification (Simionescu et al. 2005). In light of the previous results from
this chapter this suggests that activation of ER stress via TGFβ could be protective,
but too much would push the cells towards the osteogenic phenotype, therefore
TGFβ  must  be  inhibited  by  ER  stress.  In  osteoblasts  this  is  in  line  with  results
showing that TGFβ suppressed ATF4 activity by increasing vimentin expression, and
thus inhibited osteoblast differentiation (Lian et al. 2012). 
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4.5.5. Conclusions
The findings regarding the potential role of ER stress in VSMC phenotype
regulation and calcification from these first two chapters are summarised in the
schematic in Figure 4.17. In this model ER stress, which can be induced by warfarin
or  TNFα,  upregulates  some  osteogenic  genes  via  the  UPR,  which  promotes
calcification. But at the same time it triggers protective mechanisms, mediated by
ATF4,  leading  to  decreased  expression  of  osteogenic  genes.  TGFβ  promotes
contractile gene expression, but in certain conditions also the secretory phenotype.
Therefore even though TGFβ induces ER stress to activate protective mechanisms, it
is also inhibited by ER stress to prevent the maladaptive aspects of TGFβ signalling.
The outcome of all these processes might depend on the balance between all the
signalling cues, so activating ER stress could both promote calcification and inhibit



















Figure 4.17. Schematic summarising regulation of VSMC phenotype and calcification by ER stress.
In conclusion, the results in this chapter show that regulation of osteogenic
genes  in  VSMCs  in  response  to  ER  stress  is  complex  and does  not  recapitulate
osteogenic pathways in osteoblasts. Therefore, the next step was to examine the
regulation of some of the osteogenic genes in more detail, specifically Osterix and
ALP.  These  two  genes  were  consistently  upregulated  by  both  tunicamycin  and
thapsigargin and little is known about their regulation in VSMCs.
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Chapter  5:  Investigating  regulation  of  Osterix  and
alkaline  phosphatase  expression  in
response to ER stress in VSMCs
5.1. Introduction
The  results  in  the  previous  chapter  show  that  Osterix  and  ALP  were
consistently  upregulated  by  both  tunicamycin  and  thapsigargin  treatments,
suggesting that  they are likely  regulated by ER stress rather  than a non-specific
effect of the inducers. Both these factors are important for vascular calcification,
but little is known about regulation and the roles of these genes in VSMCs. 
5.1.1. Osterix
Osterix (OSX, SP7), a zinc-finger transcription factor from the SP1 family, is
expressed  in  MSCs  and  osteoblasts  and  is  essential  for  ECM  deposition  and
osteoblast maturation; bone formation does not occur in Osterix knock-out mice
(Nakashima et al. 2002). Osterix is downstream of BMP-2 signalling, and was shown
to act both downstream or independently of Runx2 (Lee et al. 2003; Matsubara et
al. 2008) and downstream of Dlx5 and Msx2 in osteoblasts (Matsubara et al. 2008;
Ulsamer et al. 2008).
Osterix  was  shown to  be  expressed in  calcified  human coronary  arteries
alongside other bone markers (Alexopoulos et al. 2011). It has been demonstrated
to be upregulated by Vitamin D, oxidised LDL and hepatocyte growth factor (HGF) in
VSMCs in vitro  (Taylor et al. 2011,  Zebger-Gong et al. 2011, Liu  et al. 2011a), but
there is a poor understanding of what its transcriptional targets and exact functions
in  those  cells  are.  No  transcriptional  targets  of  Osterix  have  been  described  in
VSMCs and it has not been studied whether its presence is required for calcification.
In osteoblasts  Osterix  was shown to be a transcriptional  target  of  the ER stress
transcription factor XBP1 (Tohmonda et al. 2011), but otherwise its regulation by ER
stress has not been studied.
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5.1.2. Alkaline phosphatase
Alkaline  phosphatase  (ALP,  TNAP,  ALPL)  is  an  enzyme  that  catalyses
dephosphorylation of PPi, and thus it inactivates this natural calcification inhibitor
and provides phosphate ions for HAp crystal formation. Mutations in the ALP gene
have  been  linked  to  hypophosphatasia,  an  autosomal  recessive  disorder,  that
manifests  with  decreased  bone  mineralisation  (Henthorn  et  al. 1992).  ALP  is
ubiquitously expressed throughout the body, but increased levels in serum and in
the vasculature  have been linked to vascular  disease and calcification (Kalantar-
Zadeh et al. 2006, Dreschler et al. 2011). Increased expression of ALP accompanies
calcification of VSMCs in vitro and it is thought to be crucial for this process (Shioi et
al. 1995, Masuda et al. 2013, Duan et al. 2013), however not in all studies (Shroff et
al. 2010). Even though it has a well-established role in vascular calcification, little is
known about the regulation of this enzyme in VSMCs or in other tissues. To date
only one transcription factor has been shown to regulate ALP expression, PPARγ
inhibits its expression in osteoblasts (Lencel  et al. 2011). No direct links between
ALP expression and ER stress have been demonstrated so far.
In this chapter I set out to characterise the cellular localisation of Osterix and
the effect of its knock-down on osteogenic differentiation of VSMCs. I also wanted
to  investigate  whether  ALP  expression  is  directly  regulated  by  ER  stress-related
transcription  factors  in  VSMCs  and  if  ALP  activity  changes  in  ER  stress-induced
calcification.
5.2. The function of Osterix in VSMCs
In  the  initial  experiments  in  Chapter  4 I  showed  that  Osterix  mRNA
expression  was  upregulated  both  by  tunicamycin  and  thapsigargin  treatments
(Figure 4.2). However, Osterix protein levels were upregulated by tunicamycin and
downregulated by thapsigargin  (Figure 5.1 and 4.3). Expression of Osterix was not
consistently affected by the knock-down of any ER stress transducer, but the knock-
down  of  IRE1  and  ATF4  caused  an  approximately  50%  decrease  in  Osterix
expression (Figure 4.9). All these results suggested that Osterix is regulated by the
UPR.
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Figure  5.1. Osterix  expression  in  response  to  ER  stress.  VSMCs  were  treated  with  0.4μg/ml
tunicamycin  (TM)  or  0.2μg/ml  thapsigargin  (TG)  for  24  hours.  A. Representative  blot  and B.
quantification.  Graph  shows  mean  and  SEM,  n=3,  ANOVA  with  Dunnett's  post  hoc tests  was
performed.
In parallel experiments I set out to characterise the function of Osterix in
VSMCs.  First,  immunocytochemical  analysis  was  performed  to  examine  the
subcellular  localisation  of  Osterix.  The  results  show  that  in  VSMCs  Osterix  was
localised in the nucleus and in the cytoplasm in foci (Figure 5.2.A). To test antibody
specificity SAOS-2 osteosarcoma cells were stained for Osterix alongside VSMCs. In
SAOS-2, Osterix was present mostly in the nuclei, but only some cells expressed it at
high  levels.  Cytoplasmic  foci  were  not  observed,  but  weak  grainy  staining  was
present in the cytoplasm. 
To further confirm the cytoplasmic localisation of Osterix in VSMCs, nuclear
fractionation was carried out, followed by Western blotting, both for VSMCs and
SAOS-2 cells (Figure 5.2.B). In both cell types Osterix was detected in both fractions,
however higher amounts were present in the cytoplasmic fractions. That suggests
that  the  cytoplasmic  foci  in  VSMCs  represent  specific  Osterix  staining.  Lower
amounts of Osterix in the nuclei of SAOS-2 cells are consistent with the fact that
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Figure 5.2. Subcellular localisation of Osterix in VSMCs and SAOS-2 cells.  A. Immunoctyochemistry
shows that  in  VSMCs Osterix  localises  to  cytoplasmic  foci  B. Nuclear  fractionation and Western
blotting analysis confirmed that Osterix was localised in the cytoplasm. 'C' – cytoplasmic fraction, 'N'
– nuclear fraction. N=3 for both experiments, representative images are shown.
In order to identify which cellular organelles these cytoplasmic Osterix foci
associated with, immunocytochemical co-stainings with various vesicular organelle
markers were carried out. Among the proteins examined were lysosome and late
endosome  marker LAMP-1 (Rohrer et al. 1996), early endosome marker EEA1 (Mu
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et al. 1995) or multivesicular body marker CD63 (Kobayashi et al. 2000) (Figure 5.3).
Osterix did not co-localise with any of these markers, which suggests that it is not






            
Figure 5.3. Analysis of Osterix foci in VSMCs by immunocytochemistry. VSMCs were co-stained with
for Osterix (green) and  lysosome and  late  endosome  marker LAMP-1, early endosome marker
EEA1 and  multivesicular body marker CD63 (red). None of these markers co-localised with Osterix.
N=3, figure shows representative images.
At  the  same  time,  siRNA  knock-downs  of  Osterix  were  carried  out  as  a
different approach to elucidating its function in VSMCs. The ultimate goal was to
examine  whether  expression  of  osteogenic  genes  in  response  to  ER  stress  is
affected by the absence of Osterix.
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A protocol previously optimised for siRNA knock-downs of UPR components
was used and then VSMCs were treated with tunicamycin and thapsigargin for 24
hours. Figure 5.4.A shows that this method resulted in only a very small decrease in
Osterix  mRNA, measured by real-time PCR.  Figure 5.4.B and C show that at  the
same  time-point  levels  of  Osterix  protein  did  not  change  at  all.  Therefore,  a
different  protocol  was  used  with  a  7  day  incubation  of  cells  with  the  siRNA
oligonucleotides.  The  results  show  that  using  this  protocol  Osterix  protein
expression  was  decreased  by  approximately  50%  (Figure  5.4.B  and  C). The
effectiveness of the siRNA oligonucleotides was tested in SAOS-2 cells,  and they
were effective in knocking down Osterix in this  cell  line  (Figure 5.4.A,  B and C).
Interestingly however, Western blotting analysis of Osterix in SAOS-2 cells showed
that the siRNA was more effective in knocking down some phosphorylation forms of
Osterix better than others. It has been shown previously that Osterix can exhibit
different  phosphorylation  forms,  which  are  visualised  as  separate  bands  on  a
Western blot (Ortuno  et al. 2010). SAOS-2 and VSMCs differ in the proportions in
which these are present (Figure 5.2 and Figure 5.4). Perhaps Osterix was difficult to
knock-down in VSMCs because some phosphorylation forms are sequestered in the
cytoplasmic  foci  and  therefore  are  more  stable.  In  addition,  alternative  splice
variants have been described for Osterix (Milona et al. 2003), that are possibly not





















Figure 5.4. SiRNA knock-down of Osterix. VSMCs and SAOS-2 cells were incubated with siRNA against
Osterix for 2 or 7 days and then treated with 0.4μg/ml tunicamycin (TM) or 0.2μg/ml thapsigargin
(TG) for 24 hours.  A. Levels of  Osterix  mRNA measured by real-time PCR after 2  days  of  siRNA
treatment,  n=3.  B. Western  blotting  for  Osterix,  after  2  or  7  days  incubation  with  siRNA.  C.
Quantification of Western blots, n=3 for 2 days, n=2 for 7 days, n=1 for SAOS-2 cells.
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Several other approaches including retroviral and lentiviral vectors carrying
shRNA targeting Osterix, and an Osterix-targetting microRNA were used in order to
achieve a more robust knock-down in VSMCs. These were also tested in SAOS-2
cells, as they endogenously express high levels of Osterix.
MiR125b, an Osterix-targeting miRNA (Goettsch et al. 2011), was applied to
VSMCs and SAOS-2 cells,  according to a  protocol  similar  to siRNA transfections.
Osterix expression was measured at the mRNA and protein levels (Figure 5.5). The
miRNA was not effective in knocking down Osterix in either cell  type. Additional
experiments were carried out in order to optimise the amount of the transfection
reagent and the miRNA applied to cells but with no success (data not shown).
168
CTRL    miR-125b 
VSMCs







Figure 5.5. MiRNA knock-down of Osterix. VSMCs and SAOS-2 cells were incubated with miR-125b
for  2  days  A. Levels  of  Osterix  mRNA measured by real-time PCR,  n=2.  B. Western  blotting for
Osterix, representative images.  C. Quantification of Western blots, n=3 for VSMCs, n=2 for SAOS-2
cells.
Next,  PG13  cells  constitutively  producing  retroviruses  carrying  human
Osterix  cDNA, a Osterix  shRNA knock-down cassette or empty retroviruses were
obtained (Zhu  et al. 2012). Media from these cells (containing retroviruses) were
applied to SAOS-2 cells and levels of Osterix were analysed by Western blotting. The
169
results  show  that  neither  the  overexpression  or  knock-down of  Osterix  worked
(Figure  5.6).  Several  transduction protocols  were also  tested,  including  different
incubation times,  centrifuging cells  in culture plates with the viral  supernatants,
different concentrations of the viral media and transducing also VSMCs, NIH 3T3
and C2C12 cells, but none proved effective (data not shown).
Figure 5.6. Retroviral overexpression and knock-down of Osterix in SAOS-2 cells. SAOS-2 cells were
incubated with viral supernatants 2 days. Western blotting for Osterix, n=1.
Finally,  commercially  available  lentiviral  particles  carrying  shRNA  Osterix
knock-down cassettes were purchased. They were applied to VSMCs and SAOS-2
cells at different multiplicity of infections (MOI),  according to the manufacturer's
protocol. Four different viral clones in total were tested, each expressing a different
Osterix-targeting shRNA, and an empty vector was used as a control.  Figure 5.7
shows results  for  one  clone  as  an  example.  Osterix  levels  were  analysed  using










Figure  5.7. Lentiviral  knock-down  of  Osterix.  VSMCs  and  SAOS-2  cells  were  incubated  with
lentiviruses expressing shRNA against Osterix for 2 days according to the manufacturer's protocol.
Western blotting for Osterix, n=1.
In  order  to  test  lentiviral  transduction  efficiencies,  the  same  vector
expressing GFP was purchased and tested in SAOS-2 cells.  GFP expression levels
were  observed  with  a  fluorescent  microscope.  At  MOI  of  20  the  transduction
efficiency was extremely low, explaining why the lentiviral  vectors did not  work























Figure  5.8. Test  of  lentiviral  vector  transduction  efficiency.  SAOS-2  cells  were  incubated  with
lentiviruses expressing GFP for 2 days according to the manufacturer's protocol, stained with nuclear
dye  DAPI,  fixed  with  PFA,  mounted  in  Mowiol  mounting  media  and  visualised  in  a  fluorescent
microscope. Scale bars are 60 μm.
To summarise, it has proven difficult to knock-down Osterix in VSMCs using
siRNA or miRNA approaches. Knock-down using viral vectors was not successful due
to technical difficulties. Therefore no further experiments on Osterix were carried
out.
5.3. Regulation of ALP expression and activity by ER stress in VSMCs
in vitro
5.3.1. ALP expression and activity are ATF4-dependent
The analysis of osteogenic gene expression presented in Chapter 2 shows
that ALP mRNA levels measured by real-time PCR were consistently upregulated in
VSMCs treated  with tunicamycin and thapsigargin  (Figure  5.9.A).  Therefore,  ALP
activity  was  measured  in  order  to  examine  whether  changes  in  mRNA  levels









increased (two-fold change) by tunicamycin treatment, but it did not change with
thapsigargin treatment (Figure 5.9.B). This suggests ALP expression was upregulated
by  ER  stress,  but  only  tunicamycin  triggered  signalling  events  that  lead  to  the
activation of this enzyme.
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Figure 5.9. Alkaline phosphatase  A. mRNA levels and B. activity are upregulated by ER stress. VSMCs
were treated with 0.4μg/ml tunicamycin (TM) or 0.2μg/ml thapsigargin (TG) for 24 hours. Graphs
show  mean  and  SEM,  n=3,  ANOVA  with  Dunnett's  post  hoc tests  was  performed.  Statistical
significance is indicated with asterisks: * denotes p between 0.05 and 0.01,  ** denotes p between
0.01 and 0.001, *** denotes p<0.001.
I  next  set  out  to  determine whether  ALP  expression and activity  can  be
directly  regulated  by  UPR signalling  in  this  context.  ALP  expression  and  activity
levels have been shown to be ATF4-dependent in calcifying rat and mouse VSMCs in
vitro (Masuda et al. 2013; Duan et al. 2013). In addition, in my experiments siRNA
knock-down of ATF4 caused the largest decrease in ALP mRNA expression of all the
UPR component knock-downs (Figure 4.10 and 5.10.A), therefore I measured ALP
activity after ATF4 knock-down to check if the decrease in mRNA observed earlier
corresponded to a decrease in ALP activity. The results in  Figure 5.10.B show that
ALP activity was increased by tunicamycin, and this increase was blocked by ATF4
knock-down. Activity at baseline and in thapsigargin-treated cells was not affected




Figure 5.10. ATF4 knock-down causes a decrease in ALP A. mRNA expression and B. activity. VSMCs
were  treated  with  ATF4  siRNA  for  48  hours  and  then  0.4μg/ml  tunicamycin  (TM)  or  0.2μg/ml
thapsigargin (TG) for 24 hours. Graphs show mean and SEM, n=3, ANOVA with Tukey's post hoc tests
was performed.  Statistical significance is indicated with asterisks:  * denotes p between 0.05 and
0.01,  ** denotes p between 0.01 and 0.001.
5.3.2. Identification of ALP transcription regulators
The next set of experiments aimed at establishing whether the increase in
ALP mRNA expression in tunicamycin- and thapsigargin-treated VSMCs was due to
increased  transcription.  The  first  step  was  to  examine  whether  ALP  promoter
activity is regulated by ER stress.  Ten constructs containing fragments of the 5'-
upstream region of the human ALP gene spanning from -122 to -4556 (counting
from the first nucleotide of the initiation codon) cloned in front of a firefly luciferase
gene were obtained (Figure 5.11). Construct 1 contained the full length sequence of
the  examined promoter  fragment  and constructs  2-10  were  deletion  constructs
derived from construct 1, which means each consecutive fragment was shorter than
the one before. VSMCs were transfected with each of the 10 constructs, treated

























Figure 5.11. Schematic showing ALP promoter constructs for luciferase assay. Construct 1 represents
the full length fragment and constructs 2-10 are shorter fragments derived by deleting increasing
portions of the full length. Based of figure from Orimo et al. 2005.
Preliminary luciferase assay results (n=1) show that constructs 1, 3, 5, 6, 7, 9
and 10 contained fragments of the ALP promoter that were transcriptionally active
in VSMCs. Furthermore, expression of luciferase was activated further in constructs
3, 5, 6 and 7 by thapsigargin treatment, and construct 6 and 7 also by tunicamycin
(Figure 5.12.A).
Further assays were carried out to validate results for constructs from which
expression  was  regulated  by  ER  stress.  The  results  confirmed  that  thapsigargin
induced  activity  of  promoter  fragments  3,  5,  6  and  7.  However,  in  this  set  of
experiments, tunicamycin did not have an effect on ALP promoter activity (Figure
5.12.B). These results further support the notion that tunicamycin and thapsigargin
regulate ALP via different pathways. They also suggest that tunicamycin-responsive
elements of the promoter might not have been encompassed by the constructs
used,  that  could  explain  why  ALP  promoter  activity  was  not  increased  by
tunicamycin and enzyme activity and mRNA expression was.
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Figure 5.12. ALP promoter activity in response to ER stress - luciferase reporter assays. VSMCs were
transfected with luciferase constructs for 24 hours and then treated with 0.4μg/ml tunicamycin (TM)
or 0.2μg/ml thapsigargin (TG) for 24 hours. A. Overview of all  promoter activity in all 10 constructs,
n=1. B. Validation of luciferase activity for constructs 3, 5, 6 and 7. Graphs show mean and SEM, n=3,
ANOVA  with  Dunnett's  post  hoc tests  was  performed.  Statistical  significance  is  indicated  with
asterisks: * denotes p between 0.05 and 0.01, *** denotes p<0.001.
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Based on the luciferase  assay  results  with the deletion constructs  it  was
possible to infer which sequences activate and which suppress transcription from
the  examined  fragment  of  the  ALP  promoter,  as  the  level  of  reporter  gene
expression  is  the  outcome  of  influences  of  both  types  of  sequences.  It  was
concluded that the examined fragment of the promoter region likely contains three
silencing sequences,  surrounded by sequences that activate  transcription.  Figure
5.13.A shows a schematic representation of the proposed silencers and enhancers
in each of the luciferase constructs.  Constructs 2, 4 and 8 showed no luciferase
activity,  and  therefore  likely  contain  silencing  sequences,  which  when  not
surrounded by activators inhibit transcription. It is also apparent that the promoter
fragment shared by constructs 3 to 7 contains a sequence that is highly active in





1 + - +
2 - - -
3 ++ + +++
4 - - -
5 ++ - ++
6 - + +++
7 + ++ +++
8 - - -
9 + - +
10 + - +
Figure  5.13. Enhancers  and  silencers  within  the  ALP  promoter.  A. Schematic  of  ALP  promoter
constructs with potential regions activating (red) and inhibiting (blue) transcription in VSCMs based
on B. luciferase assay results. '+' denotes degrees of activation, '-'  denotes lack of promoter activity.
The next step was to investigate whether there are any ER stress-related
transcription  factor  binding  sites  within  the  sequence  encompassed  by  the
promoter constructs, whether ATF4 is one of them, and whether they are located in
















subjected to bioinformatics analysis with Genomatix Matinspector, which contains a
database of known transcription factor consensus binding sequences. 
Figure  5.14.A shows  a  schematic  representation  of  the  whole  examined
promoter  fragment;  several  binding  sites  for  ATF6,  ATF4,  CHOP and XBP1  were
predicted  in  this  sequence  (the  full  annotated  sequence  can  be  found  in  the
Appendix, Figure 7.5).  Figure 5.14.B shows where each of these predicted binding
sites is located in each luciferase construct.
Two  ATF6  binding  sequences  were  identified,  both  in  activator  regions
present in constructs 1-5. Two XBP1 binding sequences were shown to be present in
an activator  region present  in all  constructs.  A CREB/ATF  binding sequence was
found in an activator only present in construct 1. There were two ATF4 binding sites
predicted, one localised in a silencer sequence and one in an enhancer, located in a
region  of  the  promoter  encompassed  by  constructs  1  to  5.  This  fact  further
supported the notion that ATF4 could be a direct regulator of ALP expression. 
It  is  also  interesting  that  CHOP  and  ATF4  binding  sites  were  found  in  a
silencer fragment that did not induce any luciferase expression (constructs 1 and 2,
Figure  5.14.B),  suggesting  that  these  transcription  factors  might  be  involved  in
inhibiting rather than promoting ALP expression in response to ER stress.
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Figure 5.14. ER stress-related transcription factor binding sites mapped to the ALP promoter.  A.
Schematic of the full length of the examined promoter fragment, numbers 1-10 refer to luciferase
constructs, in which a given fragment is at  the end. Blue star marks the transcription start site.
Arrows indicate the fragment used for DNA binding assays in later experiments.  B.  Localisation of
transcription factor binding sites in enhancer and silencer fragments of the ALP promoter constructs.
Potential  regions activating transcription (enhancers) are marked red and  regions inhibiting ALP
transcription (silencers) in VSCMs are marked blue.
To examine whether ATF4 indeed plays  a  direct  role in  activation of  the
examined fragment of the ALP promoter, luciferase assays were performed with
simultaneous  ATF4  siRNA  knock-down.  VSMCs  were  transfected  with  luciferase
vectors for 24 hours, then incubated with siRNA for 24 hours and finally treated
with  tunicamycin  and  thapsigargin  for  24  hours.  Constructs  which  showed  high
promoter activity in response to tunicamycin or thapsigargin were used in these
experiments.  Constructs 3 and 5 were chosen, as they had an ATF4 binding site
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predicted. Constructs 6 and 7 were also used, even though no ATF4 binding sites
were predicted for these fragments of the promoter. The rationale behind these
choices was that if ATF4 activated expression from the ALP promoter fragments in
construct 3 and 5, siRNA knock-down of ATF4 would decrease luciferase expression
from these two constructs, but not from constructs 6 and 7, which did not contain
the  ATF4  binding  sites.  Construct  1  and  2  were  not  used,  even  though  they
contained  another  ATF4  binding  site,  because  they  showed  very  low  promoter
activity in the initial experiments.
The results of the luciferase assays were inconclusive as the readings were
very variable, with no statistically significant differences (Figure 5.15). There was a
trend that ATF4  knock-down decreased the activity of promoter fragments 3, 5 and
6 at baseline. It  also decreased activity of cells transfected with construct 5 and
treated with thapsigargin and construct 7 with tunicamycin. However, ATF4 knock-
down increased activity of construct 3 in tunicamycin-treated cells. Therefore, there
was no ground to confirm or exclude ATF4 as a regulator of ALP activity.
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Figure  5.15. ALP  promoter  activity  after  ATF4  siRNA  knockdown.  VSMCs  were  transfected  with
luciferase vectors for 24 hours, then incubated with siRNA for 24 hours and treated with  0.4μg/ml
tunicamycin (TM) or 0.2μg/ml thapsigargin (TG) for 24 hours. Graphs show mean and SEM, n=3,
ANOVA with Tukey's post hoc tests was performed.
Since the results of luciferase assays were inconclusive, a different approach
was used to examine whether ATF4 directly regulates ALP promoter activity. The
fragment of the promoter containing both potential ATF4 binding sites (-3631 to
-2048bp from the first intron, encompassed by constructs 2 to 5, marked with two
arrows in Figure 5.14.A) was amplified using biotinylated primers. The product was
conjugated onto magnetic streptavidin beads. The beads were then incubated with
VSMC nuclear extracts, washed and proteins eluted off the DNA were analysed by
Western blotting to detect ATF4. 
Figure 5.16 shows that ATF4 was not detected in the eluted extracts. The
presence of a band corresponding to ATF4 in the lane with an unprocessed nuclear
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extract suggested that either ATF4 did not bind to the tested promoter fragment, or
that it was present in amounts too small to be detected by Western blotting.
 The gels used for ATF4 Western blots were stained with Coomassie Brilliant
Blue,  to  visualise  all  proteins  present  on  both  samples.  Figure  5.16 shows that
proteins were detected in the pulldown sample. This suggested that there might be








Figure 5.16. DNA binding assay to identify proteins bound to the ALP promoter and Western blotting
for  ATF4  (WB).  The  fragment  of  the  ALP  promoter  containing  potential  ATF4  binding  sites  was
amplified using biotinylated primers and conjugated onto magnetic streptavidin beads. The beads
were then incubated with VSMC nuclear extracts, washed and proteins were eluted off the DNA and
analysed by Western blotting. Coomassie gel demonstrates that even though ATF4 was not detected
in the pulldown sample, other proteins were present (arrows).  N=3,  figure shows representative
images.
Therefore, the DNA binding experiment was repeated and proteins bound to
the examined fragment of ALP promoter were analysed using a proteomics mass
spectrometry approach to identify additional factors that might regulate its activity. 
A  thapsigargin-treated  nuclear  extract  was  used  for  the  proteomic
experiment to increase the chances of finding protein-ALP promoter interactions
relevant  to  ER  stress.  Thapsigargin  was  chosen  for  this  experiment,  as  it  was
associated  with  more  consistently  increased  promoter  activity  in  the  luciferase
assays. The nuclear extract was bound and eluted from the biotinylated DNA on
beads (pulldown sample) and compared to an aliquot of the same extract incubated
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with beads without DNA (negative CTRL) to control for nonspecific binding to the
beads (Figure 5.17). Both samples were resolved on an acrylamide gel which was
stained with Coomassie. Even though there were many bands in the lane with the
negative control, there were a few that were present only in the pulldown sample
(indicated  with  arrows  in  Figure  5.17).  Corresponding  fragments  of  both  lanes
(marked with red boxes in Figure 5.17) were excised from the gel and subjected to













Figure 5.17. Coomassie-stained acrylamide gel used for proteomics analysis of proteins bound to the
ALP promoter.  Nuclear  extracts  were bound and eluted off  the biotinylated DNA on beads and
analysed by SDS-PAGE. Arrows indicate bands unique for the pulldown sample. Red boxes indicate
fragments of gel that were excised and analysed by LC-MS/MS.
The mass spectrometry analysis identified 447 different proteins with 95% or
more probability, for which more that 1 peptide was present, in both lanes. ATF4
was not among them. 166 of  these proteins were present only in the pulldown
sample and not in the negative  control. 17 of these have transcription regulating
activity. Table 5.1 contains a summary of information about these proteins.
None of the 17 identified proteins are known to be regulated by ER stress or
associated  with  the  ALP  promoter,  however  three  have  bone-related  functions.
DDX5 has been shown to act as a co-activator for Runx2 and to regulate osteoblast
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differentiation (Jensen et al. 2008). Another protein identified in the analysis was β-
catenin,  which  belongs  to  the  Wnt  signalling  pathway  and  is  crucial  for  bone
formation  and  has  been  implicated  in  vascular  calcification  (Shao  et  al. 2005).
Finally,  THRAP3  interacts  with  PPARγ,  which  has  been  shown  to  suppress  ALP
promoter activity in osteoblasts (Katano et al. 2013, Lencel et al. 2011, Woldt et al.
2005).
Table 5.1. Transcription-regulating proteins that bind to the ALP promoter, identified by LC-MS/MS.
















18 Functions as a bridging factor between STAT6 and the basal 
transcription factor. Plays a role in PIM1 regulation of MYB 
activity. Functions as a transcriptional coactivator for the 









19 This gene encodes a ssDNA binding protein that activates the 
far upstream element (FUSE) of c-myc and stimulates 
expression of c-myc in undifferentiated cells. This protein has 
been shown to function as an ATP-dependent DNA helicase. 










11 Involved in the alternative regulation of pre-mRNA splicing. 
Involved in transcriptional regulation; the function is 
independent of the RNA helicase activity. Transcriptional 
coactivator for estrogen receptor ESR1, androgen receptor AR 
and p53/TP53.  Synergizes with DDX17 and SRA1 RNA to 
activate MYOD1 transcriptional activity and involved in skeletal 
muscle differentiation. Transcriptional coactivator for RUNX2 
and involved in regulation of osteoblast differentiation. Acts as 
transcriptional repressor in a promoter-specific manner; the 
function probably involves association with histone 








8 Nuclear corepressor for KRAB domain-containing zinc finger 
proteins (KRAB-ZFPs). Mediates gene silencing by recruiting. 
Enhances transcriptional repression by coordinating the 
methylation and acetylation of histones. May play a role as a 
coactivator for CEBPB and NR3C1 in the transcriptional 
activation of ORM1. Also corepressor for ERBB4. Inhibits E2F1 
activity. Important regulator of CDKN1A/p21(CIP1). Mediates 











5  Nuclear receptor that binds and is activated by variety of 
endogenous and xenobiotic compounds. Transcription factor 
that activates the transcription of multiple genes involved in 
the metabolism and secretion of potentially harmful 
xenobiotics, drugs and endogenous compounds. Binds to a 



















9 RNA-dependent ATPase. Involved in transcriptional regulation. 
Transcriptional coactivator for estrogen receptor ESR1. 
Synergizes with DDX5 and SRA1 RNA to activate MYOD1 










6 ATP-dependent RNA helicase, able to unwind both RNA-RNA 
and RNA-DNA duplexes. May play a role in RNA clearance at 
DNA double-strand breaks . Together with RELA, acts as a  
coactivator to enhance NFκB-mediated transcriptional 
activation. Acts as a positive transcriptional regulator of cyclin 








6 Involved in pre-mRNA splicing as component of the U4/U6-U5 
tri-snRNP complex, one of the building blocks of the 
spliceosome. Enhances transactivation activity of AR, as well as 









5 This gene encodes a ribonucleoprotein that functions as a 
general nuclear coactivator, and an RNA splicing modulator. 
Interacts with thyroid hormone receptor-binding protein 







4 Necessary for the ATP-dependent first step of spliceosome 
assembly. Binds to the intron branch point sequence (BPS) 5'-











3 Involved in pre-mRNA splicing. Involved in response to DNA 
damage. Cooperatively with HELZ2, enhances the 
transcriptional activation mediated by PPARG, maybe through 
the stabilization of the PPARG binding to DNA in presence of 









3 Acts a co-repressor of the androgen receptor (AR) and is 
regulated by the ERBB3 ligand neuregulin-1/heregulin (HRG). 
Inhibits transcription of some E2F1-regulated promoters, 
probably by recruiting histone acetylase (HAT) activity. 
Mediates cap-independent translation of specific viral IRESs 







3 GO annotations related to this gene include heparin binding 
and sequence-specific DNA binding transcription factor activity. 
Expressed in human VSMCs. Has something to do with 







3 Key downstream component of the canonical Wnt signalling 
pathway. In the presence of Wnt ligand, CTNNB1 is not 
ubiquitinated and accumulates in the nucleus, where it acts as a
coactivator for transcription factors of the TCF/LEF family, 
leading to activate Wnt responsive genes. Involved in the 

















2 This gene encodes one of the ATPase subunits of the 26S 






2 May function as a general inhibitor of the histone deacetylase 
HDAC1. Binding to the pocket region of RB1 may displace 
HDAC1 from RB1/E2F complexes, leading to activation of E2F 
target genes and cell cycle progression. Conversely, 
displacement of HDAC1 from SP1 bound to the CDKN1A 
promoter leads to increased expression of this CDK inhibitor 
and blocks cell cycle progression. 
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Further bioinformatics analysis did not predict binding sites for any of these
proteins in the examined ALP promoter fragment. However, some of them might
not  have  known  consensus  sequences  or  not  have  DNA-binding  domains  and
therefore interact  with the promoter indirectly.  This  appeared to be true for  β-
catenin, which activates transcription of  its targets by forming a complex with TCF
and LEF (Novak et al. 1999; Westendorf et al. 2004). The bioinformatics analysis has
revealed that a TCF/LEF binding site is present in the analysed fragment of the ALP
promoter (Figure 5.18; full annotated sequence is in the Appendix, Figure 7.5). The
binding site is localised in a silencer region present in constructs 1-4, which was
responsible for the lack of promoter activity of construct 4 (Figure 5.12 and 5.13).
This suggests that β-catenin could be involved in repressing transcription of ALP.
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Figure 5.18. Analysed ALP promoter region with TCF/LEF binding site mapped. A. Schematic of the
examined promoter fragment, numbers 1-10 refer to constructs. Blue star marks the transcription
start site. Arrows indicate the fragment used for DNA binding assays. B. Localisation of transcription
factor binding sites in enhancer and silencer fragments of the ALP promoter constructs. Potential
regions activating transcription (enhancers) are marked red and regions inhibiting ALP transcription
(silencers) in VSCMs are marked blue.
Taken together these results strongly suggest that ATF4 does not bind the
tested fragment of ALP promoter. However, other proteins potentially involved in
regulating ALP expression in VSMCs have been identified.
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5.4. Alkaline phosphatase activity in mouse aortic rings
Even though ATF4 was not shown to be a direct regulator of ALP it was still
important to investigate the role of ALP in ER-stress enhanced calcification. The first
step  was  to  examine  whether  ER  stress  inducers  have  the  same effect  on  ALP
activity in an ex vivo setting of mouse aortic rings. Aortas were harvested from wild
type mice, cut into rings, treated with tunicamycin and thapsigargin for 24 hours
and then ALP  activity  was measured.  Corresponding  samples  were collected for
Western blotting analysis. 
Western blotting for Grp78 and Grp94 confirmed that ER stress was induced
in these conditions  (Figure 5.19.B and C).  Results  of activity assays  showed that
there  was  a  lot  of  variability  in  baseline  ALP  activity  in  the  aortic  rings.  After
tunicamycin treatment ALP activity was slightly decreased, but the change was not
statistically significant. Thapsigargin did not induce an overall change in ALP activity
levels (Figure 5.19.A). These results suggest that in mouse VSMCs in a vessel wall ER








Figure 5.19. Alkaline phosphatase activity in mouse aortic rings. A. Activity measured after a 24 hour
treatment with 0.4μg/ml tunicamycin (TM) or 0.2μg/ml thapsigargin (TG) and normalised to the
weight of each aortic ring. Graph shows data points and mean, n=7, ANOVA with Dunnett's post hoc
tests was performed. B.  Western blotting for ER stress markers Grp78 and Grp94 confirms that ER
stress was induced in these conditions. C. Quantification of Grp78 western blot. Graph shows mean
and SEM, n=3, ANOVA with Dunnett's post hoc tests was performed.
To investigate the possibility that a longer time-point might be required to
elicit  a more consistent response to ER stress in terms of ALP activity in mouse
aortic rings, a long-term experiment was carried out. In this experiment aortic rings
were incubated with tunicamycin or thapsigargin for 36 hours, 7 days and 14 days.
At each time-point the vessels were collected for ALP activity measurement and
Western blotting and at 14 days they were also collected for histological analysis.
Results show that at all three time-points both tunicamycin and thapsigargin
caused a decrease in alkaline phosphatase activity (Figure 5.20.A) and that at 14
days this change was statistically significant.  Figure 5.20.B shows a comparison of
ALP  activity  levels  at  baseline  (CTRLs)  at  the  three  different  time-points  and
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highlights  the fact  that  at  baseline ALP activity  increased after  7  days  and then
dropped significantly after 14 days.
A
B
Figure  5.20. Alkaline  phosphatase  activity in  mouse  aortic  rings  –  long  term  experiment.  A.
Comparison of  ALP activity measured after treatment with 0.4μg/ml tunicamycin (TM) or 0.2μg/ml
thapsigargin (TG) at different time-points and normalised to the weight of each aortic fragment. B.
Comparison of baseline ALP activity (CTRL samples) across the three time-points. All graphs show
mean and SEM, n=3, ANOVA with Dunnett's post hoc tests was performed * denotes p between 0.05
and 0.01.
Western blots for Grp78 and Grp94 were carried out to examine whether ER
stress was activated in VSMCs by incubating vessels in tunicamycin and thapsigargin
at  these  time-points.  The  results  show  that  both  at  36  hours  and  7  days  the
expression of these chaperones was increased compared to control, although at 7
days it was the case in only one sample out of three (Figure 5.21A and B). At the 14
day time-point hardly any protein was detectable making it difficult to reach any
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conclusions. 
Histological  analysis  of  aortic  rings  treated  for  14  days  revealed  that  in
tunicamycin- and thapsigargin-treated rings there were very few nuclei in the vessel
wall,  compared with the CTRL  sample (Figure  5.21.C).  This  suggests  that  the ER
stress treatments induced cell death at this time-point. This could explain why ALP
activity  decreased at  this  time-point,  as  only viable cells  are able to sustain the
synthesis of this enzyme. However, it does not explain why baseline ALP activity

















Figure 5.21. ER stress activation in mouse aortic rings.  A.  Western blot showing expression of ER
stress  markers  Grp78  and  Grp94  after  treatment  with  0.4μg/ml  tunicamycin  (TM)  or  0.2μg/ml
thapsigargin (TG) at different time-points.  B. Quantification of the Western blot, normalised to the
Coomassie stained gel. Graph shows mean and SEM, n=3, except at 14 days, where n=1, ANOVA with
Tukey's  post hoc tests was performed. C. Hematoxylin and eosin staining of mouse aortas treated
with TM and TG for 14 days, scale bars are 33 μm.
The results so far show that tunicamycin, but not thapsigargin, increased ALP
activity in human VSMCs in vitro, and that both inducers caused a decrease in ALP
activity  in  mouse  aortic  rings.  Therefore,  it  can  be  concluded  that  ER  stress
regulates ALP activity in VSMCs, however in a blood vessel wall the activity of this
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enzyme is likely affected by other factors. Next, ALP expression and activity were
examined in the context of ER stress-enhanced calcification of VSMCs  in vitro in
order to establish the importance of this enzyme for this process.
5.5.  Alkaline  phosphatase  activity  is  not  required  for  ER  stress-
enhanced calcification of VSMCs in vitro
In  Chapter 3 I  showed that tunicamycin and thapsigargin enhanced VSMC
calcification in vitro, and that could be inhibited by PBA (Figure 3.19). Similar, in the
experiments shown here cells were treated with tunicamycin and thapsigargin in
the presence of high levels of Ca and P and ER stress inhibitor PBA, ALP expression
was measured with real-time PCR and Western blotting and ALP  activity  assays
were carried out.
Figure  5.22  shows  a  comparison  of  mRNA,  protein  and  activity  levels.
Tunicamycin  and  thapsigargin  alone  did  not  change  ALP  mRNA levels  in  the
calcification  assay  conditions.  This  is  in  contrast  to  results  shown earlier  in  this
chapter in short-term experiments. The difference between these two experiments
is that here, for the purpose of calcification assays, approximately 10 times lower
concentrations of tunicamycin and thapsigargin were used, and for 8 days instead
of 24 hours. However, in the long-term calcification assay conditions tunicamycin
and thapsigargin increased ALP protein expression. This did not, however, translate
into higher activity levels, as ALP activity was slightly decreased by both ER stress
inducers.  This  suggests  that  in  these  conditions  ER  stress  does  not  induce  ALP
activity and also that ALP is synthesized inactive and needs an activation step for
the protein levels to correspond to activity.
 Surprisingly,  Ca and P alone, i.e. the baseline calcifying condition, did not
induce ALP mRNA, protein or activity levels suggesting that ALP is not required for
cells to calcify.
In the presence of high Ca and P levels tunicamycin and thapsigargin did not
change  ALP  mRNA  expression,  but  increased  protein  expression  compared  to
baseline and to Ca and P alone. Again, this did not translate into higher activity
levels. This suggests that an increase in ALP activity is not required for ER stress-
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enhanced calcification. 
The addition of PBA to VSMCs treated with thapsigargin in the presence of
high Ca and P increased ALP mRNA levels by approximately 50%, but did not change
protein or activity levels. Addition of PBA did not change ALP mRNA, protein or
activity levels in tunicamycin treated cells, both in the presence or absence of high
Ca and P. This further confirms that ER stress does not play a role in regulating ALP
in calcifying conditions.
In summary, calcifying conditions and ER stress caused an increase in protein
but  not  mRNA levels  of  ALP,  and did  not  induce any  significant  changes  in  ALP





























Figure 5.22. ALP in a calcifying VSMCs. Cells were treated with 2.7mM Ca2+, 2.5mM PO43-, 0.04μg/ml 
tunicamycin (TM) or 0.01μg/ml thapsigargin (TG), 0.5mM PBA for 8 days. A. Real-time PCR analysis of
mRNA levels. B. Western blotting and quantification of protein levels C. ALP activity.  Graphs show 
mean and SEM, n=3, ANOVA with Tukey's post hoc tests was performed. 
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Western  blotting  for  Grp78  and  Grp94  was  carried  out  at  the  same
conditions to examine whether ER stress was activated in these experiments. Figure
5.23 shows that tunicamycin and thapsigargin alone increased the expression of
these two chaperones approximately 10 and 25-fold. High Ca and P treatment alone
did  not  change  the  expression  of  these  ER  stress  markers.  Grp78  and  Grp94
expression  was  increased  by  Ca  and  P  in  combination  with  tunicamycin  and
thapsigargin, when compared to tunicamycin and thapsigargin or Ca and P alone.
PBA did not change the levels of these chaperones. None of these changes were
statistically  significant,  due to high variability  in  the levels  of  induction on thee
chaperones  by  ER  stress.  Nevertheless,  tunicamycin  and  thapsigargin  increased
their  expression  in  each  of  the  three experiments  carried out,  and  increases  in




























Figure 5.23.  Levels of ER stress markers Grp78 and Grp94 in calcifying VSMCs. Cells were treated
with 2.7mM Ca2+, 2.5mM PO43-, 0.04μg/ml tunicamycin (TM) or 0.01μg/ml thapsigargin (TG), 0.5mM
PBA for 8 days.  A. Representative Western blot.  B. Quantifications. Graphs show mean and SEM,
n=3, ANOVA with Tukey's post hoc tests was performed.
Expression of ATF4 mRNA was measured in the same calcifying conditions
(Figure 5.24) in order to examine whether it followed the same expression pattern
as ALP. This was thought likely since ATF4 knock-down decreased ALP expression.
ATF4 mRNA expression was slightly increased with tunicamycin and thapsigargin
alone, and in combination with Ca and P. PBA did not have an effect on ATF4 mRNA
expression  in  these conditions.  These results  show that  increased expression of
ATF4  is  not  required  for  VSMCs  to  calcify  and  that  it  did  not  follow  the  same
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expression pattern as ALP.
     
Figure 5.24. ATF4 expression in calcifying VSMCs. Cells were treated with 2.7mM Ca2+, 2.5mM PO43-,
0.04μg/ml tunicamycin (TM) or 0.01μg/ml thapsigargin (TG), 0.5mM PBA for 8 day, after that real-
time PCR was carried out. Graph shows mean and SEM, n=3, ANOVA with Tukey's post hoc tests was
performed.
The  results  in  this  section  show  that  in  calcifying  VSMCs,  both  in  the
presence and absence of ER stress, ALP expression or activity did not change. In
addition, ATF4 expression did not change significantly either.
5.6. Discussion
In this chapter I have explored regulation of Osterix and ALP expression in
response to ER stress in VSMCs.
5.6.1. Osterix expression is regulated by ER stress
I have shown that expression of Osterix is regulated by ER stress in VSMCs.
This has not been previously studied in VSMCs, but is consistent with studies in
mouse  osteoblasts,  where  Osterix  expression  was  induced  by  thapsigargin
(Tohmonda et al. 2011). In VSMCs Osterix localised to cytoplasmic foci of unknown
function. Literature on the function of Osterix in VSMCs is very limited and does not
offer explanations as to the subcellular localisation of this transcription factor, its
location in the cytoplasm has not been previously described.
Osterix  was mentioned as a marker of osteogenic differentiation in studies
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of the effects of Vitamin D, oxidised LDL and hepatocyte growth factor (HGF) in
VSMCs in vitro  (Taylor et al. 2011; Zebger-Gong et al. 2011; Liu  et al. 2011a), but
signalling  downstream  of  Osterix  has  not  been  looked  at.  Numerous  studies  in
osteoblasts and mesenchymal stem cells have shed light onto its functions in bone
development and highlight its importance in osteoblast differentiation (Zhang et al.
2010b). In-depth investigation of the role of Osterix was not performed, as it was
not possible to achieve an efficient knock-down of this protein in human primary
VSMCs.
In a study in SAOS-2 cells (Peng  et al. 2013) the half-life of Osterix protein
was estimated to be 12 hours, with a 36 hour cycloheximide treatment decreasing
its  levels below levels detectable by Western blotting.  This  suggests that  the 48
hour siRNA treatment protocol used in my experiments should have been effective,
and a 7 day treatment should have resulted in completely abolishing the protein,
but  this  was  not  the  case.  However,  literature  reports  of  siRNA knock-down of
Osterix, do not show complete knock-down at the protein level (Fan  et al. 2007;
Park and Kim 2013) suggesting that an approximately 50% knock-down that I have
achieved could be sufficient to observe the effects of Osterix knock-down.
Goettsch  et  al. describe  a  miRNA  targetting  Osterix,  miR-125b,  which  is
expressed in VSMCs. But rather than showing that it decreases Osterix expression
when  applied  to  cells,  they  show  that  blocking  miR-125b  increases  Osterix
expression  and  VSMC  calcification  (Goettsch  et  al. 2011).  In  the  light  of  these
findings my results suggest that Osterix is not a direct target of miR-125b.
5.6.2. ALP activity is regulated by ER stress in VSMCs in vitro
In the second part of this chapter I have shown that ALP mRNA and activity
were significantly increased by a short term, acute ER stress treatment of human
primary VSMCs in vitro. Interestingly, activity was only upregulated by tunicamycin
and  not  thapsigargin.  This  further  adds  to  the  evidence  that  tunicamycin  and
thapsigargin have different effects on osteogenic gene expression in VSMCs.
In this chapter I show strong evidence supporting the conclusion that ATF4
does  not  bind  the  examined  fragment  of  the  ALP  promoter  region  (-3631  to
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-2048bp from the first intron), despite the fact that siRNA knock-down experiments
showed that the presence of ATF4 is required for ER stress-induced ALP expression
and bioinformatics analysis predicted two ATF4 binding sites in this fragment of the
ALP  promoter.  There  are  several  possible  explanations  for  this.  Firstly,
bioinformatics predictions are not always accurate. Another reason could be that
ATF4  might  not  be  a  direct  regulator  of  ALP  expression,  it  could  act  via  other,
unknown  downstream  factors  whose  expression  would  be  downregulated  after
ATF4 knock-down. Moreover, the ATF4-responsive element could be located further
upstream or downstream of the examined promoter fragment as some regulatory
elements are known to be located very far from the genes they regulate (Kleinjan
and van Heyningen, 2005). This is supported by the fact that tunicamycin caused an
increase in  ALP  mRNA expression  and enzyme activity  levels,  but  not  promoter
activity.  That suggests that the examined fragment of the ALP promoter did not
contain  elements  responsive  to  tunicamycin  activation.  This  in  turn  means  that
ATF4  could  still  be  an  activator  of  the  ALP  promoter,  but  the  analysis  did  not
encompass the right region of the promoter.
Instead of confirming that ATF4 binds to the ALP promoter region I identified
3 other proteins that could potentially perform this function - DDX5, β-catenin and
THRAP3. All 3 are known to be involved in osteoblast differentiation, but were not
previously implicated in regulating ALP expression in VSMCs. β-catenin is of special
interest, as binding sites for its well known interacting partners TCF/LEF (Novak et
al. 1999)  were  found  in  the  examined  fragment  of  the  ALP  promoter.  Further
experiments are needed to validate the interactions of these factors with the ALP
promoter and to explore whether they can be induced by ER stress and how.
5.6.3. ER stress does not induce ALP activity in mouse aortic rings
In  mouse  aortic  rings  (an  ex  vivo  model)  ALP  activity  did  not  change
significantly  regardless  of  ER  stress  inducer  used.  The  inconsistency  of  results
between experiments in human VSMCs and mouse aortic rings could be explained
by species differences. There have been studies showing differences in VSMCs from
different species (Bonin and Damon, 1994). Another reason why VSMCs and mouse
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rings might have responded differently could be that cells in culture and the vessel
wall differ in their phenotype/ differentiation status and therefore have different
abilities to respond to ER stress treatments (Shanahan and Weissberg, 1998; Shroff
et al. 2010). Because of that it is difficult to conclude what these results could mean
in terms of ER stress regulation of VSMC phenotype.
5.6.4. The role of ALP activity in ER stress-enhanced calcification is unclear
I demonstrated that calcification of VSMCs enhanced by ER stress was not
accompanied by significant changes in ALP expression or activity in human VSMCs.
Many studies consider an increase in ALP activity as an early marker of osteogenic
transdifferentiation  of  VSMCs  (Shanahan  et  al. 1999a;  Lomashvili  et  al. 2008;
Schoppet and Shanahan, 2008). It has also been shown to be activated during ER-
stress mediated calcification in rat and mouse VSMCs (Masuda et al. 2013; Duan et
al. 2013). On the other hand, there have been studies showing that its activity levels
can be uncoupled from expression of other osteogenic markers such as Runx2 and
not  increase  after  high  Ca  and  P  treatment  (Shroff  et  al. 2010)  or  in  fact  that
calcification  of  VSMCs  can  occur  without  osteogenic  differentiation  altogether
(O'Neill and Adams, 2014). This might be the case in my model of calcification  in
vitro, as in experiments in Chapter 3 VSMCs calcified more in the presence of ER
stress transducers,  but here I  have shown that this was not accompanied by an
increase in ALP activity or ATF4 expression. To have a complete picture of what is
happening in this model of calcification, expression of more osteogenic genes would
have to be examined. Another explanation for the lack on an increase in ALP activity
could be a wrong time-point.  My calcification experiments took 8 days and ALP
activity and expression was measured on the last day. It is possible that increased
ALP  is  required  in  initial  stages  of  calcification  and  decreased  by  the  time  the
measurements were carried out.
In  the calcification experiments  ALP  activity  levels  did  not  correspond to
protein expression patterns, suggesting the enzyme is expressed but not active. In
addition to that,  it has been observed that thapsigargin increased ALP promoter
activity and mRNA expression, but not enzyme activity, at the 24 hour time-point. It
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has been shown before that ALP needs to be activated in order to form a functional
enzyme. This requires a two-step mechanism via protein stabilization followed by
enzyme conversion with zinc loaded by zinc transporter complexes (Fukunaka et al.
2011). Interestingly, it has been shown that ablation of zinc transporter proteins
ZnT5 and Znt7,  which are involved in ALP activation and provide other proteins
folded in the ER with zinc ions needed for their activation can induce ER stress and
activate the unfolded protein response (Ishihara  et al. 2006).  This  highlights the
importance of zinc homeostasis for ER function and suggests that UPR signalling can
increase the expression of ALP in VSMCs, but ER stress might inhibit formation of a
functional enzyme by disrupting zinc homeostasis. However, it has not been tested
whether ER stress disrupts zinc homeostasis.
5.6.5. Conclusions
In  conclusion,  it  has  emerged  that  regulation  of  both  Osterix  and  ALP
expression  in  response  to  ER  stress  in  human  primary  VSMCs  is  complex  and
different from that in mouse and rat cells. In addition, the results in this chapter
support  the  notion  that  increased  ALP  activity  is  not  required  for  ER-stress-
enhanced calcification. Analysis of additional osteogenic genes is required before
conclusions about the regulation of osteogenic differentiation by ER stress and its
contribution to VSMC calcification can be made.
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Chapter 6: Conclusions and future work
6.1. ER stress promotes calcification
In the course of this thesis I  presented evidence that ER stress promotes
vascular calcification. I demonstrated that pro-calcific factors including warfarin and
TNFα as well as TGFβ can induce ER stress in VSMCs, showing that factors relevant
to calcification  in vivo can induce this stress response. I also examined potential
mechanisms  via  which  ER  stress  could  increase  VSMC  calcification  in  vitro.
Apoptosis was ruled out, as it was found that ER stress actually protected cells from
death, contrary to published literature (Duan et al. 2013). 
Osteogenic differentiation was concluded to be a possible mechanism, as
expression of osteogenic markers correlated with ER stress markers in healthy and
fatty  streak  human  aortas,  suggesting  that  ER  stress  regulates  expression  of
osteogenic genes in the initial stages of vascular disease. In addition, in rat aortas
warfarin induced ER stress and expression of  Osterix  and ALP in calcified areas.
Finally, ER stress upregulated expression of some osteogenic genes (Osterix, ALP,
BSP, OPG) in VSMCs in vitro after short term treatments. I demonstrated that these
changes in gene expression were mediated by specific UPR pathways. In the same
conditions VSMC contractile markers SM22α and p-MLC were decreased, which was
consistent with decreased expression of some components of the TGFβ signalling
pathway which promotes differentiation (Shah  et al. 1996; Hirschi  et al. 1998). A
decrease  in  contractile  gene  expression  is  one  of  the  hallmarks  of  osteogenic
conversion of  VSMCs (Iyemere  et  al. 2006).  My results  are  also consistent  with
literature  showing  that  ER  stress  is  associated  with  increased  osteogenic  gene
expression in VSMCs (Liberman et al.  2011; Masuda et al. 2012, 2013; Duan et al.
2013). 
There are other mechanisms via which ER stress could enhance calcification,
one of them is an increase in Grp78 chaperone expression. Grp78 has been shown
to be expressed on the cell surface (Zhang et al. 2010), to bind to type 1 collagen
and  to  facilitate  ECM  mineralisation  by  nucleating  calcium  phosphate  crystal
formation (Ravindran  et al. 2011). I have shown that in VSMCs Grp78 expression
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was increased by tunicamycin and thapsigargin treatments in long-term calcification
assays in the presence of Ca and P, so it is possible that Grp78 was responsible for
the ER stress-enhanced increase of calcification of VSMCs in vitro in response to ER
stress.  My immunocytochemistry experiments  show that  both in  untreated cells
and when ER stress was induced, Grp78 was only localised in the ER and cytoplasm,
and therefore not exposed to the ECM. However, it is possible that the chaperone
was  loaded  into  matrix  vesicles  (MVs)  that  are  known  to  nucleate  matrix
mineralisation.  MV  release  is  a  well  established  mechanism  that  mediates
calcification  (Kapustin  et  al.  2011,  Kapustin  and  Shanahan,  2012)  and  previous
studies in our laboratory have shown that MVs from calcifying VSMCs contain ER
components and Grp78 among them (data not shown), suggesting that ER stress
might play a role in vesicle-mediated calcification. Therefore, in further experiments
calcification assays should be carried out in the absence of Grp78 to investigate
whether it is required for VSMC calcification. It would also be interesting to examine
whether ER stress can influence the number and calcification-inducing properties of
MVs released by VSMCs.
Another  mechanism  that  could  potentially  link  ER  stress  and  vascular
calcification is autophagy.  There is abundant evidence that ER stress can lead to
activation of  autophagy (Ogata  et al. 2006,  Hoyer-Hansen and Jaattela  2007).  In
addition, ATF4 has been shown to regulate autophagy in the context of hypoxia in
cancer cells (Rzymski  et al. 2009).  Autophagy has been demonstrated to protect
VSMCs from calcification induced by high levels of phosphate ions or TGFβ (Dai  et
al. 2013, Liu  et al. 2014). However, the link between ER stress and autophagy in
vascular  calcification has not been studied.  My preliminary experiments showed
that  very  high  concentrations  of  tunicamycin  and  thapsigargin  (1μg/ml  for  24h,
which is 5 times higher that what I used in experiments) can induce expression of
LC3-II,  a  marker  of  autophagy  (data  not  shown),  however  I  have  not  studied
activation of autophagy in calcification assays.
An important limitation of my experiments is the fact that most experiments
were carried out as replicates from one biological sample (VSMCs from one donor).
Therefore, future experiments should include validating the results in other VSMC
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isolates.  Nevertheless,  my results  provide the first  insight  into the effects of  ER
stress on human aortic VSMCs calcification and phenotype, as these cells were not
studied  in  research  described  in  existing  literature  on  ER  stress  in  vascular
calcification. Liberman et al. (2011) used coronary artery cells and did not mention
how many donors the cells were from; Masuda  et al. (2012, 2013) carried out all
their experiments on a mouse cell line (MOVAS-1) and Duan et al. (2013) used rat
VSMCs, which are genetically homogeneous.
6.2. Could ER stress be a protective mechanism?
Even though the majority of my findings suggest that ER stress promotes
vascular calcification, there is some data that do not support this conclusion.
Firstly,  in  calcified  human  aortas  expression  of  ER  stress  markers  is
decreased and expression of osteogenic genes increased, suggesting that these two
processes  are  uncoupled  in  the  late  stages  of  vascular  disease.  In  addition,  in
calcified rat aortas expression of osteogenic genes did not follow the same pattern
as ER stress markers, seeing that ER stress markers were increased in the whole
vessel wall and osteogenic markers only in the calcified area, further suggesting that
ER stress does not drive expression of these genes during calcification.
As  mentioned  above  I  found  that  ER  stress  modelled  in  VSMCs  in  vitro
increased  the  expression  of  some  osteogenic  genes  in  short  term  treatments.
However, in long term calcification assays, ALP activity and ATF4 expression were
not increased by ER stress both in the presence and absence of calcification media.
This is contrary to what has been shown in studies by Masuda et al. and Duan et al.,
which  found  that  ATF4  is  a  key  mediator  of  the  changes  in  osteogenic  gene
expression and that  an increase in  ALP  activity  accompanies  ER stress-mediated
VSMC  calcification  (Masuda  et  al. 2012,  2013;  Duan  et  al. 2013).  I  have  not
investigated the expression of  other genes in long term calcification assays,  but
analysis  of  some key osteogenic markers in the context of calcification assays is
necessary to ascertain whether ER stress can induce osteogenic differentiation in
the long term. Further to this, I  have shown evidence that ER stress suppressed
expression of pro-osteogenic BMP-2, increased expression of calcification inhibitor
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BMP-7 and that ATF4 inhibits expression of a number of osteogenic genes in VSMCs.
Even though the majority of the literature points to ER stress having a pro-
osteogenic effect on both osteoblasts (Tohmonda et al. 2011; Jang et al. 2011; Saito
et al. 2011) and VSMCs (Liberman et al. 2011; Masuda et al. 2012, 2013; Duan et al.
2013), the idea that ER stress inhibits osteogenic differentiation is not a completely
novel  notion.  It  has  been  shown  that  ATF4  was  required  for  TGFβ-mediated
suppression of OCN expression and osteoblast differentiation (Lian et al. 2012). This
is important, as I have shown that in VSMCs TGFβ activated ATF4 expression. It has
also been demonstrated that tunicamycin  inhibited  a  BMP-2-induced  increase  in
ALP   and   OCN   expression   in  mouse  osteoblasts  (Jang  et  al.  2013),  which  is
consistent with my results showing that ER stress decreased expression of BMP-2.
Another recent study has shown that low levels of ER stress induce osteoblastic
differentiation of bone marrow stromal cells, but high levels had an inhibitory effect
(Nakamura et al. 2013). 
In addition, in vitro, ER stress protected VSMCs from apoptosis, an important
mechanism which promotes  calcification.  Interestingly,  a  study in  mouse VSMCs
lacking the ENPP1 enzyme (which synthesizes the natural  mineralisation inhibitor
PPi)  showed  that  the  absence  of  CHOP  (which  mediates  ER  stress-induced
apoptosis)  in  these  conditions  increased  calcification  (Serrano  et  al. 2014).  This
suggests that in the absence of PPi CHOP protected cells from calcification.
I  have  shown  that  TGFβ,  which  promotes  contractile  differentiation,  can
induce  ER  stress  in  VSMCs.  Together  with  results  showing  that  also  pro-calcific
warfarin and TNFα can induce ER stress this suggests that ER stress is activated
when  cells  undergo  phenotypic  changes,  regardless  of  what  induces  them  and
regardless of whether the cells are becoming more contractile or more synthetic.
This  fact  further  supports  the  notion  that  ER  stress  is  a  physiological,  adaptive
mechanism  (Wu  et  al. 2006;  Moore  and  Hollien,  2012).  However,  I  also
demonstrated  that  ER  stress  modelled  by  tunicamycin  and  thapsigargin  induces
features  of  a  secretory  phenotype  in  VSMCs,  such  as  decrease  of  contractile
markers, suggesting that ER stress does not mediate a pro-contractile expression
programme. My findings could therefore mean that the pro-contractile features of
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TGFβ signalling are perhaps not mediated by ER stress, but the pro-calcific are (as
shown by Simionescu et al. 2005 and Liu et al. 2014). It is unclear why TGFβ has a
dual effect on VSMC phenotype and it is likely context-dependent.
It  would be interesting to further analyse what phenotypic changes TNFα
and warfarin induce and whether they are mediated by ER stress by using ER stress
inhibitors. Apart from PBA used in experiments here, specific inhibitors of IRE1 and
PERK have recently been described and could be used for  these experiments to
determine which UPR pathways are involved in phenotypic  regulation of VSMCs
(Cross et al. 2012; Axten et al. 2012). In addition, in order to examine if ER stress is
involved in physiological phenotypic regulation, or whether it is a mechanism only
activated in  response to  pathological  conditions,  it  would be also interesting  to
examine the levels of ER stress marker expression in VSMCs from different phases
of  vascular  development,  representing  different  stages  of  VSMC  differentiation
(Majesky, 2007).
6.3. Regulation of osteogenic genes by ER stress
6.3.1. The function of Osterix in VSMCs remains unknown
I  demonstrated  that  expression  of  Osterix  is  increased  in  VSMCs  by
tunicamycin, suggesting that it could play a role in ER stress-regulated osteogenic
differentiation. Expression of this osteogenic transcription factor was not analysed
in  published  studies  of  ER  stress  in  VSMCs  to  date,  therefore  my  findings  with
regards to Osterix are novel. An important next step would be to examine Osterix
expression in VSMCs calcifying in the presence of ER stress inducers, in order to
investigate whether it plays a role in ER stress-enhanced calcification of VSMCs in
vitro.
In depth studies of the function and target genes of Osterix in VSMCs were
prevented by  the  inability  to  knock  it  down efficiently  in  these  cells.  Obtaining
VSMC-specific Osx knock-out mice would be a way to overcome this problem. Mice
with floxed Osterix have been described before (Nishimura et al. 2012). They were
used to create a cartilage-specific Osterix knock-out, as they were crossed with mice
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expressing Cre from the type 2 collagen promoter. Contrary to global Osterix knock-
out mice, in which bone formation did not occur at all, in mice with chondrocyte-
specific  Osterix  knock-out  endochondral  bone  formation  was  arrested  at  the
hypertrophic  chondrocyte  stage  (Nishimura  et  al. 2012).  In  order  to  achieve  a
VSMC-specific  Osterix  knock-out,  the  Osterix-floxed  mice  could  be  crossed  with
mice expressing Cre under the SM22α promoter. SM22α-Cre mice have been used
previously  to  knock  out  Runx2  in  VSMCs (Sun  et  al. 2012).  Osteogenic  gene
expression in response to ER stress could be examined in cells from VSMC-specific
Osterix knock-out mice. The mice could be fed a calcification inducing diet (Atkinson
et al. 2008) or treated with tunicamycin (Liang  et al. 2013), and osteogenic gene
expression could be examined in their aortas, which would elucidate the function of
Osterix in VSMC calcification.
In addition, since it is unknown what regulates Osterix expression in VSMCs,
it is necessary to analyse the Osterix promoter in order to explain the mechanisms
by which its expression is upregulated by ER stress. An XBP1 binding site has already
been identified in the Osterix promoter region and XBP1 has been shown to bind
this promoter in mouse embryonic fibroblasts (Tohmonda et al. 2011). Therefore, it
would  be  interesting  to  examine  whether  XBP1  binds  the  Osterix  promoter  in
human primary VSMCs, or perhaps if ATF4 is involved, since its knock-down caused
a small decrease in Osterix expression.
6.3.2. The role of ALP in VSMC calcification is unclear
I  showed that  ALP  expression  and  activity  are  increased  by  ER  stress  in
VSMCs,  but  not  in the context  of  calcification.  Its  levels  did  not  change in  cells
calcifying  in  vitro in  the absence of  ER stress  inducers.  ALP  expression was not
different in calcified human aortas compared to healthy. These results suggest that
an increase in ALP activity is not required in all instances of calcification, both in the
context of ER stress and not. There have been studies showing that calcification can
occur  without  an  increase  in  ALP  activity  (Shroff  et  al. 2010),  even though  the
majority  of  published  research  shows  that  ALP  activity  is  increased  in  VSMCs
calcifying in the presence of ER stress (Masuda et al. 2012, 2013; Duan et al. 2013)
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or in calcification induced by other factors (Shioi  et al. 1995). This fact has several
possible explanations.  It  could mean that in some conditions VSMCs are already
expressing enough ALP in order to hydrolyse PPi and mineralise. It could also mean
that  upregulation of  ALP is  one of  many redundant  mechanisms contributing to
calcification and therefore calcification can occur without it if other mechanisms are
activated. Another alternative is that increased ALP activity is only required in initial
stages of mineralisation and that I measured it at too late a time-point. Therefore,
in order to better understand the function of ALP in VSMCs calcification, a time-
course experiment measuring ALP activity at several stages of VSMC calcification is
necessary.
I also attempted to examine whether ATF4 is a direct regulator of the ALP
promoter and cannot conclude that it is, even though I have demonstrated that ALP
activity is ATF4-dependent in VSMCs, consistent with published literature (Duan et
al. 2013). However, since ALP is often reported to be increased in the context of
calcification and it was increased by ER stress treatments it is important to find out
more about its regulation. To date only one direct regulator of ALP expression has
been described,  PPARγ (Lencel  et  al. 2011).  Interestingly,  in DNA binding assays
combined with proteomics analysis I found that THRAP3, which is known to form
complexes with PPARγ, to bind the ALP promoter, strongly suggesting that it might
be a novel regulator of ALP expression. In addition, DDX5, which forms complexes
with Runx2 (Jensen et al. 2008) and β-catenin, which forms complexes with TCF/LEF
(Novak et al. 1999), for which I found a binding site in the ALP promoter, could also
be potential regulators of ALP expression. Additional DNA binding assays should be
carried  out  to  validate  binding  of  these  factors  and  also  in  order  to  examine
whether the binding sites for XBP1, ATF6 and CHOP predicted in the ALP promoter
are real.
6.4. Conclusion
To summarise, I presented evidence supporting the notion that the role of
ER stress in VSMC calcification is not as unequivocally calcification-promoting as the
literature to date has suggested, as it also promotes protective changes in the VSMC
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phenotype.  My  findings  contribute  to  the  existing  understanding  of  molecular
mechanisms of vascular calcification.  However, more studies are needed to fully
understand the role of ER stress in regulating VSMC phenotype and calcification.
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Chapter 7: Appendix
7.1. Osteogenic gene and ER stress marker expression in human aortas
– correlation tests
Pearson correlation tests were carried out for expression values of pairs of
ER  stress  versus  osteogenic  markers  for  samples  from calcified aortas  (n=10)  or
healthy and fatty streak combined (non-calcified, n=20). Figure 7.1 shows analysis of
osteogenic markers vs ATF4, Figure 7.2 shows the analysis for ATF6, Figure 7.3 shows
CHOP and Figure 7.4 PERK.
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Figure 7.1. Correlation analysis of  ATF4  versus  osteogenic markers expression in human aortas. ΔCT
values  of  ER stress markers were plotted against ΔCT values of osteogenic genes. Linear regression
was plotted, and a two-tailed Pearson correlation test was carried out. Graphs show individual data
points.
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Figure 7.2. Correlation analysis of  ATF6 versus osteogenic markers expression in human aortas. ΔCT
values  of  ER stress markers were plotted against ΔCT values of osteogenic genes. Linear regression
was plotted, and a two-tailed Pearson correlation test was carried out. Graphs show individual data
points.
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Figure 7.3. Correlation analysis of CHOP versus osteogenic markers expression in human aortas. ΔCT
values  of  ER stress markers were plotted against ΔCT values of osteogenic genes. Linear regression
was plotted, and a two-tailed Pearson correlation test was carried out. Graphs show individual data
points.
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Figure 7.4.  Correlation analysis of  PERK versus osteogenic marker expression in human aortas. ΔCT
values  of  ER stress markers were plotted against ΔCT values of osteogenic genes. Linear regression
was plotted, and a two-tailed Pearson correlation test was carried out. Graphs show individual data
points.
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7.2. ALP promoter sequence
The  ALP promoter region sequence (-122 to -4556 from the start of the first
intron, Orimo et al. 2005) was subjected to bioinformatics analysis with Genomatix
Matinspector, which contains a database of transcription factor consensus binding
sequences. Figure 7.5. shows the full sequence with binding sites for ATF6, ATF4,
CHOP, XBP1 and TCF/LEF annotated.
       1  ACTGGGATTA CAGGCGTGTG CCACTGTGCC CGGCCCCTGT TATCTTACTA ACTTACTTAT
      61  TAATGTTTGT TGTTTATTAT CTACCTTCCC AACTAAAGTG TCAGTTCCGT GAGGATAAAC
     121  ATTCTGTTTT GTTCACTGGT ATGTCCAGTT CCTAGAAGGG TGCCTGCTGC AGAGCAGGCA
     181  TCCAATAAAC ATTTGTTGAA TGAATAAGGT TGCCAAGTCT GCCTGGGATA ACAGCCTGCT
     241  CACTGGAAAG GTGACGATGA CAACAGTGAT GGTGCTTTGG TGTTGCAGGG AGGAGCAAGT
                      CREB/ATF     
     301  TAAATCTCAC CTATAAAGAT CTTTCCATCA GGCTGCAGAC ACAGAGGGAG TCCCCAGCAA
     361  CAATAGCTCA TATATGCTTC AGTTTCCTCA TCCGTGAAGA GAGAATAAAA GTCCCTACTT
     421  TTATTAGCGT CCAATTGCCC TGGCCACGGC AGCATTGTCG GTTTAATGAT GCTGCTTCGG
     481  CTGTCGTAGT CTCTTCCACC TCATGCCTTT TGGTTCATTT TTTAACTGAG TTAAAGGTGG
     541  GGCTGTAGGT GGCACTGGGA ATCAAATGGC TGAACTTGTG CTCAGGCCTG GGCTTGAGAT
     601  AAAATGACCC CTTTAGTCCA AGCATCAAAA CAGACCAAGG TTTCAGGCCC CCTTGCCTTT
     661  AAATAGATTT CAGGGATTAT TTTCTCCAGC CCTAGACCAC AGCTGACTCC TCACCGCCTC
     721  TCCACGAACA GACCTCAGAG TTTTGTTTTC TCTGTCTCTC TCCTTTCTTT CTCCTTTATC
     781  TCTGTCTACT GAGGTCCTGG CTGTCCCCCT GCCCCACCCT ACCCTATGCT CTTGGGCTTC
     841  TGGCCTCATC TCTAACTTAG CTTCTAATTT TTTCTCTTCT TTTCCTTTCT TTTTTTGAAA
     901  CAGAGTCTCA CTCTGTCACC CAGGCTGGAG TGTAGTGGCG TGATCTCAGC  TCACTGCAAC
                                                                    CHOP
   
     961  CTC  TGCCTCC AGGGTTCAAG CGTTTCTCGT GCCTCAGCCT CCCAAGTAGC TGGGACT  ACA
    1021  GGTGTGCGTC ACCTTGC  TCG GCTAATTTTT ATGTTTTCAG TAGAGACGGG GTTTCACCGT
                ATF4
    1081  GTTGGCCAGG CTGGTCTCAA ACTCCGGACC TCAGGTGATC CACCTGCCTA GCCTCCCAAA
    1141  GTGCTGGGAT TACAGGCATG A  GCCACCACG CCCGGCCT  AA CTTAGCTTCT AATTCTAATG
                                        ATF6
 
    1201  CCTGGTGAAC CTCTTAAATT TTTTTTTCCC AAGACAAAGT CTCACTCTGT TGGCCAGGCT
    1261  GGAGTGCAGG GGTGTGATCA TAGCTCACTG CAGACTCTAA CTCCTGGACA CAAGAGACCC
    1321  TCCCATCTTG GCCTCCCAAA GTGCTGGGAT TACAGGCGTG AGCCACCATG CCTGGCCTGC
    1381  CTAGTGAACT TGAAGGTCTA GCTTGCGGCA CAGGCTCATG GCATGCACTT AACAGATACG
    1441  GAATAAATGG ATGAATGGAA AAAGCCCTGG ACTGGGAATA GTAAACCTGG TAACCAAACC
    1501  CAGCTCTGAC CCTGACCTGT AAGTAACTAC TATCTCTGGC CTTGGTGTAC CCCATGTATA
    1561  GTGGGGATTG TAAACACCTG CCCTGCCCAC CTTATGATAC TGCTGTGAGA CTCAAAAGAC
    1621  ATCATTAGCT CTTAGGCACA GGGAGCTTGG AGGTTAAATC CAATTTGTTT AGTTTTCAAC
    1681  AAGGAAGTGG TGCCCCAGGG ACAATGATGG AGAGAAATCG AATGTAATGA GCTGTTGCCA
    1741  CCAGCTGAGT GGTCCTGAAA TCATGGCATC TGGGTTGCAC TTAGAGATTG  TCCAGTTCAA
                                                                   TCF/LEF
    1801  AAGGCCA  GAA GGAATCTGAA CCTCGATGGG AAAAGTGACT TGCTCAGCTC CCCAGCAAGC
    1861  CAGGGCAGAG CTGGAGGATG GACTGGAGTC TCCTGGTTCC AGGTCCAGGA CTTCTTTCCG
    1921  CTGTGTTGAC AGAGCCAGGA GGAGGGGCAC CCGGGGAGCA GGGGAGGCAA GGGCTGCTGG
    1981  ATGCCCCATC TCAGTTGAAT TCTCCTTGAG GGACCCAGCC CAGGAGCAGA GTAAGAGGGT
    2041  TTGAGGGTGG AAGGTGGCAG GGCTGGCCAA GCAGTATAGT CCCTGCTGCT GATAACCAAT
    2101  CCCTGAAATC CCGAGGTGGA GGGACTTGAG GGCAAATCAC AGACATGGGG GACCTAATGC
    2161  TGGCCATGTG GCTCAACCAG AAGTGCCCGT CCCTCATAGC TTTGGGGAGA TCAGAAGTCA
    2221  GGGATAGGGT CGGGTGTGGT GGCTCATGCC TGTAATCCCA TCACTTTGGG ATAAGGAGGC
    2281  AGGGGGATCA CTTGAGCTTA GGAGTTCGAG ACCAGCCTGA GCAACATAGC AAAACCCTGT
    2341  TCTTTACAAA AAAATACAAA AATT  AGCCGG GCGTGGTGGT   GCACACCTGT AGTCCTGGCT
                                          ATF6
216
    2401  GCTGGGGAGG CTGAGGTGGG AAGATCACTT GAGCCCGGGA GGTCGAGGCT GCAG  TGAGCT
    2461  GACATCATGC TACTG  CATTC CAGCCTAGGC AATAGAGTGG GACCCTGTCT CAAAAAAAAA
               ATF4    
    2521  AAAAAAAAAA AGTCAGGGGT GCTGGCCCCA TGATAGGTGC AATGGGTGCC TCCAATTCCC
    2581  TCTGGCTCTG CCTCCCAGCC TCTGTCCAAG CAACAGGCAG ATTTTCCATG CCTGGGGACT
    2641  TGCCCCTGGC TCACTGATGA TGATACCATC TTAAGTCTCC TGGAATCCTT AAACCCTTCC
    2701  TTGGCATTTG TGAGCAAGTA TTGAGCCCCT CCCATGTTTT AGGCCCAGTG CTGGGTGCTT
    2761  TCACCTGCAA TTTCTTACAG AGGATGGTAT TTCCTAAACT CCATTCATTT GCTACCTCCA
    2821  TGATTTTTGC CATATCACCC AACCCATGAA ATACATAAAT AAATAGTATT TACTCAATAT
    2881  TTTGACTCAC TTTTAAAAAA CATAAACTTA TCTGAAAAGG GAACCTATGT CACGCCTCTA
    2941  AATAAACAGT ATCAACCAAA AATACAAAAG AAACAAAAAT AAATACAAAG ACATTCTTGG
    3001  TTTCTGGCAC CAGGCCCCAG TTCTGGCTCC AACCTTACTG AGAAGTCACA TGATCTCTCT
    3061  GGGCCTCAGT TTTCTCCTCT GGAAAATGGA GCTTTTGGAA GTTAATGCAT GCACAGTGCC
    3121  TGGCCCTGAG ACTGGCATGG AGTGAGTGGA AGAGAGGTTG CCTGACCTGG CTAAAATTGG
    3181  TTCTCTGGGC AGACATTTTC CCAAGGGCCA CTGAGAAGAC CCTCCTGTTA GGAGTCAGTG
    3241  AGCTCTGTCG CTGGAGGCAT TCAAACAGAG CCTGCGGACT TCTCACTGCG AAGTTGCCCA
    3301  GAGAATTCAG TGCTCAGAGG AAAGGGAGTG GTTATTCCAT CAGAGCTGGT TCCCCAGGAG
    3361  CGGGAGCAGG GCCTGTAGCA CCCAGCCTCT GTCCCTGGCT CCCGTCTATC CGGGATTTTA
    3421  GCGTTTCCTC TGTAGTTTTC AAGCACTGTC TCATATGACT CTCGCACCAG CGAGAGGCCA
    3481  GGGGAGATGG TGTCTGCCTG TTAAAGAGGG GCAGGCTGGT CCACATAGGT CAAGTGACTT
    3541  GGCCAAGGTC ACCAGAGCAG AGTTTTGAAC TTGAGCTGTC TGACTCAACT GCCTGGGAAG
    3601  TGCCTGCCCC TCCTCTGGCA TCCAGGGAGC ATGTCCTGGG GCTCTGGCTG GGACATAGCC
    3661  GGACACCTGC GGGCCCTTTA CGTCTCTAAA GAGAGAAAGA GGGAAGGGCC CCTGTCTAGG
    3721  GGGTGGTTTC CCTCCAGATG CCACCCCTCC GAGGTCCCCT TCTGCTTCTT CTTGCGGTAG
    3781  CCAGGGAGGC AGCCCACGGG CAGGGAAGCG GGGGTGGGGG TGCAGAGTCA GAGGTGCACG
                                                                   XBP1    
    3841  TGGACAGAGA CAGAGAGACA GGGACACGTG GGCAGAGACG GATAAAGACA GAGACCCAGA
                                   XBP1    
    
    3901  GAAAGCCAGA TATGTTGACA GACACAGAGA CAGACGCCAG AGAGGAAGGC AGACAAAGAG
    3961  ACGGGTGGAG ACAAAGACTC CCACCAAGAG ACGCAGAAGG AAGATGCCGA CGGTAAAGAC
    4021  AAAACAGGAG ACGCGCGCAA GGAGCAGGTC AGAGCCCAGG CTCGCTGAGA GAGGAAGGGC
    4081  TGGGCTGGGG CAGCCCGGAG GCAGAGAGAC CGAGAGTGCG GGGCGGGCGA GGGACGCCAG
    4141  GGCCGCGTCA CCCCAGCCCG TTCCTAGCTC CGCTCCCGGC AGGGGGCGCC CTGGCCTCGT
    4201  GGCACGACCG GCCCGCGGGG CGCGGGGCTC GGGCCGGGGG CGGGGCCGGG GCCGGGCTGG
    4261  GGAGGGGTTG GGGCCGGGGG CGGGGGAGGG GGCGGGCTGC CCGGGCCTCA CTCGGGCCCC
    4321  GCGGCCGCCT TTATAAGGCG GCGGGGGTGG TGGCCCGGGC CGCGTTGCGC TCCCGCCACT 
                                                        TSS
    4381  CCGCGCCCGC TATCCTGGCT CCGTGCTCCC ACGCGCTTGT GCCTGGACGG ACCC
Figure 7.5. ER  stress-related  transcription  factor  binding  sites  mapped  to  ALP  promoter region
(-122 to -4556 from the start of the first intron). TSS - transcription start site. Underline – fragment
used for DNA binding assays and proteomic analysis.
217
References
Acampora, D., Merlo, G.R., et al. (1999). "Craniofacial, vestibular and bone 
defects in mice lacking the Distal-less-related gene Dlx5." Development 
126(17): 3795-3809.
Akiyama, H. (2008). "Control of chondrogenesis by the transcription factor Sox9." 
Modern Rheumatology 18(3): 213-219.Alexopoulos, A., Peroukides, S., et 
al. (2011). "Implication of bone regulatory factors in human coronary artery
calcification." Artery Research 5(3): 101-108.
Alexopoulos, A., Peroukides, S., et al. (2011). "Implication of bone regulatory 
factors in human coronary artery calcification." Artery Research 5(3): 101-
108.
Ameri, K. and Harris, A. (2008). “Molecules in focus: Activation transcription 
factor 4” The International Journal of Biochemistry & Cell Biology 40: 14–21
Anderson, H.C. (2003). "Matrix vesicles and calcification." Current Rheumatology 
Reports 5(3): 222-226.
Aoshima, Y., Mizobuchi, M., et al. (2012). “Vitamin D receptor activators inhibit 
vascular smooth muscle cell mineralization induced by phosphate and TNF-
α.” Nephrology Dialysis Transplantation 27: 1800–1806.
Atkinson, J. (2008). “Age-related medial elastocalcinosis in arteries: mechanisms, 
animal models, and physiological consequences.” The Journal of Applied 
Physiology 105:1643-1651.
Axten, J.M., Medina, J.R., et al. (2012). “Discovery of 7-Methyl-5-(1-{[3-
(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3d] 
pyrimidin-4-amine (GSK2606414), a Potent and Selective First-in-Class 
Inhibitor of Protein Kinase R (PKR)-like Endoplasmic Reticulum Kinase 
(PERK).” Journal of Medicinal Chemistry  55: 7193−7207.
Baek, H.A., Kim, D.S.,  et al. (2011). “Involvement of Endoplasmic Reticulum 
Stress in Myofibroblastic Differentiation of Lung Fibroblasts.” Americam 
Journal of Respiratory Cell and Molecular Biology 46: 731–739.
Baek, W.Y., Kim, Y.J., et al. (2013). “Osterix is required for cranial neural crest-
derived craniofacial bone formation.” Biochemical and Biophysical Research
Communication  s 432(1): 188-192.
Baek, J.E., Choi, J.Y., et al. (2014). “Skeletal analysis and differential gene 
expression in Runx2/Osterix double heterozygous embryos.” Biochemical 
and Biophysical Research Communications 451: 442–448.
218
Balica, M., Boström, K., et al. (1997). "Calcifying Subpopulation of Bovine Aortic 
Smooth Muscle Cells Is Responsive to 17β-Estradiol." Circulation 95(7): 
1954-1960.
Ballock, R.T., Heydemann, A., et al. (1993). "TGF-β1 prevents hypertrophy of 
epiphyseal chondrocytes: Regulation of gene expression for cartilage matrix
proteins and metalloproteases." Developmental Biology 158(2): 414-429.
Barath, P., Fishbein, M.C., et al. (1990). "Detection and localization of tumor 
necrosis factor in human atheroma." The American Journal of Cardiology 
65(5): 297-302.
Berliner, J.A., Navab, M., et al. (2005). ”Atherosclerosis: Basic Mechanisms” 
Circulation 91:2488-2496.
Bertrand, R., Solary, E., et al. (1994). “Induction of a Common Pathway of 
Apoptosis by Staurosporine” Experimental Cell Research 211: 314-321.
Bi, W., Deng, J.M., et al. (1999). "Sox9 is required for cartilage formation." Nat 
Genet 22(1): 85-89.
Bialek, P., Kern, B., et al. (2004). “A Twist Code Determines the Onset of 
Osteoblast Differentiation” Developmental Cell  6: 423–435.
Block, G.A., Hulbert-Shearon, T.E., et al. (1998). "Association of Serum 
Phosphorus and Calcium x Phosphate Product With Mortality Risk in 
Chronic Hemodialysis Patients: A National Study." American Journal of 
Kidney Diseases 31(4): 607-617.
Bonin, L.R. and Damon, D.H. (1994). Vascular cell interactions modulate the 
expression of endothelin-1 and platelet-derived growth factor BB.” 
American Journal of Physiology 267 (Heart Circulation Physiololgy 36):  
H1698-H1706.
Bostrom, K., Watson, K.E., et al. (1993). "Bone morphogenetic protein expression 
in human atherosclerotic lesions." Journal of Clinical Investigation 91(4): 
1800-1809.
Bostrom, K., Rajamannan N.M., et al. (2011). “The Regulation of Valvular and 
Vascular Sclerosis by Osteogenic Morphogens” Circulation Research 109: 
564-577.
Brändström, H., Gerdhem, P., et al. (2004). "Single Nucleotide Polymorphisms in 
the Human Gene for Osteoprotegerin are Not Related to Bone Mineral 
Density or Fracture in Elderly Women." Calcified Tissue International 74(1): 
18-24.
Bucay, N., Sarosi, I., et al. (1998). "osteoprotegerin-deficient mice develop early 
onset osteoporosis and arterial calcification." Genes & Development 12(9): 
1260-1268.
219
Byon, C.H., Javed, A., et al. (2008). "Oxidative Stress Induces Vascular Calcification
through Modulation of the Osteogenic Transcription Factor Runx2 by AKT 
Signaling." The Journal of Biological Chemistry 283(22): 15319-15327.
Cai, Z., Li, F., et al. (2013). “Endoplasmic Reticulum Stress participates in Aortic 
Valve Calcification in Hypercholesterolemic Animals” Arteriosclerosis, 
Thrombosis,  and Vascular Biology 33: 2345-3254.
Calfon, M., Zeng, H., et al. (2002). "IRE1 couples endoplasmic reticulum load to 
secretory capacity by processing the XBP-1 mRNA." Nature 415(6867): 92-
96.
Cao, S.S. And Kaufman R.J. (2014). “Endoplasmic Reticulum Stress and Oxidative 
Stress in Cell Fate Decision and Human Disease.” Antioxidants and Redox 
Signaling 21(3): 396-413.
Carthew, R.W. and Sontheimer, E.J. (2009). “Origins and Mechanisms of miRNAs 
and siRNA.” Cell 136: 642–655.
Chen, N.X., O'Neill, K.D.,  et al. (2006). “The mechanisms of uremic serum-
induced expression of bone matrix proteins in bovine vascular smooth 
muscle cells.” Kidney International 70: 1046–1053.
Chen, G., Deng, C., et al. (2012). “TGF-β and BMP Signaling in Osteoblast 
Differentiation and Bone Formation.” International Journal of Biological 
Sciences 8(2): 272-288.
Chen, Y., Wang, X., et al. (2014). “Upregulated expression of PERK in spinal 
ligament fibroblasts from the patients with ossification of the posterior 
longitudinal ligament.” European Spine Journal 23: 447–454
Cheng, W.P., Hung, H.F., et al. (2008). “The molecular regulation of GADD153 in 
apoptosis of cultured vascular smooth muscle cells by cyclic mechanical 
stretch.” Cardiovascular Research 77: 551-559.
Clarke, M.C.H., Littlewood, T.D., et al. (2008). "Chronic Apoptosis of Vascular 
Smooth Muscle Cells Accelerates Atherosclerosis and Promotes 
Calcification and Medial Degeneration." Circulation Research 102: 1529-
1538.
Clauss, I.M., Gravallese, E.M., et al. (1993). "In Situ Hybridization Studies Suggest 
a Role for the Basic Region-Leucine Zipper Protein hXBP-1 in Exocrine Gland
and Skeletal Development During Mouse Embryogenesis " Developmental 
Dynamics 197: 146-156.
Collin-Osdoby, P. (2004). "Regulation of Vascular Calcification by Osteoclast 
Regulatory Factors RANKL and Osteoprotegerin." Circulation Research 
95(11): 1046-1057.
220
Cross, B.C.S., Bond, P.J., et al. (2012). “The molecular basis for selective inhibition 
of unconventional mRNA splicing by an IRE1-binding small molecule.” 
Proceedings of the National Academy of Scienc  es 109(15): E869-78.
Dai, X.Y., Zhao, M.M., et al. (2013). “Phosphate-induced autophagy counteracts 
vascular calcification by reducing matrix vesicle release.” Kidney 
International 83: 1042-1051.
Danciu, T.E., Li, Y., et al. (2102). “The Basic Helix Loop Helix Transcription Factor 
Twist1 is a Novel Regulator of ATF4 in Osteoblasts.” Journal of Cellular 
Biochemistry 113: 70-79.
Danziger, J. (2008). "Vitamin K-dependent Proteins, Warfarin, and Vascular 
Calcification." Clinical Journal of the American Society of Nephrology 3: 
1504-1510.
Das, I., Png, C.W., et al. (2013). “Glucocorticoids alleviate intestinal ER stress by 
enhancing protein folding and degradation of misfolded proteins.” Journal 
of Experimental Medicine 210(6): 1201-1216.
Davies, M.R., Lund, R.J., et al. (2005). "Low Turnover Osteodystrophy and 
Vascular Calcification Are Amenable to Skeletal Anabolism in an Animal 
Model of Chronic Kidney Disease and the Metabolic Syndrome." Journal of 
the American Society of Nephrology 16(4): 917-928.
Deegan, S., Saveljeva, S., et al. (2013). “Stress-induced self-cannibalism: on the 
regulation of autophagy by endoplasmic reticulum stress.” Cellular and 
Molecular Life Sciences 70: 2425-2441.
Demer, L.L. and Tintut, Y. (2014). “Inflammatory, Metabolic, and Genetic 
Mechanisms of  Vascular Calcification.” Arteriosclerosis, Thrombosis, and 
Vascular Biology 34:715-723.
Dennis, M.D., McGhee, N.K., et al. (2013). “Regulated in DNA damage and 
development 1 (REDD1) promotes cell survival during serum deprivation by
sustaining repression of signaling through the mechanistic target of 
rapamycin in complex 1 (mTORC1).” Cellular Signalling 25: 2709-2716.
DeVries-Seimon, T., Li, Y., et al. (2005). "Cholesterol-induced macrophage 
apoptosis requires ER stress pathways and engagement of the type A 
scavenger receptor." Journal of Cell Biology 171(1): 61-73.
Dimcheff, D.E., Askovic, S., et al. (2003). "Endoplasmic Reticulum Stress Is a 
Determinant of Retrovirus-Induced Spongiform Neurodegeneration." 
Journal of Virology 77(23): 12617-12629.
Dorai, H., Vukicevic, S., et al. (2000). "Bone morphogenetic protein-7 (osteogenic 
protein-1) inhibits smooth muscle cell proliferation and stimulates the 
expression of markers that are characteristic of SMC phenotype in vitro." 
Journal of Cellular Physiology 184(1): 37-45.
221
Dorai, H. and Sampath T.K. (2001). “Bone Morphogenetic Protein-7 Modulates 
Genes that Maintain the Vascular Smooth Muscle Cell Phenotype in 
Culture.” The Journal of Bone and Joint Surgery 83A(S1): 70-78.
Dreschler, C., Verdujin, M., et al. (2011). “Bone Alkaline Phosphatase and 
Mortality in Dialysis Patients.” Clinical Journal of the American Society of 
Nephrology 6: 1752-1759.
Droge, W. (2002). “Free Radicals in the Physiological Control of Cell Function” 
Physiological Reviews 82: 46-95.
Duan, X., Zhou, Y., et al. (2009). "Endoplasmic reticulum stress-mediated 
apoptosis is activated in vascular calciﬁcation." Biochemical and Biophysical
Research Communications 387: 694–699.
Duan, X.H., Chang, J.R., et al. (2013). “Activating transcription factor 4 is involved 
in endoplasmicvreticulum stress-mediated apoptosis contributing to 
vascular calcification.” Apoptosis 18(9): 1132-1144.
Dzau, V.J., Braun-Dullaeus, R.C., et  al. (2002). “Vascular proliferation and 
atherosclerosis: New perspectives and therapeutic strategies.” Nature 
Medicine 8(11): 1249-1256.
Ewence, A.E., Bootman, M., et al. (2008). "Calcium Phosphate Crystals Induce Cell
Death in Human Vascular Smooth Muscle Cells: A Potential Mechanism in 
Atherosclerotic Plaque Destabilization." Circulation Research 103: e28-e34.
Fan, D., Chen, Z., et al. (2007). “Osterix Is a Key Target for Mechanical Signals in 
Human Thoracic Ligament Flavum Cells.” Journal of Cellular Physiology 211: 
577-584.
Feil, S., Hofmann, F., et al. (2004). “SM22α Modulates Vascular Smooth Muscle 
Cell Phenotype During Atherogenesis.” Circulation Research 94: 863-865.
Fietta, P. and Manganelli, P. (2002). “Is fibrillin-1 the link between ankylosing 
spondylitis and Marfan's syndrome?.” The Journal of Rheumatology 29(8): 
1800-1808.
Freedman, B.I., Bowden, D.W., et al. (2009). "Bone morphogenetic protein 7 
(BMP7) gene polymorphisms are associated with inverse relationships 
between vascular calcification and BMD: The diabetes heart study." Journal 
of Bone and Mineral Research 24(10): 1719-1727.
Frid, M.G., Shekhonin, B.V., et al. (1992). “Phenotypic Changes of Human Smooth 
Muscle Cells during Development: Late Expression of Heavy Caldesmon and
Calponin.” Developmental Biology 153: 185-193.
Fujii, Y., Khoshnoodi, J., et al. (2006). "The effect of dexamethasone on defective 
nephrin transport caused by ER stress: A potential mechanism for the 
therapeutic action of glucocorticoids in the acquired glomerular diseases." 
Kidney International 69(8): 1350-1359.
222
Fukui, M., Senmaru, T., et al. (2011). "17β-Estradiol attenuates saturated fatty 
acid diet-induced liver injury in ovariectomized mice by up-regulating 
hepatic senescence marker protein-30." Biochemical and Biophysical 
Research Communications 415(2): 252-257.
Fukunaka, A., Kurokawa, Y., et al. (2011). “Tissue Nonspecific Alkaline 
Phosphatase Is Activated via a Two-step Mechanism by Zinc Transport 
Complexes in the Early Secretory Pathway.” The Journal of Biological 
Chemistry 286: 16363-16373.
Galvin, K.M., Donovan, M.J., et al. (2000). "A role for Smad6 in development and 
homeostasis of the cardiovascular system." Nat Genet 24(2): 171-174.
Garg, A.D., Kaczmarek, A., et al. (2012). "ER stress-induced inflammation: does it 
aid or impede disease progression?" Trends in Molecular Medicine 18(10): 
589-598.
Giachelli, C.M., Jono, S., et al. (2001). “Vascular Calcification and Inorganic 
Phosphate.” American Journal of Kidney Diseases 38(4): S34-S37.
Goettsch, C., Rauner, M., et al. (2011). "miR-125b Regulates Calcification of 
Vascular Smooth Muscle Cells." The American Journal of Pathology 179(4): 
1594–1600.
Gorlach, A., Klappa, P., et al. (2006). “The Endoplasmic Reticulum: Folding, 
Calcium Homeostasis, Signaling, and Redox Control.” Antioxidants and 
Redox Signaling 8(9): 1391-1418.
Grainger, D.J., Metcalfe, J.C., et al. (1998). “Transforming growth factor-β 
dynamically regulates vascular smooth muscle differentiation in vivo.” 
Journal of Cell Science 111: 2977-2988
Guo, F.J., Xiong, Z., et al. (2013). “ATF6 upregulates XBP1S and inhibits ER stress-
mediated apoptosis in osteoarthritis cartilage.” Cellular Signalling 26: 332-
342
Guo, F.J., Jiang, R., et al. (2014). “IRE1a constitutes a negative feedback loop with 
BMP2 and acts as a novel mediator in modulating osteogenic 
differentiation.”  Cell Death and Disease 5: e1239.
Guo, F.J., Jiang, R., et al. (2014b). “Regulation of chondrocyte differentiation by 
IRE1α depends on its enzymatic activity.” Cellular Signalling 26: 1998–2007.
Guo, Y.S., Sun, Z., et al. (2014c). “17β-Estradiol inhibits ER stress-induced 
apoptosis through promotion of TFII-I-dependent Grp78 induction in 
osteoblasts.” Laboratory Investigation 94: 906-916.
Haas, M.J., Raheja, P., et al. (2012). "Estrogen-dependent inhibition of dextrose-
induced endoplasmic reticulum stress and superoxide generation in 
endothelial cells." Free Radical Biology and Medicine 52(11-12): 2161-2167.
223
Han, X., Zhou, J., et al. (2013). “IRE1αdissociates with BiP and inhibits ER stress-
mediated apoptosis in cartilage development.” Cellular Signalling 25: 2136–
2146.
Harding, H.P., Zhang, Y., et al. (1999). "Protein translation and folding are coupled 
by an endoplasmic-reticulum-resident kinase." Nature 397(6716): 271-274.
Harding, H.P., Zhang, Y., et al. (2000). "Perk Is Essential for Translational 
Regulation and Cell Survival during the Unfolded Protein Response." 
Molecular Cell 5: 897–904.
Harding, H.P., Zeng, H., et al. (2001). "Diabetes Mellitus and Exocrine Pancreatic 
Dysfunction in Perk -/- Mice Reveals a Role for Translational Control in 
Secretory Cell Survival." Molecular Cell 7: 1153–1163.
Hashimoto, S., Ochs, R.L., et al. (1998). "Chondrocyte-derived apoptotic bodies 
and calcification of articular cartilage." Proceedings of the National 
Academy of Sciences 95(6): 3094-3099.
Haze, K., Yoshida, H., et al. (1999). "Mammalian Transcription Factor ATF6 Is 
Synthesized as a Transmembrane Protein and Activated by Proteolysis in 
Response to Endoplasmic Reticulum Stress." Molecular Biology of the Cell 
10: 3787–3799.
Heldin, C.H., Miyazono, K., et al. (1997). “TGF-bsignalling from cell membrane to 
nucleus through SMAD proteins.” Nature 390: 465-471.
Hellstrom, M., Kalen, M., et al. (1999). “Role of PDGF-B and PDGFR-β in 
recruitment of vascular smooth muscle cells and pericytes during 
embryonic blood vessel formation in the mouse.” Development 126: 3047-
3055.
Henthorn, P.S., Raducha, M., et al. (1992). “Different missense mutations at the 
tissue-nonspecific alkaline phosphatase gene locus in autosomal recessively
inherited forms of mild and severe hypophosphatasia.” Proceedings of the 
National Academy of Sciences 89: 9924-9928.
Herrmann, S.M., Whatling, C., et al. (2000). "Polymorphisms of the Human Matrix
Gla Protein (MGP) Gene, Vascular Calcification, and Myocardial Infarction." 
Arteriosclerosis, Thrombosis, and Vascular Biology 20: 2386-2393.
Hino, K., Saito, A., et al. (2014). “Master Regulator for Chondrogenesis, Sox9, 
Regulates Transcriptional Activation of the Endoplasmic Reticulum Stress 
Transducer BBF2H7/CREB3L2 in Chondrocytes.” The Journal of Biological 
Chemistry 289(20): 13810–13820.
Hirschi, K.K., Rohovsky, S.A., et al. (1998). “PDGF, TGF-b, and Heterotypic Cell–Cell
Interactions Mediate Endothelial Cell–induced Recruitment of 10T1/2 Cells 
and Their Differentiation to a Smooth Muscle Fate.” The Journal of Cell 
Biology 141(3): 805–814.
224
Hitomi, J., Katayama, T., et al. (2004). “Involvement of caspase-4 in endoplasmic 
reticulum stress-induced apoptosis and Aβ-induced cell death.” The Journal
of Cell Biology 165(3): 347–356.
Hollien, J. and Weissman, J.S. (2006). “Decay of Endoplasmic Reticulum-Localized 
mRNAs During the Unfolded Protein Response.” Science 312(104): 104-107.
Hoshino, T., Chow, L., et al. (2009). “Mechanical Stress Analysis of a Rigidn 
Inclusion in Distensible Material: a Model of Atherosclerotic Calcification 
and Plaque Vulnerability.” American Journal of Physiology – Heart and 
Circulatory Physiology 297(2): H802-H810.
Hosoi, T., Sasaki, M., et al. (2008). "Endoplasmic reticulum stress induces leptin 
resistance." Molecular Pharmacology 74(6): 1610-1619.
Howard, T.D., Paznekas, W.A., et al. (1997). “Mutations in TWIST, a Basci Helix-
Loop-Helix Transcription factor, in Saethre-Chotzen syndrome.” Nature 
Genetics 15: 36-41.
Hoyer-Hansen, M. and Jaattela, M. (2007). “Connecting endoplasmic reticulum 
stress to autophagy by unfolded protein response and calcium.” Cell Death 
and  Differentiation 14: 1576–1582.
Huang, Q.Q., Fisher, S.A., et al. (1999). “Forced Expression of Essential Myosin 
Light Chain Isoforms Demonstrates Their Role in Smooth Muscle Force 
Production.”  The Journal of Biological Chemistry 274 (49): 35095–35098.
Husa, M., Petursson, F., et al. (2013). “C/EBP homologous protein drives pro-
catabolic responses in chondrocytes.” Arthritis Research & Therapy 15: 
R218.
Ichida, F., Nishimura, R., et al. (2004). "Reciprocal Roles of Msx2 in Regulation of 
Osteoblast and Adipocyte Differentiation." Journal of Biological Chemistry 
279(32): 34015-34022.
Ichikawa, S., Imel, E.A., et al. (2007). "A homozygous missense mutation in 
human KLOTHO causes severe tumoral calcinosis." Journal of Clinical 
Investigation 117(9): 2684-2691.
Iribarren, C., Husson, G., et al. (2007). "Plasma Leptin Levels and Coronary Artery 
Calcification in Older Adults." Journal of Clinical Endocrinology & 
Metabolism 92(2): 729-732.
Ishihara, K, Yamazaki, T., et al. (2006). “Zinc Transport Complexes Contribute to
the Homeostatic Maintenance of Secretory Pathway Function in Vertebrate
Cells.”  Journal of Biological Chemistry 281(26): 17743-17750.
Iyemere, V.P., Proudfoot, D., et al. (2006). "Vascular smooth muscle cell 
phenotypic plasticity and the regulation of vascular calcification." Journal of
Internal Medicine 260(3): 192-210.
225
Izumi, S., Saito, A., et al. (2012). “The Endoplasmic Reticulum Stress Transducer 
BBF2H7 Suppresses Apoptosis by Activating the ATF5-MCL1 Pathway in 
Growth Plate Cartilage.”  The Journal of Biological Chemistry 287(43): 
36190–36200.
Jahnen-Dechent, W., Schinke, T., et al. (1997). "Cloning and Targeted Deletion of 
the Mouse Fetuin Gene." The Journal of Biological Chemistry 272(50): 
31496-31503.
Jang, W.G., Kim, E.J., et al. (2011). "BMP2 Protein Regulates Osteocalcin 
Expression via Runx2-mediated Atf6 Gene Transcription." The Journal of 
Biological Chemistry 287(2): 905-915.
Jang, W.G., Kim, E.J., et al. (2013). “Tunicamycin negatively regulates BMP2-
induced osteoblast differentiation through CREBH expression in MC3T3E1 
cells.” BMB Reports 44(11): 735-740.
Jena, N., Martín-Seisdedos, C., et al. (1997). "BMP7 null mutation in mice: 
Developmental defects in skeleton, kidney, and eye." Experimental Cell 
Research 230(1): 28-37.
Jensen, E.D., Niu, L., et al. (2008). “p68 (Ddx5) Interacts With Runx2 and 
Regulates Osteoblast Differentiation.” Journal of Cellular Biochemistry 103: 
1438–1451.
Jian, B., Narula, N., et al. (2003). "Progression of aortic valve stenosis: TGF-
{beta}1 is present in calcified aortic valve cusps and promotes aortic valve 
interstitial cell calcification via apoptosis." The Annals of Thoracic Surgery 
75(2): 457-465.
Jono, S., Nishizawa, Y., et al. (1998) “Parathyroid Hormone–Related Peptide as a 
Local Regulator of Vascular Calcification Its Inhibitory Action on In Vitro 
Calcification by Bovine Vascular Smooth Muscle Cells.” Arteriosclerosis, 
Thrombosis, and Vascular Biology 17:1135-1142
Kaden, J.J., Bickelhaupt, S., et al. (2004). "Expression of bone sialoprotein and 
bone morphogenetic protein-2 in calcific aortic stenosis." The Journal of 
heart valve disease 13(4): 560-566.
Kalantar-Zadeh, K., Kuwae, N., et al. (2006). “Survival predictability of time-
varying indicators of bone disease in maintenance hemodialysis patients.” 
Kidney International 70: 771–780.
Kalra, S.S. and Shanahan, C.M. (2012). "Vascular calcification and hypertension: 
Cause and effect." Annals of Medicine 44(SUPPL. 1): S85-S92.
Kaneto, H., Matsuoka, T., et al. (2005). "Oxidative stress, ER stress, and the JNK 
pathway in type 2 diabetes." The Journal of Molecular MEdicine 83: 429-
439.
226
Kapustin, A.N., Davies, J.D., et al. (2011). "Calcium regulates key components of 
vascular smooth muscle cell-derived matrix vesicles to enhance 
mineralization." Circulation Research 109(1): e1-e12.
Kapustin, A.N. and Shanahan, C.M. (2012). "Calcium Regulation of Vascular 
Smooth Muscle Cell–Derived Matrix Vesicles." Trends in Cardiovascular 
Medicine 22(5): 133-137.
Karsenty, G., Kronenberg, H.M., et al. (2009). "Genetic Control of Bone 
Formation." Annual Review of Cell and Developmental Biology 25: 629-648.
Karwowski, W., Naumnik, B., et al. (2012). "The mechanism of vascular 
calcification - a systematic review." Medical Science Monitor 18(1): RA1-11.
Kassan, M., Galán, M., et al. (2012). "Endoplasmic reticulum stress is involved in 
cardiac damage and vascular endothelial dysfunction in hypertensive 
mice." Arteriosclerosis, Thrombosis, and Vascular Biology 32(7): 1652-1661.
Katagiri, T. and Takahashi, N. (2002). "Regulatory mechanisms of osteoblast and 
osteoclast differentiation." Oral Diseases 8(3): 147-159.
Katano, A., Satoh, T., et al. (2013). “THRAP3 Interacts with HELZ2 and Plays a 
Novel Role in Adipocyte Differentiation.” Molecular Endocrinology  27(5): 
769 –780.
Kedi, X., Ming, Y., et al. (2009). "Free cholesterol overloading induced smooth 
muscle cells death and activated both ER- and mitochondrial-dependent 
death pathway." Atherosclerosis 207(1): 123-130.
Ketteler, M., Bongartz, P., et al. (2003). "Association of low fetuin-A (AHSG) 
concentrations in serum with cardiovascular mortality in patients on 
dialysis: a cross-sectional study." The Lancet 361(9360): 827-833.
Ketteler, M., Vermeer, C., et al. (2002). "Novel Insights into Uremic Vascular 
Calcification: Role of Matrix Gla Protein and Alpha-2-Heremans Schmid 
Glycoprotein/Fetuin." Blood Purification 20: 473-476.
Kim, J.W., Choi, H., et al. (2014). “transcriptional Factor AtF6 is Involved in 
Odontoblastic Differentiation.” Journal of Dental Research 93(5): 483-48.
Kleinjan, .A., and van Heyningen, V., (2005). “Long-Range Control of Gene 
Expression: Emerging Mechanisms and Disruption in Disease.” American 
Journal of Human Genetics 76: 8–32.
Kobayashi, T., Vischer, U.M., et al. (2000). "The Tetraspanin CD63/lamp3 Cycles 
between Endocytic and Secretory Compartments in Human Endothelial 
Cells." Molecular Biology of the Cell 11(5): 1829-1843.
Komori, T.  (2006). “Regulation of Osteoblast Differentiation by Transcription 
Factors.” Journal of Cellular Biochemistry 99: 1233–1239.
227
Ketteler, M., Vermeer, C., et al. (2002). "Novel Insights into Uremic Vascular 
Calcification: Role of Matrix Gla Protein and Alpha-2-Heremans Schmid 
Glycoprotein/Fetuin." Blood Purification 20: 473-476.
Kondo, S., Saito, A., et al. (2007). "BBF2H7, a Novel Transmembrane bZIP 
Transcription Factor, Is a New Type of Endoplasmic Reticulum Stress 
Transducer."
Kooptiwut, S., Mahawong, P., et al. (2014). “Estrogen  reduces  endoplasmic  
reticulum  stress  to  protect  against glucotoxicity  induced-pancreatic  β-
cell  death.” Journal of Steroid Biochemistry and Molecular Biology 139: 25-
32.
Kozutsumi, Y., Segal, M., et al. (1988). “The presence of malfolded proteins in the 
endoplasmic reticulum signals the induction of glucose-regulated proteins.”
Nature 332: 462-464.
Kuro-o, M., Matsumura, Y., et al. (1997). "Mutation of the mouse klotho gene 
leads to a syndrome resembling ageing." Nature 390(6655): 45-51.
Lee, M.-H., Kwon, T.-G., et al. (2003). "BMP-2-induced Osterix expression is 
mediated by Dlx5 but is independent of Runx2." Biochemical and 
Biophysical Research Communications 309: 689-694.
Lee, H.L., Woo, K.M., et al. (2010). “Tumor necrosis factor-aincreases alkaline 
phosphatase expression in vascular smooth muscle cells via MSX2 
induction.” Biochemical and Biophysical Research Communications 391: 
1087-1092.
Lehtinen, A.B., Burdon, K.P., et al. (2007). "Association of α2-Heremans-Schmid 
Glycoprotein Polymorphisms with Subclinical Atherosclerosis." Journal of 
Clinical Endocrinology & Metabolism 92(1): 345-352.
Lei, Y., Sinha, A., et al. (2014). “Hydroxyapatite and calcified elastin induce 
osteoblast-like differentiation in rat aortic smooth muscle cells.” 
Experimental Cell Research 323(1): 198-208. 
Lencel, P., Delplace, S., et al. (2011). “TNF-α stimulates alkaline phosphatase and 
mineralization through PPARγ inhibition in human osteoblasts.” Bone 48: 
242-249.
Leroux-Berger, M., Queguiner, I., et al. (2011). “Pathologic Calcification of Adult 
Vascular Smooth Muscle Cells Differs on Their Crest or Mesodermal 
Embryonic Origin.” Journal of Bone and Mineral Research 26(7): 1543-1553.
Li, X., Yang, H.Y., et al. (2008). "BMP-2 promotes phosphate uptake, phenotypic 
modulation, and calcification of human vascular smooth muscle cells." 
Atherosclerosis 199(2): 271-277.
228
Lian, N., Lin, T., et al. (2012). “Transforming Growth Factor#Suppresses 
Osteoblast Differentiation via the Vimentin Activating Transcription Factor 4
(ATF4) Axis.” The Journal of Biological Chemistry 287(43): 35975-35984.
Liang, B., Wang, S., et al. (2013). “Aberrant Endoplasmic Reticulum Stress in 
Vascular Smooth Muscle Increases Vascular Contractility and Blood 
Pressure in Mice Deficient of AMP-Activated Protein Kinase-α2 In Vivo.” 
Arteriosclerosis, Thrombosis, and Vascular Biology 33: 595-604.
Liberman, M., Johnson, R.C., et al. (2011). "Bone morphogenetic protein-2 
activates NADPH oxidase to increase endoplasmic reticulum stress and 
human coronary artery smooth muscle cell calciﬁcation." Biochemical and 
Biophosical Research Communications 413: 436-441.
Lim, K., Lu, T.S., et al. (2012). "Vascular Klotho Deficiency Potentiates the 
Development of Human Artery Calcification and Mediates Resistance to 
Fibroblast Growth Factor 23." Circulation 125(18): 2243-2255.
Liu, F., Hata, A., et al. (1996). "A human Mad protein acting as a BMP-regulated 
transcriptional activator." Nature 381(6583): 620-623.
Liu, C., Zhang, Y., et al. (2007). “Transcriptional activation of cartilage oligomeric 
matrix protein by Sox9, Sox5, and Sox6 transcription factors and CBP/p300 
coactivators.” Frontiers in Bioscience 12: 3899-3910.
Liu, Y., Wang, T., et al. (2011a). “HGF/c-Met signalling promotes Notch3 activation
and human vascular smooth muscle cell osteogenic differentiation in vitro.”
Atherosclerosis 219: 440-447.
Liu, Y., Wang, X., et al. (2011b). “Wogonin ameliorates lipotoxicity-induced 
apoptosis of cultured vascular smooth muscle cells via interfering with 
DAG-PKC pathway.” Acta Pharmacologica Sinica 32: 1475-1482.
Liu, Y., Zhou, J., et al. (2012). "XBP1S Associates with RUNX2 and Regulates 
Chondrocyte Hypertrophy." Journal of Biological Chemistry.
Liu, D., Cui, W., et al. (2014). “Atorvastatin Protects Vascular Smooth Muscle Cells 
From TGF-β1-Stimulated Calcification by Inducing Autophagy via 
Suppression of the β-Catenin Pathway.” Cellular Physiology and 
Biochemistry 33: 129-141.
Livak, K.J. and Schmittgen, T.D. (2001). “Analysis of Relative Gene Expression Data
Using Real-Time Quantitative PCR and the 2-ΔΔCT Method.” Methods 25: 
402-408.
Lomashvili, K.A., Garg, P., et al. (2008). "Upregulation of alkaline phosphatase and
pyrophosphate hydrolysis: Potential mechanism for uremic vascular 
calcification." Kidney International 73(9): 1024-1030.
229
Lomashvili, K.A., Wang, X., et al. (2011). "Matrix gla protein metabolism in 
vascular smooth muscle and role in uremic vascular calcification." Journal 
of  Biological Chemistry 286(33): 28715-28722.
London, G.M.  (2011). “Arterial calcification: cardiovascular function and clinical 
outcome.” Nefrologia 31(6): 644-647.
Luo, G., Ducy, P., et al. (1997). "Spontaneous calcification of arteries and cartilage 
in mice lacking matrix GLA protein." Nature 386(6620): 78-81.
Luo, S., Baumeister, P., et al. (2003). "Induction of Grp78/BiP by Translational 
Block." The Journal Of Biological Chemistry 278(39): 37375–37385.
Mackie, E.J., Ahmed, Y.A., et al. (2008). “Endochondral ossification: How cartilage 
is converted into bone in the developing skeleton.” The International 
Journal of Biochemistry and Cell Biology 40: 46–62.
Maiuri, M.C., Zalckvar, E., et al. (2007). "Self-eating and self-killing: Crosstalk 
between autophagy and apoptosis." Nature Reviews Molecular Cell Biology 
8(9): 741-752.
Makowski, A.J., Uppuganti, S., et al. (2014). “The loss of activating transcription 
factor 4 (ATF4) reduces bone toughness and fracture toughness.” Bone 62: 
1–9.
Masuda, M., Ting, T.C., et al. (2012). "Activating transcription factor 4 regulates 
stearate-induced vascular calcification." Journal of Lipid Research 53(8): 
1543-1552.
Masuda, M., Miyazaki-Anzai, S., et al. (2013). “PERK-eIF2a-ATF4-CHOP Signaling 
Contributes to TNFa-Induced Vascular Calcification.” The Journal of the 
American Heart Association 2(5): e000238.
Matsubara, T., Kida, K., et al. (2008). "BMP2 Regulates Osterix through Msx2 and 
Runx2 during Osteoblast Differentiation." The Journal of Biological 
Chemistry 283(43): 29119-29125.
Michigami, T. (2013). “Regulatory mechanisms for the development of growth  
plate cartilage.” Cellular and Molecular Life Sciences 70: 4213-4221.
Miller, J.D., Chu, Y., et al. (2008). "Dysregulation of Antioxidant Mechanisms 
Contributes to Increased Oxidative Stress in Calciﬁc Aortic Valvular Stenosis 
in Humans." Journal of the American College of Cardiology 52(10): 843-850.
Milona, M., Gough, J.E., et al. (2003). “Expression of alternatively spliced 
isoforms of human Sp7 in osteoblast-like cells.” BMC Genomics 4(43).
Minamino, T. and Kitakaze, M. (2012). "ER stress in cardiovascular disease." 
Journal of Molecular and Cellular Cardiology 48: 1105–1110.
Mizobuchi, M., Ogata, H., et al. (2009). “Vitamin D and vascular calcification in 
chronic kidney disease.” Bone 45: S26-S29.
230
Moe, S.M. and Chen, N.X. (2005). "Inflammation and vascular calcification." 
Blood Purification 23(1): 64-71.
Moore, K. and Hollien, J. (2012). “The Unfolded Protein Response in Secretory 
Cell Function.” The Annual Review of Genetics 46: 165-183.
Mori, K., Shioi, A., et al. (1999). "Dexamethasone enhances in vitro vascular 
calcification by promoting osteoblastic differentiation of vascular smooth 
muscle cells." Arteriosclerosis, Thrombosis, and Vascular Biology 19(9): 
2112-2118.
Motskin, M., Wrights, D.M., et al. (2009). “Hydroxyapatite nano and 
microparticles: Correlation of particle properties with cytotoxicity and 
biostability.” Biomaterials 30: 3307–3317
Mu, F.-T., Callaghan, J.M., et al. (1995). "EEA1, an Early Endosome-Associated 
Protein." Journal of Biological Chemistry 270(22): 13503-13511.
Mueller, S., Riedel, H.D., et al. (1997). “Determination of Catalase Activity at 
Physiological Hydrogen Peroxide Concentrations.” Analytical Biochemistry 
245: 55-60.
Munroe, P.B., Olgunturk, R.O., et al. (1999). "Mutations in the gene encoding the 
human matrix Gla protein cause Keutel syndrome." Nat Genet 21(1): 142-
144.
Murakami, T., Saito, A., et al. (2009). "Signalling mediated by the endoplasmic 
reticulum stress transducer OASIS is involved in bone formation." Nature 
Cell Biology 11(10): 1205-1211.
Murakami, T., Hino, S., et al. (2010). “Distinct mechanisms are responsible for 
osteopenia and growth retardation in OASIS-deficient mice.” Bone 48(3): 
514-523.
Musunuru, K., Nasir, K., et al. (2008). "A synergistic relationship of elevated low-
density lipoprotein cholesterol levels and systolic blood pressure with 
coronary artery calcification." Atherosclerosis 200(2): 368-373.
Nakagawa, T., Zhu, H., et al. (2000). “Caspase-12 mediates endoplasmic 
reticulum-specific apoptosis and cytotoxicity by amyloid-β.” Nature 403: 98-
103.
Nakagawa, Y., Ikeda, K., et al. (2010). "Paracrine osteogenic signals via bone 
morphogenetic protein-2 accelerate the atherosclerotic intimal calcification
in vivo." Arteriosclerosis, Thrombosis, and Vascular Biology 30(10): 1908-
1915.
Nakamura, S., Miki, H., et al. (2013). “Activating transcription factor 4, an ER 
stress mediator, is required for, but excessive ER stress suppresses 
osteoblastogenesis by bortezomib.” International Journal of Hematology 
98: 66–73.
231
Nakashima, K. and de Crombrugghe, B. (2003). "Transcriptional mechanisms in 
osteoblast differentiation and bone formation." Trends in Genetics 19(8): 
458-466.
Nakashima, K., Zhou, X., et al. (2002). "The Novel Zinc Finger-Containing 
Transcription Factor Osterix Is Required for Osteoblast Differentiation and 
Bone Formation." Cell 108: 17-29.
Neven, E., Dauwe, S., et al. (2007). "Endochondral bone formation is involved in 
media calcification in rats and in men." Kidney Int 72(5): 574-581.
Neven, E., Persy, V., et al. (2010). “Chondrocyte Rather Than Osteoblast 
Conversion of Vascular Cells Underlies Medial Calcification in Uremic Rats.” 
Arteriosclerosis, Thrombosis, and Vascular Biology 30: 1741-1750.
New, S.E., Goettsch, C., et al. (2013). “Macrophage-Derived Matrix Vesicles: An 
Alternative Novel Mechanism for Microcalcification in Atherosclerotic 
Plaques.” Circulation Research 113: 72-77.
Niederhoffer, N., Bobryshev, Y.V., et al. (1997). “Aortic Calcification Produces by 
Vitamin D3 plus Nicotine.” Journal of Vascular Rsearch 34: 386-398.
Nikaido, T., Yokoya, S., et al. (2001). "Expression of the novel transcription factor 
OASIS, which belongs to the CREB/ATF family, in mouse embryo with special
reference to bone development."  116: 141–148.
Nishimura, R., Kato, Y., et al. (1998). "Smad5 and DPC4 Are Key Molecules in 
Mediating BMP-2-induced Osteoblastic Differentiation of the Pluripotent 
Mesenchymal Precursor Cell Line C2C12." The Journal of Biological 
Chemistry 4: 1872-1879.
Nishimura, R., Wakabayashi, M., et al. (2012). “Osterix Regulates Calcification and
Degradation of Chondrogenic Matrices through Matrix Metalloproteinase 
13 (MMP13) Expression in Association with Transcription Factor Runx2 
during Endochondral Ossification.” The Journal of Biological Chemistry 
287(40): 33179-33190.
Nonaka, H., Tsujino, T., et al. (2001). “Taurine Prevents the Decrease in Expression
and Secretion of Extracellular Superoxide Dismutase Induced by 
Homocysteine.” Circulation 104: 1165-1170.
Novak, A. and Dedhar, S. (1999). “Signaling through#-catenin and Lef/Tcf.” 
Cellular  and Molecular Life Sciences 56: 523-537.
O'Neill, W.C. and Adams, A.L. (2014). “Breast arterial calcification in chronic 
kidney disease: absence of smooth muscle apoptosis and osteogenic 
transdifferentiation.” Kidney International 85: 668-676.
Obeng, E.A. and Boise, L.H. (2005). “Caspase-12 and Caspase-4 Are Not Required 
for Caspase-dependent Endoplasmic Reticulum Stress-induced Apoptosis.” 
The Journal of Biological Chemistry 280(33): 29578-29587. 
232
Ogata, M., Hino, S., et al. (2006). “Autophagy Is Activated for Cell Survival after 
Endoplasmic Reticulum Stress.” Molecular And Cellularbiology 26(24): 
9220–9231
Ohta, S., Hattori, Y., et al. (2011). “Differential Modulation of Immunostimulant-
Triggered NO Production by Endoplasmic Reticulum Stress Inducers in 
Vascular Smooth Muscle Cells.” Journal of Cardiovascular Pharmacology 
57(4): 434-438.
Okawa, A., Nakamura, I., et al. (1998). "Mutation in Npps in a mouse model of 
ossification of the posterior longitudinal ligament of the spine." Nature 
Genetics 19(3): 271-273.
Olden, K., Pratt, R.M., et al. (1979). "Evidence for role of glycoprotein 
carbohydrates in membrane transport: Specific inhibition by tunicamycin." 
Proceedings of the National Academy of Science 76(2): 791-795.
O'Neill, W.C. And Adams, A.L. (2014). “Breast arterial calcification in chronic 
kidney disease: absence of smooth muscle apoptosis and osteogenic 
transdifferentiation.” Kidney International 85(3): 668-676.
Orimo, H. and Shimada, T. (2005). “Regulation of the human tissue-nonspecific 
alkaline phosphatase gene expression by all-trans-retinoic acid in SaOS-2 
osteosarcoma cell line.” Bone 36: 866 – 876.
Orlandi, A., Ropraz, P., et al. (1994). “Proliferative Activity and α-Smooth Muscle 
Actin Expression in Cultures Rat Aortic Smooth Muscle Cells Are Differently 
Mudulated by Transforming Growth Factor-β1 and Heparin.” Experimental 
Cell Research 214: 528-536.
Orsó, E., Grandl, M., et al. (2011). "Oxidized LDL-induced endolysosomal 
phospholipidosis and enzymatically modified LDL-induced foam cell 
formation determine specific lipid species modulation in human 
macrophages." Chemistry and Physics of Lipids 164(6): 479-487.
Osako, M.K., Nakagami, H., et al. (2010). "Estrogen inhibits vascular calcification 
via vascular RANKL system: Common mechanism of osteoporosis and 
vascular calcification." Circulation Research 107(4): 466-475.
Osawa, M., Tian, W., et al. (2005). "Association of α2-HS glycoprotein (AHSG, 
fetuin-A) polymorphism with AHSG and phosphate serum levels." Human 
Genetics 116(3): 146-151.
Osinbowale, O., Malki, M., et  al. (2009). “An algorithm for managing warfarin 
resistance.” Cleveland Clinic Journal of Medicine 76(12): 724-730.
Parhami, F., Tintut, Y., et al. (2001). "Leptin Enhances the Calcification of Vascular 
Cells." Circulation Research 88(9): 954-960.
Parhami, F., Basseri, B., et al. (2002). "High-Density Lipoprotein Regulates 
Calcification of Vascular Cells." Circulation Research 91(7): 570-576.
233
Park, J., Jang, H., et al. (2012). “ER stress-inducible ATF3 suppresses BMP2-
induced ALP expression and activation in MC3T3-E1 cell.” Biochemical and 
Biophysical Research Communications 443: 333–338.
Park, S.Y. and Kim, J.E. (2013). “Differential gene expression by Osterix knockdown
in mouse chondrogenic ATDC5 cells.” Gene 518: 368–375.
Peng, Y., Shi, K., et al. (2013). “Characterization of Osterix Protein Stability and 
Physiological Role in Osteoblast Differentiation.” PloS ONE 8(2): e56451.
Pereira, L., Andrikopoulos, K., et al. (1997). "Targetting of the gene encoding 
fibrillin-1 recapitulates the vascular aspect of Marfan syndrome." Nat Genet
17(2): 218-222.
Plenz, G.A.M., Deng, M.C., et al. (2003). “Vascular collagens: spotlight on the role 
of type VIII collagen in atherogenesis.” Atherosclerosis 166: 1-11.
Price, P.A., Faus, S.A., et al. (1998). “Warfarin Causes Rapid Calcification of the 
Elastic Lamellae in Rat Arteries and Heart Valves.” Arteriosclerosis, 
Thrombosis,  and Vascular Biology 18: 1400-1407.
Proudfoot, D., Skepper, J.N., et al. (1998). "Calcification of Human Vascular Cells 
In Vitro Is Correlated With High Levels of Matrix Gla Protein and Low Levels 
of Osteopontin Expression." Arteriosclerosis, Thrombosis, and Vascular 
Biology 18: 379-388.
Proudfoot, D., Skepper, J.N., et al. (2000). "Apoptosis Regulates Human Vascular 
Calcification In Vitro: Evidence for Initiation of Vascular Calcification by 
Apoptotic Bodies." Circulation Research 87: 1055-1062.
Proudfoot, D. and Shanahan, C.M. (2001). "Biology of Calcification in Vascular 
Cells: Intima versus Media." Herz 26(4): 245-251.
Proudfoot, D., Davies, J.D., et al. (2002). "Acetylated Low-Density Lipoprotein 
Stimulates Human Vascular Smooth Muscle Cell Calcification by Promoting 
Osteoblastic Differentiation and Inhibiting Phagocytosis." Circulation 
106(24): 3044-3050.
Qiao, J.H., Mertens, R.B., et al. (2003). “Cartilaginous Metaplasia in Calcified 
Diabetic Peripheral Vascular Disease: Morphologic Evidence of Enchondral 
Ossification.” Human Pathology 34(4): 402–407.
Ramirez, F., Gayraud, B., et al. (1999a). "Marfan syndrome: New clues to 
genotype-phenotype correlations." Annals of Medicine 31(3): 202-207.
Ramirez, F. and Pereira, L. (1999b). "Mutations of extracellular matrix 
components in vascular disease." The Annals of Thoracic Surgery 67(6): 
1857-1858.
Rao, R.V., Ellerby, H.M., et al. (2004). “Coupling endoplasmic reticulum stress to 
the cell death program.” Cell Death and Differentiation 11: 372–380.
234
Rasheed, Z. and Haqqi, T.M. (2012). “Endoplasmic reticulum stress induces the 
expression of COX-2 through activation of eIF2α, p38-MAPK and NF-κB in 
advanced glycation end products stimulated human chondrocytes.” 
Biochimica et Biophysica Acta 1823: 2179–2189.
Ravindran, S., Gao, Q., et al. (2011). "Stress Chaperone GRP-78 Functions in 
Mineralized Matrix Formation." The Journal Of Biological Chemistry 
286(11): 8729–8739.
Ravindran, S., Gao, Q., et al. (2012). “Expression and distribution of grp-78/bip in 
mineralizing tissues and mesenchymal cells.” Histochemistry abd Cell 
Biology 138: 113–125.
Reimold, A.M., Iwakoshi, N.N., et al. (2001). "Plasma cell differentiation requires 
the transcription factor XBP-1." Nature 412(6844): 300-307.
Ren, X., Shao, H., et al. (2009). “Advanced Glycation End-products Enhance 
Calcification in Vascular Smooth Muscle Cells.” The Journal of International 
Medical Research 37: 847-854.
Rennenberg, R.J.M., Kessels, A.G.H., et al. (2009). “Vascular calcifications as a 
marker of increased cardiovascular risk: A meta-analysis.” Vascular Health 
and Risk Management 5: 185–197.
Reynolds, J.L., Joannides, A.J., et al. (2004). "Human Vascular Smooth Muscle 
Cells Undergo Vesicle-Mediated Calcification in Response to Changes in 
Extracellular Calcium and Phosphate Concentrations: A Potential 
Mechanism for Accelerated Vascular Calcification in ESRD." Journal of the 
American Society of Nephrology 15: 2857–2867.
Reynolds, J.L., Skepper, J.N., et al. (2005). "Multifunctional Roles for Serum 
Protein Fetuin-A in Inhibition of Human Vascular Smooth Muscle Cell 
Calcification." Journal of the American Society of Nephrology 16: 2920-
2930.
Riek, A.E., Oh, J., et al. (2012). “Vitamin D Suppression of Endoplasmic Reticulum 
Stress Promotes an Antiatherogenic Monocyte/Macrophage Phenotype in 
Type 2 Diabetic Patients.” The Journal of Biological Chemistry 287(46): 
38482-38494.
Rohrer, J., Schweizer, A., et al. (1996). "The targeting of Lamp1 to lysosomes is 
dependent on the spacing of its cytoplasmic tail tyrosine sorting motif 
relative to the membrane." The Journal of Cell Biology 132(4): 565-576.
Ron, D. and Walter, P. (2007). "Signal integration in the endoplasmic reticulum 
unfolded protein response." Nature Reviews Molecular Cell Biology 8: 519-
530.
Rost, S., Fregin, A., et al. (2004), “Mutations in VKORC1 cause warfarin resistance 
and multiple coagulation factor deficiency type 2.” Nature 427: 537-541.
235
Rowe, P.S.N. (2012). “Regulation of Bone–Renal Mineral and Energy Metabolism: 
The PHEX, FGF23, DMP1, MEPE ASARM Pathway.” Critical Reviews in 
Eukaryotic Gene Expression 22(1): 61–86.
Rutsch, F., Ruf, N., et al. (2003). "Mutations in ENPP1 are associated with 
'idiopathic' infantile arterial calcification." Nature Genetics 34(4): 379-381.
Rzymski, T.,  Milani, M., et al. (2009). “Role of ATF4 in regulation of autophagy 
and resistance to drugs and hypoxia.” Cell Cycle 8(23): 3838-3847.
Sage, A.P., Tintut, Y., et al. (2010). “Regulatory mechanisms in vascular 
calcification.”Nature Reviews Cardiology 7: 528–536.
Sage, A.P., Lu, X., et al. (2011). “Hyperphosphatemia-induced nanocrystal 
upregulate the expression of bone morphogenetic protein-2 and 
osteopontin genes in mouse smooth muscle cells in vitro.” Kidney 
International 79(4): 414-22.
Saito, A., Hino, S.I., et al. (2009). "Regulation of endoplasmic reticulum stress 
response by a BBF2H7-mediated Sec23a pathway is essential for 
chondrogenesis." Nature Cell Biology 11(10): 1197-1204.
Saito, A., Ochiai, K., et al. (2011). "Endoplasmic ReticulumStress Response 
Mediated by the PERK-eIF2a-ATF4 Pathway Is Involved in Osteoblast 
Differentiation Induced by BMP2." The Journal of Biological Chemistry 
286(6): 4809-4818.
Salabei, J.K., Cummins, T.D., et al. (2013). “PDGF-mediated autophagy regulates 
vascular smooth muscle cell phenotype and resistance to oxidative stress.” 
Biochemical Journal 451: 375–388.
Sano, R. and Reed, J.C. (2013). “ER stress-induced cell death mechanisms.” 
Biochimica et Biophysica Acta 1833:3460–3470.
Sanson, M., Augé, N., et al. (2009). "Oxidized low-density lipoproteins trigger 
endoplasmic reticulum stress in vascular cells: Prevention by oxygen-
regulated protein 150 expression." Circulation Research 104(3): 328-336.
Schafer, C., Heiss, A., et al. (2003). "The serum protein α2–Heremans-Schmid 
glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic 
calcification." The Journal of Clinical Investigation 112(3): 357-366.
Schmidt, A., Lorkowski, S., et al. (2006). “TGF-β1 generates a specific 
multicomponent extracellular matrix in human coronary SMC.” European 
Journal of Clinical Investigation 36: 473-482.
Schoppet, M. and Shanahan, C.M. (2008). “Role for alkaline phosphatase as an 
inducer of vascular calcification in renal failure?” Kidney International 73: 
989-991.
236
Scorrano, L., Oakes, S.A., et al. (2013). “BAX and BAK Regulation of Endoplasmic 
Reticulum Ca2+: A Control Point for Apoptosis.” Science 300(135): 135-139.
Serrano, R.L., Yu, W., et al. (2014). “Mono-allelic and bi-allelic ENPP1 deficiency 
promote post-injury neointimal hyperplasia associated with increased 
C/EBP homologous protein expression.” Atherosclerosis 233: 493-502.
Shah, N.M., Groves, A.K., et al. (1996). “Alternative Neural Crest Cell Fates Are 
Instructively Promoted by TGFβ Superfamily Members.” Cell  85: 331-343.
Shah, G.N., Bonapace, G., et al. (2004). "Carbonic anhydrase II deficiency 
syndrome (osteopetrosis with renal tubular acidosis and brain calcification):
Novel mutations in CA2 identified by direct sequencing expand the 
opportunity for genotype-phenotype correlation." Human Mutation 24(3): 
272-272.
Shamu, C.E. and Walter, P. (1996). "Oligomerization and phosphorylation of the 
Irelp kinase during intracellular signaling from the endoplasmic reticulum to
the nucleus." The EMBO Journal 15(12): 3028-3039.
Shanahan, C.M., Weissberg, P.L., et al. (1993). "Isolation of gene markers of 
differentiated and proliferating vascular smooth muscle cells." Circulation 
Research 73(1): 193-204.
Shanahan, C.M., Cary, N.R.B., et al. (1994). "High expression of genes for 
calcification-regulating proteins in human atherosclerotic plaques." Journal 
of Clinical Investigation 93(6): 2393-2402.
Shanahan, C.M. and Weissberg, P.L. (1998). "Smooth muscle cell heterogeneity: 
Patterns of gene expression in vascular smooth muscle cells in vitro and in 
vivo." Arteriosclerosis, Thrombosis, and Vascular Biology 18(3): 333-338.
Shanahan, C.M., Cary, N.R.B., et al. (1999a). “Medial Localization of 
Mineralization-Regulating Proteins in Association With Monckeberg’s 
Sclerosis: Evidence for Smooth Muscle Cell–Mediated Vascular 
Calcification.” Circulation 100: 2168-2176.
Shanahan, C.M. and Weissberg, P.L. (1999b). “Smooth Muscle Cell Phenotypes in 
Atherosclerotic Lesions.” Current Opinion in Lipidology 10: 507-513.
Shanahan, C.M. (2005). "Vascular Calcification." Current Opinion in Nephrology 
and Hypertension 14: 361-367.
Shanahan, C.M., Crouthamel, M.H., et al. (2011). "Arterial Calcification in Chronic 
Kidney Disease: Key Roles for Calcium and Phosphate." Circulation Research
109(6): 697-711.
Shanahan, C.M. (2013) “Mechanisms of vascular calcification in CKD - evidence 
for premature ageing?” Nature Reviews Nephrology 9: 661-670.
237
Shao, J.S., Cheng, S.L., et al. (2005). "Msx2 promotes cardiovascular calcification 
by activating paracrine Wnt signals." Journal of Clinical Investigation 115(5):
1210-1220.
Shao, J.S., Cai, J., et al. (2006). “Molecular Mechanisms of Vascular Calcification: 
Lessons Learned From The Aorta.” Arteriosclerosis, Thrombosis, and 
Vascular Biology 26: 1423-1430.
Shimokado, A., Sun, Y., et al. (2014). “Smad3 plays an inhibitory role in 
phosphate-induced vascular smooth muscle cell calcification.” Experimental
and Molecular Pathology 97: 458–464.
Shioi, A., Nishizawa, Y., et al. (1995). "β-Glycerophosphate accelerates 
calcification in cultured bovine vascular smooth muscle cells." 
Arteriosclerosis, Thrombosis, and Vascular Biology 15(11): 2003-2009.
Shroff, R.C. and Shanahan, C.M. (2007). "The Vascular Biology of Calciﬁcation." 
Seminars in Dialysis 20(2): 103-109.
Shroff, R.C., McNair, R., et al. (2008). "Muscle Cell Apoptosis Dialysis Accelerates 
Medial Vascular Calcification in Part by Triggering Smooth Muscle Cell 
Apoptosis." Circulation 118: 1748-1757.
Shroff, R.C., McNair, R., et al. (2010). “Chronic Mineral Dysregulation Promotes 
Vascular Smooth Muscle Cell Adaptation and Extracellular Matrix 
Calcification.” Journal of the American Society of Nephrology 21: 103–112.
Simionescu, A., Philips, K., et al. (2005). "Elastin-derived peptides and TGF-β1 
induce osteogenic responses in smooth muscle cells." Biochemical and 
Biophysical Research Communications 334(2): 524-532.
Speer, M.Y. and Giachelli, C.M. (2004). "Regulation of cardiovascular calcification."
Cardiovascular Pathology 13: 63-70.
Speer, M.Y., Yang, H.-Y., et al. (2009). "Smooth Muscle Cells Give Rise to 
Osteochondrogenic Precursors and Chondrocytes in Calcifying Arteries." 
Circulation Research 104(6): 733-741.
Spicer, S.S., Lewis, S.E., et al. (1989). "Mice carrying a CAR-2 null allele lack 
carbonic anhydrase II immunohistochemically and show vascular 
calcification." The American Journal of Pathology 134(4): 947-954.
Sriburi, R., Jackowski, S., et al. (2004). "XBP1: a link between the unfolded protein
response, lipid biosynthesis, and biogenesis of the endoplasmic reticulum." 
The Journal of Cell Biology 167(1): 35-41.
Steitz, S.A., Speer, M.Y., et al. (2001), “Smooth Muscle Cell Phenotypic Transition 
Associated With Calcification: Upregulation of Cbfa1 and Downregulation of
Smooth Muscle Lineage Markers.” Circulation Research 89: 1147-1154.
238
Stenvinkel, P., Wang, K. et al. (2005). “Low fetuin-A levels are accociated with 
cardiovascular death: Impact of variations in the gene encoding fetuin.” 
Kidney International 76: 2383-2392.
Sun, Y., Byon, C.H., et al. (2012). “Smooth Muscle Cell–Specific Runx2 Deficiency 
Inhibits Vascular Calcification.” Circulation Research 111: 543-552.
Symoens, S., Malfait, F., et al. (2013). “Deficiency for the ER-stress transducer 
OASIS causes severe recessive osteogenesis imperfecta in humans.” 
Orphanet Journal of Rare Diseases 8:154.
Szegezdi, E., Logue, S.E., et al. (2006). "Mediators of endoplasmic reticulum 
stress-induced apoptosis." EMBO reports 7(9): 880-885.
Tanaka, K., Yamaguchi, T., et al. (2013). “Advanced glycation end products 
suppress osteoblastic differentiation of stromal cells by activating 
endoplasmic reticulum stress.” Biochemical and Biophysical Research 
Communications 438: 463-467.
Tanaka, K., Kaji, H., et al. (2014). “Involvement of the Osteoinductive Factors, 
Tmem119 and BMP-2, and the ER Stress Response PERK–eIF2a–ATF4 
Pathway in the Commitment of Myoblastic into Osteoblastic Cells.” 
Calcified Tissue International 94: 454–464.
Tang, A., Wang, A., et al. (2012). “Differentiation of multipotent vascular stem 
cells  contributes to vascular diseases.” Nature Communications 3: 875.
Taylor, J., Butcher, M., et al. (2011). "Oxidized Low-Density Lipoprotein Promotes 
Osteoblast Differentiation in Primary Cultures of Vascular Smooth Muscle 
Cells by Up-regulating Osterix Expression in an Msx2-Dependent Manner." 
Journal of Cellular Biochemistry 112: 581-588.
Ting, T.C., Miyazaki-Anzai, S., et al. (2011). “Increased Lipogenesis and Stearate 
Accelerate Vascular Calcification in Calcifying Vascular Cell.” The Journal of 
Biological Chemistry 286 (27): 23938-23949.
Tintut, Y., Patel, J., et al. (2000). "Tumor Necrosis Factor-α Promotes In Vitro 
Calcification of Vascular Cells via the cAMP Pathway." Circulation 102(21): 
2636-2642.
Tohmonda, T., Miyauchi, Y., et al. (2011). "The IRE1a–XBP1 pathway is essential 
for osteoblast differentiation through promoting transcription of Osterix." 
EMBO reports 12: 451-457.
Tohmonda, T., Yoda, M., et al. (2013). “The IRE1α-XBP1 Pathway Positively 
Regulates Parathyroid Hormone (PTH)/PTH-related Peptide Receptor 
Expression and Is Involved in PTH-induced Osteoclastogenesis.” The Journal
of Biological Chemistry 288(3): 1691-1695.
239
Travers, K.J., Patil, C.K., et al. (2000). "Functional and genomic analyses reveal an 
essential coordination between the unfolded protein response and ER-
associated degradation." Cell 101(3): 249-258.
Tsang, K.Y., Chan, D., et al. (2010). "In vivo cellular adaptation to ER stress: 
survival strategies with double-edged consequences." Journal of Cell 
Science 123: 2145-2154.
Tyson, K.L., Reynolds, J.L., et al. (2003). "Arteriosclerosis, Thrombosis, and 
Vascular Biology."  23: 489-494.
Ulsamer, A., Ortuno, M.J., et al. (2008). "BMP-2 Induces Osterix Expression 
through Up-regulation of Dlx5 and Its Phosphorylation by p38." The Journal
of Biological Chemistry 283(7): 3816-3826.
Urano, F., Wang, X.Z., et al. (2000). “Coupling of Stress in the ER to Activation of 
JNK Protein Kinases by Transmembrane Protein Kinase IRE1.” Science 287: 
664-666.
Vattem, K.M. and Wek, R.C. (2004). "Reinitiation involving upstream ORFs 
regulates ATF4 mRNA translation in mammalian cells." Proceedings of the 
National Academy of Sciences of the United States of America 101(31): 
11269-11274.
Walter, P. and Ron, D. (2011). “The Unfolded Protein Response: From Stress 
Pathway to Homeostatic Regulation.” Science 334: 1081-1086.
Wang, X.Z., Harding, H.P., et al. (1998). “Cloning of mammalian Ire1 reveals 
diversity in the ER stress responses.” The EMBO Journal 17(19): 5708-5717.
Wang, Y., Shen, J., et al. (2000). “Activation of ATF6 and an ATF6 DNA binding site 
by the ER stress response.” The Journal of Biological Chemistry 275(35): 
27013-27020.
Wang, W., Lian, N., et al. (2009). "Atf4 regulates chondrocyte proliferation and 
differentiation during endochondral ossification by activating Ihh 
transcription." Development 136: 4143-4153.
Wang, Z., Jiang., Y., et al. (2012a).”Advanced  glycation  end-product  Nε-
carboxymethyl-Lysine  accelerates progression  of  atherosclerotic  
calcification  in  diabetes.” Atherosclerosis 221: 387- 396.
Wang, W., Lian, N., et al. (2012b). "Chondrocytic Atf4 regulates osteoblast 
differentiation and function via Ihh." Development 139: 601-611.
Wang, X., Guo, B., et al. (2013). “miR-214 targets ATF4 to inhibit bone formation.”
Nature Medicine 19(1): 93-100.
Watson, K.E., Boström, K., et al. (1994). "TGF-beta 1 and 25-hydroxycholesterol 
stimulate osteoblast-like vascular cells to calcify." The Journal of Clinical 
Investigation 93(5): 2106-2113.
240
Weber, C. and Noels, H. (2011). “Atherosclerosis: current pathogenesis and  
therapeutic options.” Nature Medicine 17(11): 1410-1422.
Wei, J., Sheng, X., et al. (2008). "PERK Is Essential for Neonatal Skeletal 
Development to Regulate Osteoblast Proliferation and Differentiation." 
Journal of Cellular Physiology 217: 693-707.
Welch, W. and  Brown, C.R. (1996). “Influence of Molecular and Chemical 
Chaperones on Protein Folding.” Cell Stress and Chaperones 1(2): 109-115.
Westendorf, J.J., Kahler, R.A., et al. (2004). “Wnt signaling in osteoblasts and bone
diseases.” Gene 341: 19 – 39.
Willems, B.A., Vermeer, C., et al. (2014). “The realm of vitamin K dependent 
proteins: Shifting from coagulation toward calcification.” Molecular 
Nutrition and Food Research 58: 1620-1635.
Wilson, E., Mai, Q., et al. (1993). “Mechanical Strain Induces Growth of Vascular 
Smooth Muscle Cells via Autocrine Action of PDGF.” The Journal of Cell 
Biology 123(3): 741-747.
Woldt, E., Terrand, J., et al. (2005). “The nuclear hormone receptor PPARγ 
counteracts vascular calcification by inhibiting Wnt5a signalling in vascular 
smooth muscle cells.” Nature Communications 3:1077.
Wolisi, G.O. and Moe, S.M. (2005). "The Role of Vitamin D in Vascular 
Calcification in Chronic Kidney Disease." Seminars in Dialysis 18(4): 307-
314.
Wu, J. and Kaufman, R.J. (2006). “From acute ER stress to physiological roles of 
the Unfolded Protein Response.” Cell Death and Differentiation 13: 374-
384.
Wu, L., Wang, D., et al. (2014). “Endoplasmic reticulum stress plays a role in the 
advanced glycation end product-induced inflammatory response in 
endothelial cells.” Life Sciences 110: 44-51.
Xiong, Y., Zhang, J., et al. (2014) “Human leptin protein activates the growth of 
HepG2 cells by inhibiting PERK-mediated ER stress and apoptosis.” 
Molecular Medicine Reports 10(3): 1649-1655
Xu, Z., Ji, G., et al. (2012). "SOX9 and myocardin counteract each other in 
regulating vascular smooth muscle cell differentiation." Biochemical and 
Biophysical Research Communications 422(2): 285-290.
Xuan, Y.T., Wang, O.L., et al. (1992). "Thapsigargin stimulates Ca2+ entry in 
vascular smooth muscle cells: nicardipine-sensitive and -insensitive 
pathways " American Journal of Physiology 262(Cell Physiol. 31): C1258-
C1265.
241
Xue, X., Piao, J.-H., et al. (2005). "Tumor Necrosis Factor α (TNFα) Induces the 
Unfolded Protein Response (UPR) in a Reactive Oxygen Species (ROS)-
dependent Fashion, and the UPR Counteracts ROS Accumulation by TNFα." 
Journal of Biological Chemistry 280(40): 33917-33925.
Yamabe, S., Hirose, J., et al. (2013). “Intracellular accumulation of advanced 
glycation end products induces apoptosis via endoplasmic reticulum stress 
in chondrocytes.” The FEBS Journal 280: 1617-1629.
Yamaguchi, H. and Wang, H.G. (2004). “CHOP Is Involved in Endoplasmic 
Reticulum Stress-induced Apoptosis by Enhancing DR5 Expression in 
Human Carcinoma Cells.”  The Journal of Biological Chemistry 279(44): 
45495-45502.
Yang, X. and Karsenty, G. (2004a). "ATF4, the Osteoblast Accumulation of Which Is
Determined Post-translationally, Can Induce Osteoblast-specific Gene 
Expression in Non-osteoblastic Cells." The Journal of Biological Chemistry 
279(45): 47109–47114.
Yang, X., Matsuda, K., et al. (2004b). "ATF4 Is a Substrate of RSK2 and an Essential
Regulator of Osteoblast Biology: Implication for Coffin-Lowry Syndrome." 
Cell 117: 387–398.
Yao, Y., Jumabay, M., et al. (2013). “A Role for the Endothelium in Vascular 
Calcification”Circulation Research 113: 495-504.
Yi, N., Chen, S.Y., et al. (2012). “Tunicamycin Inhibits PDGF-BB-Induced 
Proliferation and Migration of Vascular Smooth Muscle Cells Through 
Induction of HO-1.” The Anatomical Record 295: 1462-1472.
Yin, Q.Q., Dong, C.F., et al. (2012). “AGEs Induce Cell Death via Oxidative and 
Endoplasmic Reticulum Stresses in Both Human SH-SY5Y Neuroblastoma 
Cells and Rat Cortical Neurons.” Cell Mol Neurobiol (2012) 32:1299–1309
Yoshida, H., Matsui, T., et al. (2001). "XBP1 mRNA Is Induced by ATF6 and Spliced 
by IRE1 in Response to ER Stress to Produce a Highly Active Transcription 
Factor." Cell 107: 881-891.
Yousfi, M., Lasmoles, F., et al. (2002). “TWIST inactivation reduces CBFA1/RUNX2 
expression and DNA bindingto the osteocalcin promoter in osteoblasts.” 
Biochemical and Biophysical Research Communications 297: 641-644.
Yu, S., Zhu, K., et al. (2013). “ATF4 Promotes β-Catenin Expression and 
Osteoblastic Differentiation of Bone Marrow Mesenchymal Stem Cells.” 
Interntional Journal of Biological Sciences 9(3): 256-266.
Zebboudj, A.F., Imura, M., et al. (2002). "Matrix GLA Protein, a Regulatory Protein
for Bone Morphogenetic Protein-2." Journal of Biological Chemistry 277(6): 
4388-4394.
242
Zebger-Gong, H., Muller, D., et al. (2011). "1,25-Dihydroxyvitamin D3-induced 
aortic calciﬁcations in experimental uremia: up-regulation of osteoblast 
markers, calcium-transporting proteins and osterix." Journal of 
Hypertension 29: 339-348.
Zhang, H. and Bradley, B. (1996). “Mice deficient for BMP2 are nonviable and 
have defects in amnion/chorion and cardiac development.” Development 
122: 2977-2986.
Zhang, P., McGrath, B., et al. (2002). "The PERK Eukaryotic Initiation Factor 2a 
Kinase Is Required for the Development of the Skeletal System, Postnatal 
Growth, and the Function and Viability of the Pancreas." Molecular and 
Cellular Biology 22(11): 3864-3874.
Zhang, K. and Kaufman, R.J. (2008). “From endoplasmic-reticulum stress to the 
inflammatory response.” Nature 45: 455-462.
Zhang, Y., Liu, R., et al. (2010a). “Cell Surface Relocalization of the Endoplasmic 
Reticulum Chaperone and Unfolded Protein Response Regulator 
GRP78/BiP.” The Journal of Biological Chemistry 285(20): 15065–15075.
Zhang, C. (2010b). ”Transcriptional regulation of bone formation by the 
osteoblast-specific transcription factor Osx.”  Journal of Orthopaedic 
Surgery and Research 5(37).
Zhang, X.W., Zhang, B.Y., et al. (2014). “Twist-related protein 1 negatively 
regulated osteoblastic transdifferentiation of human aortic valve interstitial 
cells by directly inhibiting runt-related transcription factor 2.” The Journal 
of Thoracic and Cardiovascular Surgery 148(4): 1700-1708.
Zhu, F., Friedman, M.S., et al. (2012). “The Transcription Factor Osterix (SP7) 
Regulates BMP6-Induced Human Osteoblast Differentiation.” Journal of 
Cellular Physiology 227: 2677-2685.
Zinszner, H., Kuroda, M., et al. (1998). “CHOP is implicated in programmed cell 
death in response to impaired function of the endoplasmic reticulum.“ 
Genes and Development 12: 982-995.
243
